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Abstract 
 
To ameliorate Hepatitis C Virus (HCV) therapeutic and diagnostic challenges requires 
robust intervention strategies, including approaches that leverage the plethora of rich data 
published in biomedical literature to gain greater understanding of HCV pathobiological 
mechanisms. The multitudes of metadata originating from HCV clinical trials as well as 
low and high-throughput experiments embedded in text corpora can be mined as data 
sources for the implementation of HCV-specific resources. HCV-customized resources 
may support the generation of worthy and testable hypothesis and reveal potential 
research clues to augment the pursuit of efficient diagnostic biomarkers and therapeutic 
targets. This research thesis report the development of two freely available HCV-specific 
web-based resources: (i) Dragon Exploratory System on Hepatitis C Virus (DESHCV) 
accessible via http://apps.sanbi.ac.za/DESHCV/ or http://cbrc.kaust.edu.sa/deshcv/ and 
(ii) Hepatitis C Virus Protein Interaction Database (HCVpro) accessible via 
http://apps.sanbi.ac.za/hcvpro/ or http://cbrc.kaust.edu.sa/hcvpro/.  
 
DESHCV is a text mining system implemented using named concept recognition and co-
occurrence based approaches to computationally analyze about 32, 000 HCV related 
abstracts obtained from PubMed. As part of DESHCV development, the pre-constructed 
dictionaries of the Dragon Exploratory System (DES) were enriched with HCV 
biomedical concepts, including HCV proteins, name variants and symbols to enable HCV 
knowledge specific exploration. The DESHCV query inputs consist of user-defined 
keywords, phrases and concepts. DESHCV is therefore an information extraction tool 
that enables users to computationally generate association between concepts and support 
the prediction of potential hypothesis with diagnostic and therapeutic relevance. 
Additionally, users can retrieve a list of abstracts containing tagged concepts that can be 
used to overcome the herculean task of manual biocuration. DESHCV has been used to 
simulate previously reported thalidomide-chronic hepatitis C hypothesis and also to 
model a potentially novel thalidomide-amantadine hypothesis. 
 
HCVpro is a relational knowledgebase dedicated to housing experimentally detected 
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HCV-HCV and HCV-human protein interaction information obtained from other 
databases and curated from biomedical journal articles. Additionally, the database 
contains consolidated biological information consisting of hepatocellular carcinoma 
(HCC) related genes, comprehensive reviews on HCV biology and drug development, 
functional genomics and molecular biology data, and cross-referenced links to canonical 
pathways and other essential biomedical databases. Users can retrieve enriched 
information including interaction metadata from HCVpro by using protein identifiers, 
gene chromosomal locations, experiment types used in detecting the interactions, 
PubMed IDs of journal articles reporting the interactions, annotated protein interaction 
IDs from external databases, and via “string searches”. The utility of HCVpro has been 
demonstrated by harnessing integrated data to suggest putative baseline clues that seem to 
support current diagnostic exploratory efforts directed towards vimentin. Furthermore, 
eight genes comprising of ACLY, AZGP1, DDX3X, FGG, H19, SIAH1, SERPING1 and 
THBS1 have been recommended for possible investigation to evaluate their diagnostic 
potential. The data archived in HCVpro can be utilized to support protein-protein 
interaction network-based candidate HCC gene prioritization for possible validation by 
experimental biologists. 
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1.1 Overview  
This chapter provides a brief overview on Hepatitis C Virus biology as well as 
therapeutic challenges. It also elaborates on the basic principles underlying text mining 
and provides a brief discussion on concerted efforts directed toward harvesting and 
harnessing protein-protein interactions. Furthermore, it provides the rationale 
underpinning the research thesis reported here.  
 
 
1.2 Hepatitis C Virus Pathobiology 
The identification and characterization of Hepatitis C Virus (HCV) had proved elusive in 
the 1970s and early 1980s, and HCV was inadvertently referred to as non-A, non-B 
associated hepatitis. However, with the advent of sophisticated molecular cloning 
techniques, HCV cDNA was finally isolated and characterized in 1988 (Choo et al., 
1998). Although this significant discovery has proved useful, thorough understanding of 
HCV infection, replication and propagation in cellular hosts remains elusive. 
Furthermore, elucidation of the molecular pathogenesis and design of appropriate 
therapeutic interventions are hindered by lack of suitable animal models for HCV 
infection and appropriate medium for in vitro cultivation or propagation of HCV. Even 
though certain small animal models are permissive to HCV infection or allow protein 
expression, there is no single suitable small animal model that supports appropriately the 
full replication cycle of HCV. Nevertheless, rodent models obtained from rat and mice 
appear to have enhanced our current understanding of some aspects of the molecular 
etiology underlying HCV infection. Indeed significant progress could be made by 
developing rodent models which are capable of harboring both human immune system 
and human liver cells that are susceptible to HCV infection (Kremsdorf and Brezillon, 
2007). The chimpanzee offers a suitable animal model susceptible to HCV infections 
(Lanford et al., 2001) but its usage is expensive, laborious and besieged with ethical 
furore.  Recent development of cell cultures that support HCV infection (Wakita et al., 
2005) and replication of subgenomic HCV RNAs in hepatoma cell lines (Lohmann et al., 
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1999; Long et al., 2011) may contribute to understanding of HCV pathophysiological 
mechanisms.  
 
1.2.1 Molecular Biology of HCV 
Hepatitis C Virus (HCV) is a small, spherical, enveloped, hepatotropic RNA virus, 
belonging to the family Flaviviridae, in the genus of hepacivirus (Figure 1.1). The HCV 
genome is a single-stranded positive sense RNA of about 9600 bases, flanked by 5' and 3' 
non-coding regions (Figure 1.2). The genome is made up of a single, large open reading 
frame encoding a single polyprotein consisting of about 3000 amino acid residues. The 
polyprotein is cleaved by both viral proteases and host cellular signalases into 10 distinct 
proteins in the order as follows: NH2-Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-
NS5B-COOH (Suzuki et al., 1999; Figure 1.3). The 5' non-coding region contains the 
internal ribosomal entry site (IRES), which is implicated in translation initiation. An 
additional HCV protein, alternative reading frame protein (ARFP) or otherwise known as 
F protein produced by ribosomal frameshift within the capsid-encoding region has been 
described (Xu et al., 2001). The HCV proteins Core, E1 and E2 constitute the structural 
proteins whilst NS2, NS3, NS4A, NS4B, NS5A and NS5B are nonstructural proteins. 
The structural and nonstructural proteins are cleaved by host and viral proteinases 
respectively. The p7 protein, a member of the viroporin family forms a bridge connecting 
the structural and nonstructural proteins and is cleaved by host proteinases. As pestivirus 
p7 was suggested not to be a major structural constituent, it can be presumed that HCV 
p7 protein is not a structural protein (Elbers, 1996). The major roles played by the various 
HCV proteins have been summarized in Table 1.1 and detailed reviews on the 
biochemical and functional proteins can be found elsewhere (Bartenschlager, 2004; Penin 
et al., 2004; Chevaliez and Pawlotsky, 2006; Dubuisson, 2007; Vassilaki and Mavromara, 
2009). 
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TABLE 1.1. HCV PROTEINS, THEIR MOLECULAR WEIGHTS AND FUNCTIONS. 
(Table adapted from Penin et al., 2004; Chaveliez and Pawlotsky, 2006; Dubuisson 
2007). 
HCV 
Protein Function 
Molecular mass by 
SDS page (kDa) 
Apparent molecular 
weight (kDa) 
Core 
RNA binding; 
nucleocapsid 21 
23 (precursor); 21 
(mature) 
E1 
Envelope glycoprotein; 
associate with E2 31-35 33-35 
E2 
Envelope glycoprotein; 
receptor binding; associate 
with E1 70 70-72 
P7 Ion channel 7 7 
NS2 
Component of NS2-3 
proteinase 21 21-23 
NS3 
NS2/3 proteinase; NS3/4 
proteinase; NTPase; RNA 
helicase; RNA binding 69 69 
NS4A 
NS3-4A proteinase 
cofactor 6 6 
NS4B 
NS5A phosphorylation; 
membranous web 
induction 27 27 
NS5A 
Phosphoprotein; RNA 
replication by formation of 
replication complexes; 
possibly involved in 
inhibition of  INF-alpha; 
inhibition of apoptosis 56-58 
56 (basal form); 58 
(hyperphosphorylated) 
NS5B 
 RNA-dependent RNA 
polymerase 68 68 
F/ARF-
protein 
Possibly involved in HCV 
core protein RNA binding 
activities 17 16-17 
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FIGURE 1.1. A MODEL OF HCV PARTICLE. 
A diagram showing the molecular organization involving viral proteins and RNA 
(Krekulová et al., 2006). 
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FIGURE 1.2. HCV GENOME ORGANIZATION.  
The blue and red coloured segments of the genome encode structural and nonstructural 
proteins respectively (Dubuisson, 2007). 
 
 
 
 
 
 
 
 
 
FIGURE 1.3. POST TRANSLATIONALLY PROCESSED HCV POLYPROTEIN 
Diagram shows the 10 distinct structural and nonstructural proteins as well as junction 
protein p7. The scissors represent proteolytic cleavages by host peptidases, arrows 
indicate NS2-3 and NS3-4A cleavages. The transmembrane arrows show cleavage by 
host signal peptidases (Dubuisson, 2007). 
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1.2.2 HCV LIFE CYCLE 
HCV host cell entry and tissue tropism seems poorly understood even though significant 
advances have been made by elucidating viral-cellular protein interactions as well as 
associated essential pathways. HCV glycoproteins E1 and E2 binds host cellular 
membranous constituents enabling viral interaction with a complex set of cell-surface 
molecules or cellular co-receptors, including tetraspanin (CD81) (Pileri et al., 1998; Flint 
et al., 1999; Petracca et al., 2000), human scavenger receptor class B type I (SR-BI) 
(Scarselli et al., 2002; Bartosch et al., 2003), dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin (DC-SIGN) (Gardner et al., 2003; Lozach et al., 2004), 
liver/lymph node-specific intracellular adhesion molecule-3 (ICAM-3)-grabbing integrin 
(L-SIGN) (Gardner et al., 2003; Lozach et al., 2004), low-density lipoprotein receptor 
(LDL-R) (Agnello et al., 1999; Monazahian et al., 1999), asialoglycoprotein receptor 
(ASGP-R) (Saunier et al., 2003), glycosaminoglycans (HSPG) (Barth et al., 2003), 
claudin-1 and occludin (Figure 1.4).  Tight junction proteins claudin-1 and occludin are 
thought to control hepatitis C virus entry by mediating virion internalization processes in 
host cells (Yang et al., 2008; Liu et al., 2009; Ploss et al., 2009). Viral-cell entry also 
depends on clathrin-mediated endocytic pathway mechanisms, accompanied by a fusion 
process that appears to require an acidic endosomal environment (Codran et al., 2006). 
The fusion arises from conformational changes in the glycoproteins triggering 
decapsidation of viral nulceocapsids to release free positive-strand RNA into the 
cytoplasm. The liberated RNAs undergoes translation to produce a large HCV 
polyprotein precursor via the internal ribosome entry site located in the 5‟ untranslated 
region of the HCV genome, after which viral proteases and host signalases process the 
obtained polyprotein into distinct structural and nonstructural proteins through co-
translation and post-translation mechanisms. Thereafter, a NS4B-induced membranous 
web, consisting of a membrane-associated multiprotein complex constitutes the viral 
replication complex (Egger et al., 2002; Elazar et al., 2004). HCV replication then 
proceeds via two stages catalyzed by NS5B (Chevaliez and Pawlotsky, 2006): (1) 
synthesis of a negative-strand RNA intermediate from a template composed of the 
positive-strand genome RNA and (2) negative-strand RNA intermediate then serves as 
template for synthesis of several progeny positive-strand RNA, which are then packaged 
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into new virions (Bartenschlager et al, 2004) assembled on lipid droplets (Gouttenoire et 
al., 2010). The matured viral particles are then released. However, the mechanisms 
underlying the maturation and release are still unclear. Comprehensive reviews on the 
HCV life and intricacies have been discussed elsewhere (Rychłowska and Bieńkowska-
Szewczyk, 2007; Dubuisson et al., 2008). 
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FIGURE 1.4. DETAILS OF HCV LIFECYCLE.  
(1) Binding of HCV to cell surface receptors; (2) entry of HCV into the cell via 
endocytosis; (3) viral genome is released into cytoplasm; (4) internal ribosomal entry 
site-mediated polyprotein translation; (5) polyprotein processing; (6) formation of 
membranous web as part of replication complexes); (7) viral RNA replication; (8) 
packaging and assembly of progeny virions; and (9) matured virions are released via the 
host cellular secretory system (Tencate et al., 2010). 
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1.2.3 HCV nomenclature and classification 
Ever since the HCV genome sequence was elucidated and vast amount of sequenced 
nucleotide, proteins and epitope data became available, several recommendations have 
emanated from various fora with the sole aim of unifying the nomenclature and 
classification of HCV isolates to conform to the guidelines stipulated by the International 
Committee on Virus Taxonomy (ICVT) (Simmonds et al., 1993; Simmonds et al., 1994; 
Robertson et al., 1998; Simmonds et al., 2005; Kuiken and Simmonds, 2009). This 
taxonomic framework guides the deposition of HCV sequences in online databases for 
further exploration by researchers. Furthermore, it allows the resolution of conflict 
pertaining to assignment of genotypes and any novel isolate that may be discovered in the 
future. As a result of HCV sequence variability and genetic heterogeneity, the 
standardization is relevant to research relating to the epidemiology, evolution and 
pathobiology of HCV associated infections (Kuiken and Simmonds, 2009). 
 
By using comparative techniques including phylogenetic analysis, numerous distinct 
relationships have been established between HCV isolates thereby leading to the 
identification of six major genotypes (Simmonds et al., 1993; Simmonds et al., 1994). 
These divisions are further elaborated using phylogenetic trees (Figures 1.5). 
Additionally, the system of nomenclature has adopted the full-length genome sequence of 
isolate H77 (accession number AF009606) as a reference strain for annotation of other 
variants. The quasispecies nature of HCV allows the coexistence of multiple genetically 
different but closely related variants in infected individuals (Martell et al., 1992). The 
genotypes differ in their nucleotide sequence by 31-33% whilst the subtypes differ by 20-
25%. The proteins are also known to differ by about 30% in amino acid sequences 
(Suzuki et al., 2007). The high degree of genetic variability exhibited by HCV could be 
attributed to the inability of the error-prone RNA-dependent RNA polymerase to 
proofread, high rate of viral replication and typical larger population size. 
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FIGURE 1.5. AN EVOLUTIONARY TREE DEPICTING THE MAJOR HCV GENOTYPES.  
It shows prevalence according to different geographic regions or countries. (Kuiken and 
Simmonds, 2009). 
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1.2.4 HCV epidemiology and therapeutic challenges 
Currently, about 3% of the global population is infected with HCV, a foremost risk factor 
and major causative agent for development of acute and chronic hepatic infections. The 
chronification rate is about 70-80% (Krekulová et al., 2006). HCV infected individuals 
can develop chronic hepatitis, which may progress from fibrosis to HCV-induced 
cirrhosis with some subsequently developing hepatocellular carcinoma (HCC) (Figure 
1.6). HCC is the 3
rd
 most deadly and 5
th
 most frequent cancer globally (Zender and 
Kubicka, 2008) and the epidemiology is further exacerbated by the asymptomatic as well 
as occasionally undetectable nature of HCV infections. HCV infected individuals in the 
long term may ultimately require liver transplant to abort death from liver impairment. As 
reported by the Eurasian Harm Reduction Network (EHRN), the World Health 
Organization (WHO) in 2002 estimated 53,700 annual global deaths could be directly 
associated with HCV infection. The scale of the infection is further exacerbated by the 
revelation that liver cancer caused by HCV may be likely linked to 308,000 deaths 
annually. In total, HCV could be implicated in about 500,000 global deaths annually 
(EHRN, 2007) and the potential exists for these mortality and morbidity rates to increase 
in the near future.  
 
The HCV prevalence have been shown to differ amongst various geographic regions in 
the world (Sy and Jamal, 2006; Baldo et al., 2008). Infection figures from the World 
Health Organization (2009) are reported here. HCV prevalence was less than 1% in 
Australia, Canada and Northern Europe; about 1% in USA and most of Europe; and more 
than 2% in most countries found in Africa, Latin America and Central and South-Eastern 
Asia. Furthermore, HCV prevalence figures between 5 and 10% are usually reported in 
certain countries in the aforementioned regions. Countries with relatively high prevalence 
rates include Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%) (Sievert et al., 2011). 
Particularly, the Nile delta region of Egypt has significantly higher seroprevalence of 
HCV, which was revealed to increase with age from 19% in persons of 10-19 years old to 
approximately 60% in persons of 30 years of age.   The Egyptian HCV crisis could be 
attributed to the earlier lapses that existed during the nationwide campaign to help reduce 
the prevalence of schistosomiasis (Yahia, 2011). Intravenous drug use and blood 
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transfusion-related infections appear as the emerging risk factors in both developed and 
developing countries, respectively (Sy and Jamal, 2006). 
 
Diagnostically, histologic liver biopsy, ultrasound, and biomarkers are among the variety 
of techniques employed to evaluate progression of chronic infections to HCC and hepatic 
steatosis (Kim et al., 2002; Mas et al. 2009; Yu et al., 2010). Unfortunately, liver biopsy 
is invasive with possible complications (Caillot et al., 2009) whilst reduced sensitivity 
and specificity can hamper the effectiveness of diagnostic techniques (Outwater et al., 
2010). The need for diagnoses or evaluation of liver disease progression with a 
combination of biomarkers has been proposed (Gangadharan et al., 2007).  
 
The most effective treatment for HCV infection is a combination therapy of 
pharmacokinetically enhanced pegylated interferon alpha (peginterferon alpha) and 
nucleoside analogue ribavirin (Fried et al., 2002; Krekulová et al., 2006), but it is 
sometimes accompanied by undesirable side effects and reduced quality of life during 
medication. Under standard care medication, this combination treatment cures about 80% 
of individuals infected with genotype 2 or 3, and 40% of genotype 1 (Strader et al., 2004; 
Suzuki et al., 2007; Gambarin-Gelwan and Jacobson, 2008; WHO, 2010). It is perceived 
that about half of infected individuals do not derive significant long term benefit from the 
combination therapy. It is proposed that the current treatment options can be augmented 
with an immunotherapeutic vaccine which may be beneficial in immunocompromised 
individuals (Sharma, 2010). Recently, the search for HCV therapy was vigorously 
focused on the development of anti-viral drugs targeting host cellular proteins and also 
protease/polymerase inhibitors specifically designed to disrupt the role of the HCV 
proteins during viral propagation and replication (Tencate et al., 2010). Some of the HCV 
or host protein-specific drugs under considerations include lectin cyanovirin-N (CV-N) 
(Helle et al., 2006), alpha-glucosidase I inhibitor (Celgosivir) (Durantel, 2009), n-butyl 
deoxynojirimycin (nB-DNJ) (Ouzounov et al., 2002), class of compounds with a 
thiazolidinone core structure (BMS-824) (Lemm et al., 2010), zinc mesoporphyrin 
(ZnMP) (Hou et al., 2010) and valyl ester prodrug (NM283) (Gardelli et al, 2009) whilst 
non HCV-specific anti-viral drugs comprises of nitazoxanide (Rossignol et al., 2010), 
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cyclophilin inhibitors (NIM811) (Ma et al., 2006; Lawitz et al, 2011) and silibinin (Payer 
et al., 2010). 
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FIGURE 1.6. VARIOUS DISEASE STAGES FOLLOWING HCV INFECTIONS  
(This diagram was modified from Sharma, 2010) 
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1.3 Text mining 
Nowadays, most biomedical research institutions around the world have been expending 
significant proportions of their budgetary allocations in both material and human resource 
capacity development, thereby making it easier for them to generate large amount of 
potentially meaningful results for exploration in a short span of time through the usage of 
high throughput techniques such as genomics, proteomics, and microarray. The myriad of 
information derived from both low and high-throughput experiments published in 
journals can be located in the main body text or as supplementary information for easy 
electronic accessibility. As a result, biomedical researchers have adopted integrated 
natural language processing approaches to harness the available information in the 
published text as part of the strategies used in answering relevant biological questions. 
This is due to the fact that it is practically impossible to manually sift through the huge 
volumes of biomedical literature in order to unravel any meaningful latent semantic 
connections between different parts of the text due to potential human curation errors. 
The advent of online manuscript submission for journal publications may have 
contributed in the reported exponential growth in the amount of published biomedical 
literature recently (Hunter and Cohen, 2006). Currently, PubMed database (Sayers et al., 
2011) has grown rapidly to over 20 million indexed citations (Figure 1.7) and houses 
abstracts from over 5000 life science journals from biomedical articles dating back to 
1948 (Lu, 2011). Similarly, the National Library of Medicine expects 1 million journal 
articles to be indexed annually by 2015, indicating a 50% potential rise in number of 
processed articles when compared to 2004 (Neveol et al., 2006). By searching for global 
trends, the number of new journal articles reporting results on certain research topics such 
as “cell cycle” has also increased appreciably over the years (Jensen et al., 2006). 
Interestingly, new articles reporting previous popular topics, notable “protein Cdc28” 
seems to have declined. The rise in scientific review articles and concomitant explosion 
of scientific publications require the use of automated strategies such as text mining to 
computationally harvest the vast quantities of knowledge or otherwise may be referred to 
as knowledge about knowledge (metaknowledge) embedded in the text (Evans and 
Foster, 2011). Although biomedical text mining techniques and related application tools 
are increasingly becoming popular with bench biologists, they still face significant 
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challenges in extracting relevant information from texts. Nevertheless, significant 
improvement has been achieved through the incorporation of computational linguistics 
techniques. Text mining has been defined in a broader sense as any system capable of 
retrieving knowledge from text; and in strictest sense as a system that extracts implicit 
knowledge not obviously stated in the text (Zweigenbaum et al., 2007). The field of text 
mining can be divided into the following domains: (1) information retrieval, (2) 
information extraction, (3) entity recognition, and (4) analysis of text-image data. 
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FIGURE 1.7. A GRAPH SHOWING THE TOTAL GROWTH OF PUBMED CITATIONS. 
The graph was generated with citations from 1986 to 2010. PubMed currently houses 
over 20-million citations and grows at an annual rate of about 4% (Lu, 2011). 
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1.3.1 Analysis of text-image data 
Most non-textual data such as figures and tables in published full-text articles convey 
varying degrees of experimental outcomes which aid in the interpretation of research 
findings. Figure legends comprising of text of sentences are used to describe or annotate 
non-textual data. With the increase in amount of published articles and associated text-
image datasets, natural language processing and image processing techniques are 
employed in concert to automatically extract structured information from text. This 
approach has been implemented in the development of the Structured Literature Image 
Finder (SLIF) project, a pipeline that enables the extraction of structured information 
from full-text articles and also provides a user-friendly web-based tool for accessing 
information about subcellular location from fluorescence microscopy images (Coelho et 
al., 2010). The pipeline consists of three main stages, namely caption processing, image 
processing and latent topic discovery. During the first two stages, figures and their 
respective captions are extracted from a collection of papers and are used as entries to 
create a database. The captions are further analysed to obtain biological entities such as 
proteins, cell types or lines and are then mapped onto external databases. Next, the 
figures are panel-segmented and fluorescence microscopy images are then classified 
according to depicted subcellular location. The final stage is to uncover a core set of 
themes known as latent topics from the processed full-text papers which then form the 
basis for visualization and semantic interpretation that aid in new knowledge discovery. 
Another usefulness of a text-image mining system such as SLIF is illustrated by the fact 
that users can retrieve articles with images for which a topic, for instance “tumorigenesis” 
is overly represented for future exploration. Other publicly available online resources for 
retrieving images and associated papers from image caption text are Yale Image Finder 
(Xu et al., 2008) and GoldMiner (Kahn and Thao, 2007). Comprehensive reviews and 
research involving text-image dataset processing have been reported elsewhere (Müller et 
al., 2004a; Shatkay et al., 2006; Uwimana and Ruiz, 2008; Qian and Murphy, 2008). 
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1.3.2 Information retrieval (IR) 
IR entails using automated systems, particularly a search engine to identify and rank any 
list of documents or portion of text relevant to user interest or based on the user‟s query. 
Simplistically, IR filters the relevant documents from a large pool of documents. The 
retrieved text corpora can consist of any documents comprising of full-text articles, 
abstracts or phrases. IR can be separated into two distinct domains consisting of ad hoc 
and text categorization systems. 
 
 
1.3.2.1 Ad hoc information retrieval systems 
Ad hoc information retrieval involves the use of user-supplied keyword queries to return 
subset of documents containing the queried keywords (Figure 1.8). A popular ad hoc IR 
system is PubMed, which take as input natural language in the form of free-text 
keywords to recover a list of citations that match the queried text (Lu, 2011). PubMed 
search strategy is based on both Boolean model and automatic term mapping (ATM) 
techniques. For a typical Boolean query, the Boolean operator “AND” is inserted 
between multi-term user defined query such as „vulval cell‟ to retrieve a list of documents 
containing the search string „vulva AND cell‟. Additionally, stop words such as “the” and 
“it” are removed while common words ending with “-ing” and “-s” are truncated to 
enable name variants of the queried word to match documents (Jensen et al., 2006). The 
ATM system compares and maps the user-constructed keywords to a set of pre-indexed 
terms, for example the Medical Subject Headings (MeSH).  Documents containing the 
user keywords as well as the mapped MeSH pre-indexed terms are retrieved as the query 
output (Lu, 2011). Additionally, Current IR systems being developed have been enhanced 
by their ability to allow flexible ranking of articles (MedlineRanker, Fontaine et al., 
2009), prioritize (Pubfocus, Plikus et al., 2006) or generate multi-level relevance 
feedback upon querying without expert knowledge (RefMed, Yu et al., 2011). Similarly, 
design of a dynamic user query interface for MEDLINE database is actively being 
pursued with a notable example being iPubMed (Wang et al., 2010), a system that 
enables interactive queries with on the spot feedback to users' searches letter by letter as 
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well as an extra feature for fuzzy search. Also since some users of IR systems possess 
different language backgrounds, BabelMeSH has been designed as a platform to allow 
cross-language querying via MEDLINE/PubMed (Liu et al., 2006). 
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FIGURE 1.8.  INFORMATION RETRIEVAL AND EXTRACTION SYSTEMS. 
Diagram depicting the variety of results obtained by querying both information retrieval 
and extraction systems (modified from Lu, 2011). 
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1.3.2.2 Text categorization system 
It is often not possible to use keyword queries to retrieve a subset of published 
biomedical documents sharing common topical characteristics among a large set of 
documents. Biologists confronted with large numbers of routinely published articles may 
require classifying these papers into smaller topic-specific groups or subgroups to 
enhance knowledge retrieval (Shatkay et al., 2006). For instance, a researcher may like to 
retrieve a set of documents pertaining to current or future research interest with ease. 
Text categorization therefore provides efficient approach to cluster documents into 
various taxonomies based on pre-defined set of categories. In this way papers reporting 
research in a similar domain can belong to the same category. The cluster labels assigned 
to taxonomies aid new researchers to locate new concepts among the pool of papers, 
whilst allowing experts to explore hierarchically clustered documents to effectively 
identify papers reporting specific concepts (Chen et al., 2006).  
 
The categories used for clustering could be Gene Ontologies, genomic features or any 
shared biomedical concepts. Notable projects such as BioCreAtIvE challenge (Critical 
Assessment of Information Extraction in Biology) and Knowledge Discovery and Data 
Mining (KDD) Challenge Cup (Yeh et al., 2003) developed systems to locate short text 
passages that shared similar Gene Ontology annotations for specific proteins found in 
full-text articles. Text categorization concept has been implemented in the development 
of the automatic classification software, a document classification engine capable of 
classifying papers into topic-based hierarchy (Chen et al., 2006). The engine classifies 
over 7000 papers housed in Textpresso (Müller et al., 2004b) by using two-stage 
technique composed of a support vector machine-based classifier and a newly developed 
phrase-based clustering algorithm. Although the text classification has been optimized for 
Caenorhabditis elegans related papers by using human-created rules composed of an 
inventory of terms associated with each topic, it is amenable to any types of document 
sources. The usefulness of this system is illustrated as follows: classification of papers 
based on “Sex Determination category” returned the following top ranked clustered 
output: “hermaphrodite male”, “sex determination”, “development gene”, “development 
cells”, “cells fate”, „vulval cells”, “cell signaling”, “fate signaling”, “precursor cell” and 
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“signaling induction”. These results allow the user to analyze the papers according to sex 
determination sub-categories making it easier to avoid the herculean task of manual 
sorting. Another popular text categorization software platform developed by Vivisimo 
(Taylor, 2007) uses a different approach by allowing documents to be categorized into 
descriptive folders without classifying into taxonomies. Elsewhere (Aphinyanaphongs 
and Aliferis 2003; 2005), text categorization models were built to successfully categorize 
content-specific and high-quality PubMed articles to aid in Evidence Based Medicine 
(EBM) and were reported to outperform text mining systems employing preconstructed 
Boolean-based queries such as PubMed clinical query filters. On the contrary, caution 
must be exercised when comparing the performances of two different text mining 
systems since it is very tempting to make conclusive inferences based on recall, precision 
and F-score values without considering the fact that each system operates under 
characteristically different environment with unique merit. 
 
 
1.3.4 Named Entity Recognition (NER) 
This process identifies and extracts biomedical entity names from published text and 
assigns them to predefined semantic categories with similar topical characteristics. In 
certain instances, the terms “entity” and “concept” are interchangeable leading to the 
analogy “named concept recognition”. Therefore concepts or entities can be names of 
genes, proteins, diseases, pathways, drugs or pharmacological substances and may belong 
to different categories which can be referred to as dictionaries (Kwofie et al., 2011). 
There are instances where categories consisting of biomedical entities are organized into 
ontologies, a catalogue of concepts, objects and their relationship (Müller et al., 2004b). 
Some of the relations generally present in almost any domains are “-is a” and “part-of”, 
whiles model domain-specific relations are exemplified by “has-location” and “clinically-
associated-with” (Spasic et al., 2005). NER is particularly useful since it circumvents the 
difficult process of biologists having to manually scan through a large amount of 
published articles to locate biomedical entities. Accurately predicted terms (entities) can 
be used to augment existing biological database entries or used to infer relationships for 
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hypothesis generation. Additionally, the terms may provide indices into literature to aid 
in research result communication (Hirschman et al., 2002). The earlier NER tools were 
designed based on variety of techniques that sought to tackle some of the major 
difficulties usually encountered in developing automated text recognition systems, 
including named entity variant structural characteristics, name ambiguities, the 
unavailability of common standards and fixed nomenclatures, and different 
morphological description of entities in the biomedical text (Franzén et al., 2002). 
Furthermore, systems developed from precompiled dictionaries may not be able to 
recognize new entities present in recently published text.  
 
Approaches used in developing NER systems have been categorized into 3 broad 
techniques (Cohen and Hunter, 2008; Torii et al., 2009) consisting of (i) rule/pattern-
based systems characterized by hand-written rules, (ii) statistics or machine-learning-
based systems and (iii) entity lookup system via pre-compiled dictionary. Some of the 
systems employing the handcrafted rule-based techniques are PROSPER (Fukuda et al., 
1998), Yapex (Franzén et al., 2002), ProMiner (Hanisch et al., 2003; 2005), GAPSCORE 
(Chang et al., 2004), Text Detective (Tamames, 2005) and another described elsewhere 
(Narayanaswamy et al., 2003). The dictionary lookup systems are ProtScan (Egorov et 
al., 2004), HMMs (Kou et al., 2005), NLProt (Mika et al., 2004) and others (Tsuruoka 
and Tsujii, 2004; Koike et al., 2005; Tsuruoka et al., 2007; Sasak et al., 2008). Examples 
of machine learning-based systems are BANNER (Leaman and Gonzalez, 2008), 
PowerBioNE (Zhou et al., 2004), BioCreAtIvE task 1A/II (Yeh et al., 2005; Smith et al., 
2008), POSBIOTM-NER (Song et al., 2005) and others (Proux et al., 1998; Lee et al., 
2004; Li et al., 2011). Ideally, NER systems are developed by combining all or some of 
the above-mentioned approaches (BioTagger-GM, Torii et al., 2009). 
 
Additionally, each text mining implementation approach has peculiar advantages or 
disadvantages over others. For instance, dictionary-based systems intrinsically provide ID 
information for recognized terms by matching them to identical terms in the pre-
constructed dictionary, thereby making this approach the preferable choice within the 
earlier stages of the named entity extraction pipelines (Tsuruoka and Tsujii, 2004). 
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Unfortunately, dictionary-based approach is besieged with poor recognition of short 
names resulting in high rate of false positives with concomitant decrease in overall 
precision during evaluation, and this hurdle is remedied by using machine learning 
approaches to heuristically filter out the false positives (Tsuruoka and Tsujii, 2004). 
Concerning fine-tuning of systems, machine learning techniques are easy to tune to new 
domains once the tagged training dataset is available but the rule-based system requires 
laborious human analysis to obtain a transparent system easier to fine-tune, expand and 
support (Franzén et al., 2002). Interestingly, the supervised machine learning approach 
has a disadvantage since it sometimes requires a large amount of error-free annotated 
corpus that needs a lot of time and extensive energy to create (Narayanaswamy et al., 
2003). This deficiency has been circumvented by using rule-based approaches which 
exploits surface clues and simple linguistic as well as domain knowledge to locate 
relevant named entities in biomedical text (Narayanaswamy et al., 2003). 
 
 
1.3.5 Information extraction (IE) 
IE is the automated extraction of structured information from bibliome to generate 
relationships between biomedical concepts and hypothesis (Figure 1.8). The notable 
approaches for relation extraction are co-occurrence-based, pattern-matching, and natural 
language processing systems.  
 
 
1.3.5.1 Co-occurrence methods 
The simplest IE approach used to infer relationship between entities is the detection of 
co-occurring entities within an abstract, sentence or a phrase (Ding et al., 2002; Wren and 
Garner, 2004). If two biomedical concepts such as proteins appear together frequently in 
separate abstracts, the likelihood that a functionally relevant relationship exist between 
these proteins is high. Ideally, relationships suggested from co-occurrences are usually 
vague and it is impossible to infer the type or direction of the relationships (Fundel et al., 
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2007). Furthermore, it is not easy to differentiate between either direct or indirect 
relationships amongst entities (Jensen, 2006). 
 
Generally, co-occurrence-based methods are combined with other machine learning or 
natural language processing techniques to detect relationships between entities. For 
instance, a Hebbbian-type of learning algorithm, known as associative concept space 
(ACS) has been employed in combination with co-occurrence method to extract 
biological relationships between genes using meta-analysis of scientific texts (Jelier et al., 
2005). Two genes co-occur if they are co-mentioned in the abstract, title or medical 
subject headings (MeSH) index of the text document. Co-occurrences between genes are 
weighted by using a co-occurrence matrix containing the number of times genes from a 
given set co-occur. For integration with ACS, only co-occurrences weighted above a 
specified minimum threshold are included for further analysis. ACS is a 
multidimensional Euclidean space composed of thesaurus concepts which are positioned 
in space and the computed distance existing between concepts is an indication of their 
supposed relatedness. ACS is ideal for relationship extraction when compared to a simple 
co-occurrence method because ACS has the potential to identify more detailed functional 
biological relationships and can also achieve better results with less literature per gene 
(Jelier et al., 2005). Similarly, co-occurrence method was integrated into the 
implementation of PubGene, an online database with variety of tools for gene-expression 
analysis (Jenssen et al., 2001). Pre-constructed gene-article index was used to generate a 
network composed of nodes denoting genes and edges representing co-occurrence of 
genes symbols or short gene names in the title or abstract of the same MEDLINE article. 
The detected associations between genes were mapped onto Gene Ontologies and MeSH 
index annotations. As usual, co-occurrence support the premise of meaningful biological 
relatedness and this assertion was validated to a reasonable extent by analyzing data from 
three large-scale experiments. Other works describing the use of co-occurrence methods 
for elucidating biological relationships between entities are reported elsewhere (Stapley 
and Benoit, 2000; Chaussabel and Sher, 2002; Alako et al., 2005; Chun et al., 2006; 
Gabow et al., 2008). Under certain circumstances, co-occurrence based IE methods can 
provide high recall but may possess poor precision than natural language processing, and 
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are employed preferable as baseline method for comparing other techniques 
(Zweigenbaum et al., 2007). Additionally, co-occurrence method is employed suitably as 
a component of exploratory tools such as STRING (von Mering et al., 2005) and Prolinks 
(Bowers et al., 2004) because of their potential to identify almost any kind of 
relationships (Jensen, 2006).  
 
 
1.3.5.2 Natural language processing 
Natural language processing (NLP) employs parser-based techniques that involve 
automated analysis of sentence syntax and semantic structures to recognize meaningful 
relationships between concepts or entities found in biomedical text corpus. NLP 
relationship extraction techniques can be loosely categorized into full parser-based and 
shallow parser-based systems. Shallow parsers partially reconstruct the structure of an 
entire sentence and are based on extraction of local dependencies between phrasal 
components. Shallow parsers are very simple to implement, much more efficient and 
robust. On the contrary, full parsers consider the structure of an entire sentence and 
though they appear inherently complex, domain sensitive and time consuming, they can 
be fine-tuned to provide more accurate results (Daraselia et al., 2004; Huang et al., 2006). 
 
A full parser-based approach was implemented in MedScan, an automated system for 
extracting interactions between proteins from MEDLINE abstracts (Daraselia et al., 
2004). Additionally, the system is capable of extracting different types of protein function 
information encoded as extendable ontology with high precision. MedScan is 
implemented in three steps: (i) preprocessor module for tagging protein names, (ii) NLP 
engine composed of syntactic parser and semantic processors, and (iii) information 
extraction module which function as a domain-specific filter for sentence structures and 
present extracted information as concept graph. A total of 2976 human protein 
interactions have been extracted from MEDLINE abstracts published after 1988 and it 
achieved precision of 91%. When MedScan interactions were compared with key 
databases (BIND and DIP), about 96% of extracted information were novel. Interestingly, 
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the system achieved a recall rate of 21%. Other systems incorporating full parsing 
techniques are described elsewhere (Park et al., 2001; Leroy and Chen, 2002). 
 
A foremost example of NLP shallow parser-based system was implemented in 
Genescence, a database housing relations extracted from MEDLINE abstracts pertaining 
to essential topics such as p53, AP-1 and yeast (Leroy et al., 2003). This parser is 
composed of semantic module for capturing abstract contents and structure module 
composed of cascaded finite state automata (FSA) for capturing sentence structure as 
well as modeling relations. Sentence structure capture involves shallow parsing closed 
class English words for effective detection of relations between noun phrases in 
biomedical text. Three cancer researchers from the Arizona Cancer Center evaluated 330 
relations extracted from 26 abstracts in their area of expertise. A total of 296 relations 
were rightly extracted from the abstracts resulting in precision of 90% and overall 
average of 11 rightly extracted relations per abstract. The system is able to extract variety 
of relations using small number of rules and also mines more relations per abstract since 
relations are not restricted to specific verbs or unique entities (Leroy et al., 2003). 
Relationship extraction has been employed as part of the techniques to successful mine 
gene/protein biological functions from biomedical literature (Koike et al., 2005). In this 
system, a text sentence is shallowly parsed after which an adopted rule-based sentence 
structure analysis approach is used to extract the ACTOR (doer of action) and OBJECT 
(receiver of action) relationships. This system extracted from PubMed more than 190 000 
gene-gene ontology (GO) relationships and 150 000 family-GO relationships for major 
eukaryotes. Additionally, it achieved recall and precision ranges of 54-64% and 91-94% 
respectively for actual functions described in abstracts. An earlier system developed 
based on a shallow parser (EngCG) was able to retrieve interaction between genes and 
gene products based on frequently seen verbs in MEDLINE abstracts (Sekimizu et al., 
1998). It achieved precision rates of 90% and about 73% in identifying noun phrases and 
the right subject and object for each verb in text corpus respectively. Pustejovsky et al. 
(2002) developed a robust system for extracting inhibition relations from biomedical text. 
The system involves the construction of semantic automata from UMLS database to aid 
extraction of target relations and application of corpus analytics on MEDLINE sentences 
 
 
 
 
 30 
pertaining to the target relations. Broadly, it consists of shallow parsing, relation 
identification and anaphora resolution modules. System evaluation achieved precision of 
90%, recall 57% and partial recall 22%, consolidating its potential as an efficient corpus-
based linguistic system. A pragmatic approach for the automatic extraction of 
information concerning gene interactions was reported (Proux et al., 2000). The approach 
entails the use of linguistics systems consisting of part-of-speech tagger and shallow 
parser, and knowledge processing module for generating semantic representation from 
pre-extracted syntactic dependencies. The text corpus consists of a set of 1200 sentences 
enriched with gene interaction information obtained from FlyBase, a database on 
Drosophila melanogaster (FlyBase Consortium, 2002).  
 
A NLP-based tool using semantic dependency parse trees for extracting physical, genetic 
and regulatory relations between gene and proteins from MEDLINE abstract is RelEx 
(Fundel et al., 2007). This system employs dependency, part-of-speech taggers, simple 
rules and noun phrase-chunker. The dependency parse trees are built using Stanford 
Lexicalized Parser and they enhance the harnessing of complex phrasal relationships 
using few tree rules. RelEx identifies potential candidate relations by harvesting paths 
connecting pairs of nodes consisting of genes in the dependency parse trees. The system 
was used to mine about 150 000 relations from one million MEDLINE abstracts 
pertaining to gene and protein relations, and achieved 80% precision and 80% recall. 
RelEx is simple to implement and reproducible, can deal with complex sentences and 
also identity various types of interactions. 
 
 
1.3.5.3 Pattern-matching  
This approach is based on the premise that word patterns surrounding protein names 
embedded in text sentences can be harnessed to discover clues pertaining to the 
relationships amongst them. It matches part-of-speech tags obtained from segmented text 
sentences against pre-constructed patterns and simple matching rules. The pattern-
matching system avoids the complex sentence analysis of NLP by focusing on a 
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restricted area of interest such as protein-protein interactions, which seem to appear as 
sources of flaws and decreased performance in NLP. A popular pattern-based system for 
automated extraction of protein-protein interaction from biological text has been 
described by (Ono et al., 2001). This system combines protein name lookup via named 
protein dictionary, surface clues on word pattern and rule-based part-of-speech tagging. 
The performance of this system was evaluated on text sentences using yeast (recall = 
86.8% and precision = 94.3%) and E.coli (recall= 82.5% and precision = 93.5%) protein 
named dictionaries. The high rates of precision and recall achieved pinpoint to the fact 
that this approach can be adopted for any species-specific name protein dictionary.  
 
SUISEKI is another system for automated detection of protein names as well as 
biological interactions (Blaschke and Valencia, 2001). The steps here describe the 
implementation of SUISEKI: (1) text corpus obtained from user query via MEDLINE is 
segmented and parsed by part-of-speech tagger to serve as data source. Rule-based 
algorithm and dictionaries are combined with data source to detect protein names, (2) 
sentences containing a minimum of two detected proteins are matched against predefined 
protein interaction description frames and (3) the resultant data is housed in a protein-
protein interaction database equipped with an integrated user query interface which 
provide modules for analysis and protein information extraction on synonyms and 
functional descriptions. The efficiency of SUISEKI is demonstrated by the fact that 
majority of identified interactions have higher chances of being true interactions. A total 
of 4657 interactions were extracted from 5283 abstracts pertaining to cell cycle corpus. 
The system achieved between 80% to 50% precision range for high scoring interactions 
to low scoring ones, and relatively highly recall of more than 70%.  
 
The HypertenGene system automatically extracts etiological relations among genes and 
diseases in text sentences by combining the advantages of machine learning models and 
pattern matching including part-of-speech (POS) patterns and extracted phrase chunk 
features (Tsai et al., 2009). Both NLP and pattern match-based systems display 
deficiencies in their output results.  Even though NLP defy the simplicity and robust 
character of pattern matching systems, pattern-matching systems overlooks coordinative, 
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conjunctive and appositive grammatical structures of text (Huang et al., 2006). A hybrid 
system has been developed as response to the above deficiencies, by integrating a shallow 
parser to improve remarkably the performance of pattern matching to extract relations 
between proteins from biomedical texts (Huang et al., 2006). This system achieved an 
average F-score of 80% and 66% on individual verbs and all verbs respectively. The 
shallow parser enabled the system to achieve 7% increase in both F-score and precision 
when compared to the traditional pattern matching-based systems. As part of the 
implementation, the shallow parser analyzes the coordinative and appositive structures, 
followed by the application of pattern matching on segmented long sentences to enhance 
matching precision. Prior to matching, the coordinative structures are encapsulated and 
then unfolded after extracting. A dynamic programming algorithm computes unique 
patterns by aligning relevant sentences and key verbs that describe protein interactions 
and thereafter, a matching algorithm extract the interaction relations (Huang et al., 
2004a). 
 
 
1.3.5.4 Hypothesis generation and Literature-based discovery (LBD) 
Relationship extraction deals with harvesting relationships between biomedical entities 
explicitly stated in a text corpus whiles hypothesis generation aims to unravel implicit 
relationships existing between disjoint sets of literature pertaining to biomedical 
concepts. The implicit relations could lead to unraveling of plausible novel 
knowledge/discovery, which is potentially testable and worthy of further exploration. 
Swanson originally popularized the concept of text-mined hypothesis in his famous 
derivation of fish oil/Raynaud‟s diseases hypothesis. He used disjointed sets of literature 
pertaining to both fish oil and Raynaud‟s diseases to propose a therapeutic relationship 
between them. The fish oil/Raynaud‟s disease hypothesis relied on the premises that: (a) 
fish oil decreases platelet activities, vascular reactivity, and blood viscosity, and (b) these 
same physiological changes ameliorate Raynaud‟s symptoms (Swanson, 1986). This 
“premier” hypothesis was confirmed later in a study involving the clinical effects of fish-
oil fatty acid ingestion in patients with Raynaud‟s symptoms (DiGiacomo et al., 1989), 
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where fish oil was demonstrated to have beneficial effects by delaying the onset of 
Raynaud‟s disease complications. Similar hypothesis were proposed for Migraine and 
Magnesium, as well as Somatomedin C and Arginine (Swanson et al., 1990). The above 
hypothesized discourses influenced the proposition of the concept known as the 
complementary structures in disjoint science literatures (CSD) (Swanson, 1991). 
Complementary means the relationship between two separate scientific arguments, which 
when consolidated together could yield inferences or insights that are not obvious in the 
separate arguments. Disjoint literature refers to the scenario when literatures are not co-
cited or co-mentioned and have no articles in common. The CSD has been simplified in a 
concept widely referred to as Swanson‟s ABC discovery model (Figure 1.9), which 
stipulates that if a concept A associate with B, and B associate with C, then there could 
be implicit relationship between concepts A and C (Weeber et al., 2003). A current 
approach assigns statistical weights to the strength of the hidden relationship (Frijters et 
al., 2010). The ABC model is further reconstructed separately into hypothesis generating 
approach referred to as the open discovery system (Figure 1.10) and a testing approach 
known as the closed discovery system (Weeber et al., 2001; Figure 1.11). The open 
discovery system is analogous to Swanson‟s Fish/Raynaud‟s disease hypothesis, where a 
starting concept that connects to a linking concept, also connect to the target concept. The 
open discovery approach leads to hypothesis generation that originate from the quest to 
answer a specific scientific problem. The closed discovery system involves the use of a 
bridging concept to establish a link between two other concepts that do not directly co-
occur. This also involves the testing and explanation of already generated hypothesis. For 
example, starting from a disease concept C and substance A, the researcher can 
intuitively find common intermediate B-terms. If reasonable number of “pathways” are 
found between A and C, then the propensity for it to be a potentially insightful hypothesis 
is high (Figure 1.11). The differences between the two discovery approaches are that, 
literatures pertaining to C and B are interrogated in the open discovery whiles literatures 
on C and A are interrogated in the closed discovery system. The open and closed 
discovery processes have been simplified in Figure 1.12 (Cohen et al., 2010a). 
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FIGURE 1.9. THE SWANSON‟S ABC DISCOVERY MODEL.  
The solid arrows denoted by AB and BC represent explicit relationships. The dashed 
arrows denoted by AC represent an implicit relationship and may serve as a potential 
source of novel hypothesis (Weeber et al., 2003). 
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FIGURE 1.10. OPEN DISCOVERY SYSTEM.  
The starting, linking and target concepts are CBA respectively. Solid arrows indicate 
“pathways” worthy of further exploration for discovery, and the dashed ones are 
“pathways” that do not lead to discoveries (Weeber et al., 2001). 
 
 
 
FIGURE 1.11. CLOSED DISCOVERY SYSTEM.  
The starting concepts are C and A. Concept Bs result from C and A overlapping. Solid 
arrows indicate “pathways” worthy of further exploration for discovery, and the dashed 
ones are “pathways” that do not lead to discoveries (Weeber et al., 2001). 
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FIGURE 1.12. A SIMPLIFIED VERSION OF THE OPEN AND CLOSED DISCOVERY SYSTEMS.  
In both instances, the starting concept A for generating discoveries has thick borders, and 
the target or endpoint concepts are surrounded by starbursts (Cohen et al., 2010a). 
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A typical biological example of closed discovery system is illustrated here. Among 
patients suffering from multiple myeloma treated with thalidomide, some experienced 
improvement in chronic hepatitis C. A closed system approach will involve trying to 
unravel the potential mechanisms underpinning how thalidomide treats chronic hepatitis 
C (Weeber et al., 2005).  
 
Although original implementation of LBD involved overwhelming human intervention, 
current approaches are augmented with automated systems developed using machine 
learning/statistical models and/or NLP techniques. LBD is defined as computer-aided 
generation of functionally relevant hypotheses with potential for further scientific 
exploration. A number of LBD systems have been implemented using co-occurrence-
based approaches (Cohen and Hersh, 2005; Weeber et al., 2005). Additionally, LBDs 
have been utilized to simulate already published or described novel discoveries (Weeber 
et al., 2000; Weeber et al., 2003; Kwofie et al., 2011). The limitations of co-occurrence-
based systems are that they sometimes overlook semantic nature of the inferred relations 
and may not offer any concrete explanation for the generated hypothesis, and users are 
required to scrutinize manually the myriad of texts accompanying the suggested 
hypothesis (Hristovski et al., 2006). The performance of co-occurrence-based approach 
has been improved in BITOLA (Hristovski et al., 2005) by integrating with NLP derived 
semantic predications extracted from SemRep (Rindflesch and Fiszman, 2003) and 
BioMedLee (Lussier et al., 2006). This integrated approach provides details and support 
explanation for inferred discoveries or relationships. The system exhibited the potential to 
achieve fewer numbers of false positive results. Another LBD system, EpiphaNet (Cohen 
et al., 2010a), has been implemented using predication-based semantic indexing (PSI) 
and reflective random indexing (RRI). RRI is a scalable method for detecting implicit 
connections (Cohen et al., 2010b). Additionally, RRI methods augment the ability of 
EpiphaNet to harvest associations between concepts or terms that do not directly co-
occur. The predications used in EpiphaNet were also obtained from SemRep (Rindflesch 
and Fiszman, 2003) by mining abstracts and MEDLINE titles. In simple terms, 
predications are also referred to as "object relation object triplets", for example, "merlot 
IS-A wine". PSI enables the quick extraction of strongly associated concepts based on 
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their distribution across all of the predications present in SemRep (Cohen et al., 2010a). 
A similar LBD approach which does not depend on direct co-occurrence of concepts 
within abstracts of journal articles was used to generate a ranked hit list of genes related 
to periodontitis and atherosclerosis (Hettne et al., 2007). This approach generates concept 
vectors that represent the textual context surrounding a specific concept. Entities sharing 
most common concepts have much higher likelihood of being associated with each other 
and likely to be assigned higher association scores. Association based on overlapping or 
sharing of concepts has also been implemented in CoPub, a LBD system (Frijters et al., 
2010). 
 
The future potential of text mining systems, including LBDs far outweighs their 
limitations for the simple reason that information retrieval/extraction systems are still 
considered as potent approaches that can be used to glean knowledge from enormous 
amounts of published texts. Irrespective of the accuracy or statistical scores assigned to 
generated hypothesis, interpretive exploration of biomedical literature can still serve to 
augment the logic underpinning the discovery.  
 
 
1.4 Protein-Protein Interactions 
A typical pathway consists of a series of interconnected cellular events between 
biomolecular entities such as proteins, genes and metabolites (Chowbina et al., 2009). 
Furthermore, it is estimated that 80% of proteins do not operate alone but in complexes, 
and protein-protein interactions (PPIs) constitute a part of a bigger cellular network 
(Berggård et al., 2007). Therefore cataloging PPIs is key for the study of protein 
interactome to enhance current understanding of regulatory mechanisms.  
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1.4.1 Efforts towards harnessing predicted protein-protein interactions 
Section 1.3.5 of this thesis deals comprehensively with text mining approaches and tools 
used in extracting PPI information from published biomedical texts. Efforts towards 
developing robust and efficient text mining extraction models were given a boost under 
BioCreative II (Krallinger et al., 2008), a community platform that dealt with tasks for 
evaluating algorithms employed in extracting PPI. The task assigned to the teams were (i) 
identifying protein interaction relevant articles; (ii) harvesting and normalizing protein 
interaction pairs; (iii) cataloging experimental methods used in detecting interactions; and 
(iv) retrieving the blocks of text reporting the protein interactions. Some of the 
difficulties encountered by the task teams were: conversion of full text article formats, 
detecting, annotating and cross referencing of PPI to external databases. Other limitations 
were in the field of protein name normalization, restricting PPIs elucidation to co-
occurrence techniques and the complexities involved in distinguishing between novel, 
already known or experimentally determined PPI. Nevertheless, BioCreative II was 
useful because benchmark datasets for both training and testing of models were made 
available for comparing the performance of various algorithms and it also provided 
standardized approaches for comparing text-mining procedures with manual annotation 
of PPIs (Chatr-aryamontri et al., 2008). 
 
Other computational methods used for modeling and predicting PPI are based on co-
evolution (Pazos et al., 2008; Sharon et al., 2009; Lewis et al., 2010), combination of 
structural information and sequence pattern in protein interfaces (Aytuna et al., 2005; 
Espadaler et al., 2005; Keskin et al., 2008), and domain-domain interactions (Singhal and 
Resat, 2007; Yellaboina et al., 2011). To support current usage of machine learning 
models for predicting PPIs (Chen et al., 2008; Martin et al., 2008; Guo et al., 2010), a 
number of resources are being developed to provide protein specific features as training 
datasets. KUPS (The University of Kansas Proteomics Service) provides high quality 
benchmark data for developing and evaluating PPI prediction algorithms (Chen et al., 
2011). KUPS provides lists comprising of interacting protein pairs (IPPs) as positive data 
and non-interacting protein pairs (NIPs) as negative data, as well their features for each 
data point (instance). While protein interaction datasets are currently readily available for 
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downloads from many databases but obtaining non-interaction datasets with computed 
machine learning features used to be a difficult task. Negatome (Smialowski et al., 2010) 
and GRIP (Browne et al., 2009) are additional web-based resources providing non-
interacting protein pairs for mammalian models (experimentally supported) and 
Saccharomyces cerevisiae (both IPPs and NIPs) respectively. Even though both 
Negatome and GRIP presently do not provide computed features, they do in fact augment 
existing PPI resources. Another community platform that provide benchmark dataset for 
assessing the quality of predicted PPI through structural analysis of protein complexes is 
the Critical Assessment of PRedicted Interactions (CAPRI) experiment which started in 
2000 (Janin, 2005). These efforts have led to the introduction of two scoring functions 
based on the similarity of the interfaces of the complex, namely interfacial Template 
Modeling score (iTM-score) and Interface Similarity score (IS-score). The iTM-score 
calculates the geometric distance between the protein interfaces whiles the IS-score 
calculates residue-residue contact similarity plus their geometric similarity (Gao and 
Skolnick, 2011). Plewczyński and Ginalski (2008) have comprehensively reviewed some 
of the approaches and challenges involved in predicting PPIs, and additionally have 
supported the consensus approach adopted by Sen et al. (2004). Sen et al. (2004) 
employed a metadata mining approach by combining support vector models, protein 
structural threading, phylogenetic analysis to predict conserved residues on protein 
interfaces, and the Conservatism of Conservatism method of Mirny and Shakhnovich 
(1999). It was illustrated that the combinatorial approach yielded improved predictions 
over the individual methods. 
 
A trend has emerged where some databases house both experimental and computationally 
derived PPI obtained from multiple data sources. HAPPI, the Human Annotated Protein-
Protein Interactions contains data integrated from complementary sources consisting of 
the HPRD, BIND, MINT, STRING, and OPHID databases (Chen et al., 2009). 
Experimentally derived PPIs data from both low and high-throughput techniques are 
obtained from BIND and HPRD; literature curated PPI from BIND; text-mined PPI from 
STRING; and computationally predicted PPI from both STRING and OPHID. HAPPI 
assigns confidence scores ranging from 1 to 5 to enable users gauge the reliability of the 
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interactions and also enhance the generation of high confidence interaction networks. The 
interaction data in HAPPI is also enriched with computed annotations, including 
biological pathways, gene functions, protein families, protein structures, sequence 
features, and literature sources. 
 
As mentioned earlier, STRING, a Search Tool for the Retrieval of Interacting Genes also 
provides comprehensive and reliable PPI data composed of both experimentally 
determined and predicted interaction information (Szklarczyk et al., 2011). As in the case 
of HAPPI, STRING also provides confidence scores for judging reliability of interactions 
and interacting partners are mutually cross-referenced via HTML with a number of 
popular knowledgebases, including UniProt (UniProt Consortium, 2010), SMART 
(Letunic et al., 2009), GeneCards (Safran et al., 2010) and SwissModelRepository (Kiefer 
et al., 2009). In STRING, interactions are not restricted to direct, physical interactions 
between two proteins but proteins can also be linked when they exhibit a genetic 
interaction or are reported to catalyze subsequent steps in a regulatory or metabolic 
pathway. Most associations between proteins inferred using prediction algorithms cannot 
be defined precisely in the context of their mode of interaction, nor cellular conditions 
under which they occur, and may be viewed rather as functional associations (Szklarczyk 
et al., 2011). Other resources providing predicted PPI data are PIPs (McDowall et al., 
2009), IntNetDB (Xia et al., 2006), POINT (Huang et al., 2004b), HPID (Han et al., 
2004a), PreSPI (Han et al., 2004b), PIPE (Pitre et al., 2006) and OPHID (Brown and 
Jurisica, 2005). 
 
 
1.4.2 Towards the storage and utilization of curated protein-protein 
interactions 
Experimentally derived PPI data is primarily obtained from: (i) literature-curated 
interactions and (ii) directly from both low throughput and large scale screening of pair-
wise physical interactions (de Chassey et al., 2008). Literature-curated interaction 
datasets are hypothesis-driven and may allow the determination of biological functions of 
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the interacting proteins from the actual study while high-throughput datasets are 
discovery-based but are not geared towards inferring of functions of the interacting 
proteins (Cusick et al., 2009). High-quality binary interaction information is warehoused 
in public databases for protein interactome exploration. The notable detection and 
analysis methods (Phizicky and Fields, 1995) for protein-protein interactions are: (i) 
physical methods to select and detect proteins that bind another protein (e.g. affinity 
chromatography, affinity blotting, immunopreciptation and cross-linking); (ii) library-
based methods (e.g. protein probing, phage display and two-hybrid system (high-
throughput technique)); and  (iii) genetic methods (e.g. extragenic suppressors, synthetic 
lethal effects and overproduction phenotypes). Techniques for verifying PPIs are 
confocal microscopy for intracellular colocalization of proteins, coimmunoprecipitation, 
surface plasmon and spectroscopic studies (Berggård et al., 2007). Additionally, 3-
dimensional X-ray crystallography and nuclear magnetic resonance structural analysis are 
used to elucidate PPI. Comprehensive reviews detailing the merits and demerits of the 
various interaction detection methods are discussed elsewhere (Lalonde et al., 2008). 
 
Since curated interactions and their associated metadata can be obtained from multiple 
database sources, a concerted effort must be made to provide standardized and 
comprehensive procedures for judging the quality of the data sources. Metamining 
databases consist of consolidated PPIs obtained from multiple source databases. 
Metamining database authors may choose not to integrate some data from their sources 
based on in-house curation quality checks. Therefore a user queried interaction may fail 
in the metamining database, even though it is present in the source data (Plewczynski and 
Klingström, 2011). Furthermore, each source database may assign its own unique 
identifiers to interaction metadata, necessitating the need to unify multiple database 
identifiers pertaining to the same query. The “Good Interaction Data Metamining 
Practice” standard (GIDMP) has been proposed (Plewczynski and Klingström, 2011) and 
when adopted could provide PPI warehousing community with: (i) a standardized 
approach to judging the statistics made available by each metamining database, thus 
enhancing user satisfaction; (ii) a stable contact point for each database, enabling the 
smooth transition of statistics; and (iii) a fully automated system, enhancing time- and 
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cost-effectiveness. It is recommended that databases complying with GIDMP standards 
should provide a page titled Source Databases (SourceDB) composed of a table 
consisting of columns that capture relevant information and statistics. The table would 
consist of seven columns arranged in the order: name of source database, link to resource, 
notes, version, latest version, and coverage. The first five columns are static data 
provided by the metamining database authors and the last two are obtained from the 
source database. It is expected that a simple script would be embedded within the www 
pages of both metamining and source databases to automatically update the last two 
columns thereby providing synchronized information including statistics.  
 
An empirical approach has been employed to quantitatively evaluate the level of 
agreement across major public databases concerning curated PPI data (Turinsky et al., 
2010). The analysis was carried out on a global landscape of PPI data that was 
consolidated from nine key databases that are known to be composed primarily of curated 
experimentally detected physical interactions: BIND, BioGRID, CORUM, DIP, IntAct, 
HPRD, MINT, MPact and MPPI. The iRefIndex (Razick et al., 2008) and iRefWeb 
(Turner et al., 2010) were used for both data consolidation and analysis. The analysed 
data comprised of 271,716 distinct physical interactions involving 7,449 proteins 
associated with 1324 different organism-taxonomy identifiers and were gleaned from 
42,651 publications. Computationally predicted and genetic interactions representing 
phenotype alterations produced by the mutation/deletion of genes were excluded from the 
analysis. Annotated PPI data derived from the same journal article but co-cited by 
different databases were evaluated for agreement using similarity scores. After 
quantifying agreement between curated interactions from a total of 15,471 publications, 
the results revealed that on average, two databases fully agree on 42% of the interactions 
and 62% of the proteins curated from the same publication. It further revealed that a 
sizeable portion of the measured differences could be attributed divergent annotations of 
organism or splice isoforms, different organism focus and alternative representations of 
multi-protein complexes. This study highlights the impact of the divergent in-house 
curation policies of data providers (Turinsky et al., 2010) and is a motivator for the PPI 
research community to adopt data standardization practices. To buttress above concerns, 
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evaluation of existing curations of protein interaction experiments reported in journal 
articles revealed that curation could be error-prone and that the quality may be of lower 
standard than what is already assumed (Cusick et al., 2009). 
 
A large amount of PPI data emanating from both small- and large-scale experiments are 
scattered across databases, web pages or in journal articles prompting the need to unify 
and standardize details describing such interactions. The Human Proteome Organization 
Proteomics Standards Initiative Molecular Interactions (HUPO PSI-MI) format XML1.0 
was established as a single, unified format by which molecular interactions, particularly 
PPIs are presented (Hermjakob et al., 2004). Notable interaction data producers and 
providers, including BIND, DIP, IntAct, MINT, MIPS, Hybrigenics and STRING, jointly 
formulated this community standard data model for representation and exchanging of PPI 
data. Included in the PSI-MI schema are the controlled vocabularies (CVs), which are 
used to standardize the meaning of data objects. The continuous use of CVs prevents data 
providers from using synonyms or name variants repeatedly and also allow consistent 
interpretation of terms among multiple data producers and users. The CVs are 
hierarchically structured and consist of higher and lower level descriptors assigned to 
parents and child terms. This organization enables data to be annotated to an appropriate 
level of granularity and enhance easy retrieval of information by search tools via the child 
and parents terms when applicable. The CVs are maintained in the Open Biological and 
Biomedical Ontologies web pages (Smith et al., 2007) accessible via 
http://www.obofoundry.org/ and can also be retrieved using the EBI Ontology Lookup 
Service (Barsnes et al., 2010) accessible via http://www.ebi.ac.uk/ontology-lookup/. For 
illustration purposes, a binary protein interaction between two protein molecules inferred 
using yeast two hybrid as detection method is assigned the PSI-MI term name “two 
hybrid” and term ID “MI:0018”. Currently, PSI-MI has been updated to PSI-MI XML2.5 
and MITAB2.5 formats to facilitate data exchange among repositories and users without 
loss of information. The updated version expanded the scope of the described interactions 
to cover a broader range of molecular types, including nucleic acids, chemical entities, 
and molecular complexes. PSI-MI XML2.5 provides detailed description about each 
molecular interaction, including the biological role of each interacting molecule, 
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interacting domains, and the kinetic parameters governing the interactions. MITAB2.5 
provides only minimal interaction information in a tab-delimited format for easy systems 
configuration through fast Perl parsing or loading into Microsoft Excel (Kerrien et al., 
2007). 
 
It is extremely difficult for curators to extract all the essential information describing PPI 
and associated metadata from published journal articles when authors of such articles 
provide sparse details describing the interactions. Even though enormous amount of 
energy may be spent in trying to guess the missing data in the poorly described 
interaction, this approach is still fraught with error. According to anecdotal estimates, 
about 70% of total curation time is spent by curators on disambiguating molecule 
identifiers (Orchard et al., 2005). The minimum information required for reporting a 
molecular interaction experiment (MIMIx), a community effort seek to provide a 
checklist on information to supply when describing experimental molecular interaction 
data in a journal article, displaying on a web page or incorporating into PPI repositories 
(Orchard et al., 2005). The MIMIx checklist provides details on: (i) interaction 
submission profile, including author contact addresses and publication identifier; (ii) 
experimental setup including host organism taxonomy and interactions in PSI-MI 
ontology vocabularies; (iii) interaction participant list; and (iv) confidence scores 
assigned to the interactions. 
 
Although PPI databases constitute a smaller portion of the total number of reported 
biological databases, it is important that they comply with global approaches aimed at 
promoting consistency and interoperability among knowledgebases as well as semantic 
and syntactic standards. BioDBCore, a community-defined, uniform, generic description 
of the core attributes of biological databases seek to provide guidelines that would help 
achieve the above (Gaudet et al., 2011). BioDBCore would make available a catalogue of 
database attributes contained in a checklist to facilitate the sharing of rich information 
among diverse research communities. Researchers may have easy access to information 
outside their area of expertise by way of browsing the descriptors for various biological 
databases. This approach may enable developers to avoid repeating of routine mistakes 
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committed when implementing new resources. The proposed BioDBCore descriptors are: 
database name, main resource URL, contact information, date resource established, 
conditions of use (free, or type of license), scope (data types captured, curation policy, 
and standards used), Standards (data formats and terminologies), taxonomic coverage, 
data accessibility/output options, data release frequency, versioning policy and access to 
historical files, documentation availability, user support options, data submission policy, 
relevant publications, resource‟s Wikipedia URL, and tools available. BioDBCore is in 
line with the MIBBI project, which aims to promote coherent minimum reporting 
guidelines for biological and biomedical investigations (Taylor et al., 2008). Embracing 
the BioDBCore project could make PPI databases accessible to the greater biological 
community and enhance cross integration of PPI data with other high-throughput data for 
exploration.  
 
 
1.4.3 Available resources and tools for exploring PPI data 
Online repositories do not merely warehouse PPI information but also provide means for 
data exploration, comparison and integration into other secondary databases. Key among 
them is iRefIndex (Razick et al., 2008) and its update iRefWeb (Turner et al., 2010). 
Currently, iRefWeb is made up of data consolidated from 10 public PPI databases, 
comprising of BIND, BioGRID, CORUM, DIP, IntAct, HPRD, MINT, MPact, MPPI and 
OPHID. Notably, iRefWeb provides global view of PPI exploration and also gives users 
the option to examine discrepancies among same PPI information provided by multiple 
databases and be able to choose interactions that closely resemble the reported interaction 
in the journal article. Additionally, statistical summaries of interactions across data 
sources are provided and it also enable evaluation of reliability of interactions based on 
simple modalities such as the number of journal articles reporting interactions and 
whether the detection methods were low or high throughout techniques. The iRefIndex 
database originally provided a unifying index for retrieving PPI data and assigned a key 
for each PPI record and a key for each interacting partner. Using primary sequences of 
the interacting proteins, their taxonomy identifiers and the Secure Hash Algorithm, users 
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can generate these keys. The indexing is useful because redundant or equivalent PPIs are 
assigned as a single group. Additionally, the system enables data integrity to be verified 
and helps to identify problematic PPI entries across different repositories. Other web 
servers or software plug-ins that allow retrieval of consolidated interaction datasets and 
generation of interaction networks are APID (Prieto and De Las Rivas, 2006), 
APID2NET (Hernandez-Toro et al., 2007), MiMI (Tarcea et al., 2008), UniHI (Chaurasia 
et al., 2007), DASMI (Blankenburg et al., 2009), ConsensusPathDB (Kamburov et al., 
2011), BisoGenet (Martin et al., 2010), PIANA (Aragues et al., 2006), BioNetBuilder 
(Avila-Campillo et al., 2007), cPath (Cerami et al., 2006) and BioGRID access tools, 
namely BioGRID REST Service, BiogridPlugin2 and BioGRID WebGraph (Winter et al., 
2011). 
 
Users of PPI data aim to identify multiple-drug targets within pathogenic protein-protein 
interaction networks (PPINs) by way of perturbing known pathways or complexes 
(Hormozdiari et al., 2010) and also by analyzing protein-protein interaction binding 
pockets (Meireles et al., 2010). It is also interesting to note that topological and clustering 
analysis of PPI networks have been employed to predict new interactions (Bu et al., 2003; 
Sen et al., 2006). Therefore software systems and web servers that enable graph theoric 
analysis and modeling of both experimentally and predicted interactions are of optimal 
importance. Some of the available tools for analysis and graph theoric explorations of PPI 
networks are BiNoM (Zinovyev et al., 2008), NetworkAnalyzer (Assenov et al, 2008), 
NeAT (Brohée et al., 2008) and frequently used software libraries, including JUNG- the 
Java Universal Network/Graph Framework (http://jung.sourceforge.net/), LEDA 
(http://algorithmic-solutions.com/leda/index.htm), NetworkX (https://networkx.lanl.gov/) 
and yFiles (http://www.yworks.com/en/index.html). PPI visualization tools or platforms 
are Cytoscape (Smoot et al., 2011), ProViz (Iragne et al., 2005), PIMWalker (Meil et al., 
2005), VisANT (Hu et al., 2009), Osprey (Breitkreutz et al., 2003), and PATIKA (Demir 
et al., 2002) and its web version PATIKAweb (Dogrusoz et al., 2006). A comprehensive 
review on tools for visualizing biological networks is presented elsewhere (Suderman and 
Hallett, 2007). 
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1.5 THESIS RATIONALE 
From the aforementioned (Section 1.2) with particular emphasis on HCV pathobiology 
and therapeutic challenges, it is imperative that diverse approaches must be adapted to 
outwit a “skillful and deceitful medical foe” such as HCV and its accompanying 
pathobiological ramifications. Provision of resources that separately integrate text mining 
and protein-protein interactions can go a long way to aid in the search for therapeutic 
drugs and possibly augment efforts to generate functional hypotheses that can be further 
investigated for the development of non-invasive diagnostic biomarkers and novel 
therapeutics. Computational text mining has been highlighted as an important component 
of the modern-day drug discovery pipelines (Yao et al., 2009, 2010). It has particular 
utility in the following stages: analysis of disease mechanisms and “disease genes”, 
genomics, structure-based compound design, analysis of mechanisms of drug actions, 
toxicology, pharmcovigilance, and drug repurposing. Similarly, text mining and PPI 
feature prominently as part of workflows for the discovery of therapeutic targets or 
diagnostic biomarkers (Figure 1.13). This thesis aims to develop freely available HCV-
focused integrated online resources providing enriched biomedical knowledge as baseline 
information for further exploration and to also aid in computational prediction of 
functional hypothesis of therapeutic relevance. 
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FIGURE 1.13. A DRUG DISCOVERY WORKFLOW. 
The workflow incorporating text mining and protein interaction data combined with other 
high-throughput data (e.g. microarray data mining) to aid discovery of therapeutic targets 
or diagnostic biomarkers (modified from Yang et al., 2009). This workflow supports the 
data mining approach adopted in this research, which involved harnessing of integrated 
data consisting of protein-protein interactions and HCV related hepatocellular carcinoma 
associated genes identified from proteomic and microarray experiments. Text mining 
approach was utilized in proposing literature-based discoveries of therapeutic relevance. 
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1.5.1 Aims and Objectives 
1. Development of HCV-focused web-based text mining resource 
2. Development of HCV online protein knowledgebase 
3. Harnessing the myriad of data in the developed knowledgebases to facilitate 
generation of functional hypothesis of therapeutic relevance. 
 
 
1.5.2 Thesis outline 
This thesis consists of four chapters: 
Chapter 1: 
 Gives a brief over view on: (i) HCV biology and therapeutic challenges, (ii) 
general text mining principles and applications, (iii) extraction and utilization of 
protein-protein interactions, and (iv) thesis rationale and aims (as outlined in this 
section 1.5). 
 
Chapter 2  
 Provides an overview on the development and implementation of an HCV-
customized web-based text mining resource known as the Dragon Exploratory 
System on Hepatitis C Virus (DESHCV) (Kwofie et al., 2011). It further 
describes how DESHCV has been used to reproduce already published literature-
based discovery and also generate novel hypothesis relevant to the current efforts 
geared towards HCV combination therapy search. 
 
Chapter 3 
 Describes the development and implementation of HCVpro, Hepatitis C Virus 
Protein Interaction Database. And demonstrate how the incorporated data in 
HCVpro could be used to generate baseline hypothesis relevant to unraveling 
potential diagnostic markers and therapeutic targets. 
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Chapter 4 
 Discusses the relevance of this work towards ongoing HCV research efforts and 
provides the conclusion of this thesis. Additionally, it discusses the limitations 
and proposes future work.  
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CHAPTER 2: Dragon Exploratory System on Hepatitis C Virus 
(DESHCV) 
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2.1 Abstract 
Even though Hepatitis C Virus (HCV) cDNA was characterized about 20 years ago, there 
is insufficient understanding of the molecular etiology underlying HCV infections. 
Current global rates of infection and its increasingly chronic character are causes of 
concern for health policy experts. Vast amount of data accumulated from biochemical, 
genomic, proteomic, and other biological analyses allows for novel insights into the HCV 
viral structure, life cycle and functions of its proteins. Biomedical text-mining is a useful 
approach for analyzing the increasing corpus of published scientific literature on HCV. 
This is the first reported comprehensive HCV customized biomedical text-mining based 
online web resource, dragon exploratory system on Hepatitis C Virus (DESHCV), a 
biomedical text-mining and relationship exploring knowledgebase was developed by 
exploring literature on HCV. The pre-compiled dictionaries existing in the dragon 
exploratory system (DES) were enriched with biomedical concepts pertaining to HCV 
proteins, their name variants and symbols to make it suitable for targeted information 
exploration and knowledge extraction as focused on HCV. A list of 32,895 abstracts 
retrieved via the PubMed database using specific keywords searches related to HCV were 
processed based on concept recognition of terms from several dictionaries. The web 
query interface enables retrieval of information using specified concepts, keywords and 
phrases, generating text-derived association networks and hypotheses, which could be 
tested to identify potentially novel relationships between different concepts. Such an 
approach could also augment efforts in the search for diagnostic or even therapeutic 
targets. DESHCV thus represents an online literature-based discovery resource freely 
accessible for academic and non-profit users via http://apps.sanbi.ac.za/DESHCV/ and its 
mirror site http://cbrc.kaust.edu.sa/deshcv/. 
 
 
2.2 Introduction 
The skyrocketing chronicity and global infection rate of Hepatitis C Virus (HCV) 
necessitate the need to unlock the molecular etiology underlying the pathophysiology of 
HCV related diseases such as liver cancer. The plethora of essential molecular data in the 
corpus of published biomedical literature could be leveraged to augment efforts towards 
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discovery of novel anti-viral drugs, cellular receptors and appropriate predictive 
biomarkers. Most of the data derived from high throughput and “omics” experiments 
exist in variety of formats, thereby making cross data integration difficult. The 
development of HCV specific databases as repositories of information utilizable in cross 
discipline biology research is therefore vital. The Los Alamos Hepatitis C Virus sequence 
database (http://hcv.lanl.gov) offers annotated sequences and analysis tools (Kuiken et 
al., 2005). The Los Alamos hepatitis C immunology database 
(http://hcv.lanl.gov/content/immuno/immuno-main.html) is a repository of biocurated 
immunological epitopes integrated with retrieval and analysis tools (Yusim et al., 2005). 
The Japanese HCV database integrated in the HVDB (http://s2as02.genes.nig.ac.jp) 
comprises data on phylogenetic and provides java embedded viewers for visualizing 
phylogenetic trees and the HCV genome. The European Hepatitis C Virus database 
(euHCVdb, http://euhcvdb.ibcp.fr) provides annotated sequences and tools for analysis, 
and information on protein structure and function (Combet et al., 2007). Hepatitis C 
Virus sequence and immunology database and analytical applications (HCVdb, 
http://www.hcvdb.org/index.asp?bhcp=1) offers data on analyzed protein sequence and 
features, epitopes, and curated knowledge on protein interactions and function. Binding 
site finder (BSFINDER, http://wilab.inha.ac.kr/bsfinder) enables prediction of HCV 
binding site residues and potential interacting protein partners using support vector 
machine (Chen and Han, 2009). A comprehensive review of selected HCV related 
database has highlighted the useful capabilities, utilities and applications of these 
resources (Kuiken et al., 2006). Hepatitis C Virus-specific databases store useful 
information on molecular biology, sequences, immunology, protein structure and 
function, viral evolution and genetics. Nevertheless, there is no resource that allows for 
the exploration of potential links (associations) between different biomedical concepts of 
relevance to HCV. One such resource is the dragon exploratory system on Hepatitis C 
Virus (DESHCV, http://apps.sanbi.ac.za/DESHCV/ and its mirror site 
http://cbrc.kaust.edu.sa/deshcv/), based on text-mining approach to complement the 
existing HCV resources and to enable different insights into the molecular context of 
HCV functioning. 
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As reported by Cohen and Hersh (2005), the biomedical knowledgebase is growing at an 
increasing rate. PubMed database is currently a repository of about 20 million citations 
for biomedical articles from MEDLINE and life science related journals. MeSH indexers 
index about 500,000 journal articles annually for PubMed/MEDLINE (Mitchell et al., 
2003). A search by publication dates in PubMed shows over 20,000 HCV related records 
published over the last decade. At the time when this study was conducted a total of 
32,895 HCV related documents were available that makes it virtually impossible for a 
single researcher or a research group to process in any reasonable time. However, a 
biomedical text-mining approach could be utilized to analyze this large volume of 
scientific data and reports published on HCV. Biomedical text-mining employs different 
techniques to extract and summarize information from text (Cohen and Hunter, 2008). Its 
algorithms may derive putative relationships between disjunct sets of concepts to unravel 
potentially new associations and hypotheses for possible novel discovery. The co-
occurrence of the concepts of interests, either in a portion of text (say abstract) or in a 
sentence, is identified computationally, and provides useful clues on the potential 
associations between these concepts, some of which may be completely new. For 
example, using text-mining techniques fish oil was proposed to have a potential 
therapeutic effect on Raynaud's disease (Swanson, 1986). The relationship between fish 
oil and Raynaud's disease was hypothesized via physiological concepts such as high 
blood pressure and platelet aggregation and subsequently this relationship was confirmed. 
As another example, literature based discovery was previously used to predict 
thalidomide as a possible therapeutic drug for HCV infection after detecting implicit 
associations in biomedical text (Weeber et al., 2003). A text-mining approach was also 
employed in identifying some of the hepatocellular proteins used in generating the human 
HCV interactome (de Chassey et al., 2008). 
The essential features and characteristics of some of the available text-mining tools have 
been discussed elsewhere (Bajic et al., 2005; Weeber et al., 2005). Shi and Campagne 
(2005) have described in detail the various concepts, principles, challenges and 
algorithms behind development of biomedical text-mining tools during the building of 
protein catalogue and implementation of the Textractor Framework 
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(http://icb.med.cornell.edu/crt/textractor/index.xml). Anni 2.0 
(http://biosemantics.org/anni/), a web-based biomedical text-mining tool offers an 
ontology-based interface to MEDLINE and enables retrieval of documents and possible 
association amongst biomedical concepts (Jelier et al., 2008). PolySearch 
(http://wishart.biology.ualberta.ca/polysearch), a web-based text-mining system allows 
the retrieval of relationships between human diseases, genes, mutations, drugs and 
metabolites (Cheng et al., 2008). Nowadays, customized knowledgebases or topic-
specific text-mining resources are increasingly becoming popular. Typical examples are 
the dragon exploratory system (DES) based resources: dragon TF association miner 
(DTFAM, http://research.i2r.a-star.edu.sg/DRAGON/TFAM), useful for exploring 
functional association amongst transcription factors (Pan et al., 2004); dragon database 
for exploration of sodium channels in human (DDESC, http://apps.sanbi.ac.za/ddesc), 
which provides comprehensive text-mining information related to sodium channels 
(Sagar et al., 2008). DES and its previous versions were successfully used in compilation 
of several other resources such as in database on ovarian cancer (Kaur et al., 2009) and 
esophageal cancer (Essack et al., 2009), as well as in studies on prioritizing disease genes 
(Tiffin et al., 2005; Lombard et al., 2007). 
At the time of initiating this thesis project, there was no single database solely focused on 
HCV research that allowed for the comprehensive exploration of the association between 
the biomedical concepts related to HCV. This thesis describes dragon exploratory system 
on Hepatitis C Virus (DESHCV), the previous version of it being reported earlier 
(Kwofie et al., 2009). DESHCV is developed using DES. The HCV proteins and their 
name variants have been integrated into the pre-compiled dictionaries of biological 
concepts present in DES. These concepts are cross-referenced to database such as gene 
ontologies (GO), UNIPROT, KEGG Pathway, REACTOME and Entrez Gene. A list of 
abstracts was retrieved via PubMed database using keywords related to HCV. These 
abstracts were analyzed using concepts in the following dictionaries: “human genes and 
proteins”, “metabolites and enzymes”, “pathways”, “chemicals with pharmacological 
effects”, “Hepatitis C Virus concepts”, and “disease concepts”. 
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The user-friendly online interface allows concepts, keywords and phrases searches. A 
concept query could generate networks and hypothesis. The computationally suggested 
associations between genes and other concepts such as diseases may assist experimental 
biologist to explore which genes amongst a pool of genes need to be characterized for 
further molecular analysis. Such an approach could in principle also lead to possible 
discovery of new vaccines; and enhance the development of appropriate diagnostic 
method. The user has the possibility to inspect the post-processed PubMed abstracts with 
colour-coded tagged concepts from the used dictionaries as found in the text. The 
downloadable concept lists sheet could be a primary source of data for biocuration. The 
paired concept list spreadsheet can serve as the essential preliminary data for exploring 
associations between concepts and can be converted easily into simple interaction file 
format (SIF) compatible with some of the interaction visualization and analysis tools such 
as Cytoscape (Killcoyne et al., 2009). Researchers with minimal or no knowledge on 
text-mining can explore DESHCV with ease via system's simplified user query interface. 
The integrated downloadable tutorial manual and frequently asked questions (FAQ) 
information further aids easy use of the system (appendix I and II). DESHCV is an online 
text-mining developed knowledgebase freely available for non-commercial use via 
http://apps.sanbi.ac.za/DESHCV and http://cbrc.kaust.edu.sa/deshcv. 
 
 
2.3 Construction and content 
2.3.1 Implementation 
A list of 32,895 MEDLINE abstracts was collected via PubMed interface using the 
following keywords query: HCV OR “Hepatitis C Virus”. The PubMed textual data 
downloaded in the extensible markup language (XML) format allow for easy data 
integration into DES for semantic processing and analysis. The DESHCV data files were 
generated by DES, a proprietary biomedical text-mining tool of OrionCell 
(http://www.orioncell.org). The HCV proteins symbols and name variants were added to 
the “human protein and genes” dictionaries, and were mapped onto external annotation 
database. The HCV name variants have been disambiguated and integrated in the 
database. For example, a concept query with the word “core” retrieves “core protein” and 
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not the words “score” or “core”. The word core apart from being part of the 
morphological features of HCV core protein has different meanings in various English 
dictionaries. 
Post processed PubMed abstracts containing found concepts from used dictionaries 
constitute part of the database files. The DESHCV precompiled dictionary data files 
systems are composed of categories of terms such as names of “genes”, “proteins”, 
“metabolites”, enzymes”, “pathways”, “pharmacological chemicals”, and “diseases”. The 
categories of terms consist of biological entities that are referred to as concepts. 
Therefore for the purpose of this work, each dictionary consists of a catalogue of related 
concepts. The DESHCV system is organized into 6 distinct dictionaries: “human genes 
and proteins”, “metabolites and enzymes”, “pathways”, “chemicals with pharmacological 
effects”, “Hepatitis C Virus concepts”, and “disease concepts”. Hierarchically, each 
dictionary is considered as a parent with no subcategories. For example, both human gene 
“interferon alpha 2” and human protein “alanine aminotransferase” are concepts 
belonging to the same parent “human genes and proteins” dictionary and not separate 
subcategories. In some instances certain concepts are assigned to one dictionary, even 
though they could belong to another. For example the concept name ribavirin, a 
therapeutic drug for hepatitis C infection has been assigned to the “metabolites and 
enzymes” dictionary, even though it could also belong to “chemicals with 
pharmacological effects” dictionary. The decision is influenced by the belief that most 
literature reports ribavirin as a metabolite. 
For the purpose of hypothesis generation, the DES association module generates 
association maps in the form of graphs. The nodes of these graphs represent various 
concepts and the edges linking the nodes are weighted with frequencies of occurrence in 
the PubMed abstracts. Hypotheses are generated if for example, concepts X and Y are 
correlated, as well as concepts Y and Z, but no correlation is found between X and Z. 
Then the hypotheses generator module will suggest a potential link between concepts X 
and Z. 
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2.3.2 Database architecture 
The database comprises of an Apache HTTP web server integrated with a back-end 
MySQL server whilst HTML/CSS and JavaScript scripts constitute the front-end (Figure 
2.1). The data files consist of precompiled concept dictionaries, post processed PubMed 
abstracts, and cross-referenced annotations. The logic systems consist of Perl and PHP 
modules. 
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FIGURE 2.1. SCHEMATIC DIAGRAM OF THE INTEGRATED DATABASE OF DESHCV.  
A layout of the DESHCV database architecture showing the relationship between the 
incorporated data files, logic systems and user query interface. 
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2.3.3 The database interfaces 
DESHCV is based on a client-server model and can be accessed by any user with a 
standard web browser. The user interfaces in DESHCV allow easy navigation, query, 
inspection, and retrieval of data. It comprises of concept and abstract search menus 
(Figure 2.2). The concept search menu allows users to search the database using specified 
concepts. The hypothesis generator is an integral functional component of the concept 
search menu. 
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FIGURE 2.2. DESHCV DATA FLOW SCHEMA DIAGRAM.  
A structured workflow outlining the various steps and decision-making processes 
involved in retrieving enriched biological data from DESHCV. 
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2.4 Results and discussions 
2.4.1 Concepts queries 
DESHCV is the first text-mining based web accessible resource developed using 
published abstracts of scientific reports on HCV as referenced in PubMed. DESHCV 
provides comprehensive information on HCV and enables users to gain easy insights 
through exploration of potential associations between the concepts of interest. Users can 
query the database using concepts such as genes, proteins, metabolites, enzymes, 
pathway, disease concepts, and pharmacological chemicals to retrieve useful associations 
that may suggest new insights into the problem. DESHCV provides users the chance to 
query the compiled abstracts within the framework of concept-based retrieval and 
extraction system. 
For example, a concept query “thalidomide” retrieves all associated concepts from their 
respective dictionaries found in the analyzed text. These could be displayed either in a 
graphical or tabular format. These identified concepts co-occur with thalidomide in the 
PubMed abstracts. The frequency of occurrence of the concepts is shown and the link can 
be clicked to view the abstracts. The user has the option of either viewing the abstract 
with or without tagged concepts. All disease concepts associated with thalidomide are 
retrieved including chronic hepatitis C, which co-occurs with thalidomide within three 
abstracts. This result can be displayed in the form of an association map by using the 
“draw network” generator. The association map is a graph consisting of interacting 
network of nodes representing thalidomide and its associated concepts. The edges linking 
the nodes shows the relationship between the concepts and are weighted with the 
frequency of co-occurrence. To ensure effective interpretation and evaluation of results, 
users have the option of limiting the number of interactions for display by ignoring links 
with fewer frequencies. The association map can be resized from A0 to A5 and the detail 
slider can be used to alter viewing capabilities. For the purpose of this discussion, 
concepts with less than three links were ignored to obtain high degree of details without 
obscuring vital information. The association established between thalidomide and chronic 
hepatitis C is a loose relationship and no inference may be deduced until the literature is 
manually verified to either accept or reject the relationship (Figure 2.3). The linking 
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abstracts were manually inspected to ascertain the proposed relationship. Accordingly, 
thalidomide is a promising novel compound for chronic hepatitis C therapy since 
thalidomide decreased liver enzymes in six out of eight patients suffering from chronic 
hepatitis C (Milazzo et al., 2006). 
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FIGURE 2.3. A DIAGRAM DISPLAYING THALIDOMIDE CONCEPT QUERY OUTPUT.  
This shows the association map comprising of a network of interaction nodes consisting 
of concepts assigned to various biomedical dictionaries.  
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2.4.2 Abstract queries 
The abstract search menu allows users to do keywords searches, use quotes for “phrase 
search”, and Boolean logical operators such as “OR”, “AND” or “NOT”. An abstract 
search with the keyword “hypervariability” therefore returns a list of abstracts containing 
the queried keyword “hypervariability”. The retrieved abstracts also contain tagged 
colour-coded concepts assigned to their respective dictionaries. The abstract search 
results can serve as rich source of data useful for curation since it contains automatically 
identified biomedical concepts. Even though manual curation using human expertise 
could yield high quality results (Muller et al., 2004), it is sometimes fraught with errors 
since the human eyes may unintentionally overlook useful data. In addition, the rapidly 
increasing volume of published literature sometimes could render it herculean for 
researchers to manually inspect and efficiently locate or identify biomedical concepts of 
interest embedded in literature. This feature of DESHCV is aimed at complimenting the 
already existing information search, retrieval and extraction resources. 
 
 
2.4.3 Evaluation of DES by reproducing a known hypothesis 
The performance of DES has been evaluated recently by Sagar et al. (2008) in the context 
of sodium channels in human. Since it was not possible to evaluate all the concepts 
embedded in the 5243 documents used in Sagar's analysis, SCN1A was chosen as a 
reference gene for the analysis. DES accurately identified most of the concepts present in 
the 131 abstracts associated with SCN1A. The analysis showed both precision and recall 
for identified concepts from different dictionaries that ranged between 81% and 100% 
whilst the F-measure was between 87% and 100%. 
In this report, a different approach was used to evaluate the performance of DES by 
simulating an already confirmed scientific discovery. Such approach has been used 
during the implementation of the DAD-system, Swanson's Raynaud's disease-fish oil 
discovery was simulated to test the performance of the system (Weeber et al., 2000). 
Swanson's discovery of a hidden connection between disjunct literatures on magnesium 
and migraine was successfully re-implemented in the LitLinker systems (Meredith et al., 
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2005). Anni biomedical text-mining tool was used to reproduce a previously published 
thalidomide-chronic hepatitis C discovery (Jelier et al., 2008). Here, DESHCV is used 
successfully to simulate the thalidomide-chronic hepatitis C association (Weeber et al., 
2003). By clicking on the hypothesis generator, the user can retrieve hypothesis to reveal 
potential relationships existing between concepts. The hypothesis generator query menu 
allows users to automatically or manually select categories with which to generate 
hypothesis. The open discovery approach previously described by Swanson and adapted 
by Meredith has been employed here. Thalidomide (from “metabolites and enzymes” 
dictionaries) was used as the starting term to retrieve all linking concepts within the 
human proteins and genes category. The tumor necrosis factor (TNF) was manually 
selected as the linking term whilst concepts within the diseases catalogues were defined 
as the target (Figure 2.4). The system successfully generated hypothesis to infer potential 
relationships between thalidomide and the following disease concepts: chronic liver 
disease, chronic viral hepatitis, chronic persistent hepatitis and chronic renal failure. The 
system used disjuncted literature between the different concepts to predict implicit 
relationship amongst them. Chronic liver disease, chronic viral hepatitis and chronic 
persistent hepatitis are possible name variants and these conditions are implicated in liver 
failure. By clicking on the test button linking the chronic viral hepatitis and thalidomide 
retrieved an abstract on a case report concerning thalidomide-associated hepatitis where 
the patient had medical history including chronic hepatitis C (Fowler and Imrie, 2001). 
The hypothesis generated by DESHCV was reasonable since the verification of the 
literature supported the “discovery”. 
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FIGURE 2.4. A DIAGRAM DISPLAYING THALIDOMIDE-CHRONIC HEPATITIS C HYPOTHESIS.  
This shows an implicit relationship between thalidomide and chronic hepatitis C inferring 
potentially new hypotheses. The biomedical concepts “thalidomide”, “tumor necrosis 
factor” and “chronic hepatitis C” belongs to the “metabolites and enzymes”, “human 
genes and proteins”, and „disease concepts” dictionaries respectively.  
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2.4.4 Generation of thalidomide-amantadine association 
DESHCV has also been used to generate potentially new hypotheses, which propose 
relationships between thalidomide and amantadine as possible combination therapy for 
chronic viral hepatitis C. All disease concepts associated with thalidomide were retrieved 
and chronic hepatitis C was selected as linking term with concepts in metabolites and 
enzymes dictionaries considered as target terms. This hypothesis was tested automatically 
by checking the auto test radio button. This inferred an implicit relationship between 
thalidomide and amantadine but no PubMed abstract was retrieved implying a potentially 
new discovery (Figure 2.5). This means that these two concepts do not co-occur in any of 
the PubMed abstracts. This potential discovery is based on textual analysis of abstracts 
and not full text papers. The standard treatment for chronic hepatitis C is a combination 
therapy of pegylated IFN-alpha to elicit immune response and antiviral effect of ribavirin. 
Patients infected with certain genotypes of HCV do not respond to this treatment, 
necessitating the need for enhanced combination therapy. Reports on available data 
concerning triple therapy comprising of pegylated IFN-alpha, ribavirin and protease 
inhibitors targeting NS3-4SA protease looks promising, and this could become standard 
treatment feature in the near future (Zeuzem, 2008; Flisiak and Parfieniuk, 2010). The 
usage of thalidomide in the treatment of chronic hepatitis C unresponsive to alpha-
interferon and ribavirin has been investigated (Caseiro, 2006; Milazzo et al., 2006), 
whilst amantadine has been combined with interferon-alpha plus ribavirin (Chrissafidou 
and Musch, 2009; von Wagner et al., 2008). 
The possibility of a triple therapy for effective management of chronic hepatitis C should 
prompt researchers on the need to investigate combining any one of the available 
treatment drugs (IFN-alpha and ribavirin) or possibly protease inhibitors to thalidomide 
and amantadine as implied by the generated hypotheses. Although the beneficial effect of 
amantadine and other antiviral drug for the treatment of chronic hepatitis C is 
controversial and sometimes contentious, potent analogues with less toxicity, augmented 
pharmacophore and enhanced pharmacokinetics could be explored further. The 
possibility of augmenting the above therapy with hepatoprotective drug such as silibinin 
could be explored. Any discovery proposed using biomedical text-mining approach 
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should undergo the rigour of laboratory evaluations and ethical consideration and 
possibly must conform to existing legislation before usage. 
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FIGURE 2.5. A DIAGRAM DISPLAYING THALIDOMIDE-AMANTADINE HYPOTHESIS. 
This shows an implicit relationship between thalidomide and amantadine inferring 
potentially new hypotheses. The biomedical concepts “thalidomide” and “amantadine” 
belong to the “metabolites and enzymes” dictionaries whilst “chronic hepatitis C” 
concept belongs to the “disease” dictionary. 
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2.4.5 Systems reports 
Comprehensive summary reports generated from DESHCV are made available on the left 
menu of the user interface. The “concept list report” groups concepts by dictionaries and 
frequency of appearance inside documents. The frequency of document report lists 
abstract with their total number of embedded tagged concepts. The frequencies of pairs 
report group pairs of concepts that co-occur in documents. Another useful feature is the 
document clustering report which displays clusters of concepts sorted by frequency of 
appearance and is compiled using artificial neural networking algorithm. Its usefulness 
lies in the fact that similar documents tend to cluster together, thereby allowing biologist 
to harness potential information amongst clustered abstracts. Recommended readings 
displays the link to top 10 documents with most concepts, though not manually generated 
they could give an overview of HCV research to a new researcher in virology. For 
example, the most recommended reading is an abstract on a review describing in detail 
the current antiviral drugs in clinical usage (De Clercq, 2004). 
 
 
2.5 Limitations 
Associations generated between paired concepts are inferred from co-occurrences and 
may not necessarily relate to any molecular functionality. Textual data is obtained from 
abstracts, which are easy to index. Some details of research are present in full body text 
and as such vital information may not be reported in abstract. Full text documents were 
not analyzed in this study. 
 
 
2.6 Future directions 
Integrating blast and identifier queries to enhance querying capabilities of DESHCV is 
currently being investigated. The possibility of integrating full text document is currently 
being explored and could be added to the database as a separate feature. The database 
would be updated every six months to meet the demands of ever increasing PubMed 
records related to HCV. 
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2.7 Conclusions 
This chapter described the implementation of Hepatitis C Virus customized web-based 
text-mining resource that allows researchers to intuitively use the system to get insight 
into possible novel associations between concepts. This system has been used 
successfully to reproduce already published thalidomide-chronic hepatitis C biomedical 
text-mining discovery (Weeber et al., 2003). DESHCV database is free to use for 
academic and non-profit purposes. 
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Chapter 3: Hepatitis C Virus Protein Interaction Database (HCVpro) 
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3.1 ABSTRACT 
It is essential to catalog characterized Hepatitis C Virus (HCV) protein-protein 
interaction (PPI) data and the associated plethora of vital functional information to 
augment the search for therapies, vaccines and diagnostic biomarkers. Hepatitis C Virus 
Protein Interaction Database (HCVpro) has been developed in furtherance of these goals. 
HCVpro contains manually verified hepatitis C virus-virus and virus-human protein 
interactions curated from literature and databases. HCVpro is a comprehensive and 
integrated HCV-specific knowledgebase housing consolidated information on PPIs, 
functional genomics and molecular data obtained a from variety of virus databases 
(VirHostNet, VirusMint, HCVdb and euHCVdb), and from BIND and other relevant 
biology repositories. HCVpro is further populated with information on hepatocellular 
carcinoma (HCC) related genes that are mapped onto their encoded cellular proteins. 
Incorporated proteins have been mapped onto Gene Ontologies, canonical pathways, 
Online Mendelian Inheritance in Man (OMIM) and extensively cross-referenced to other 
essential annotations. The database is enriched with exhaustive reviews on structure and 
functions of HCV proteins, current state of drug and vaccine development, and links to 
recommended journal articles. Users can query the database using specific protein 
identifiers (IDs), chromosomal locations of a gene, interaction detection methods, 
indexed PubMed sources as well as HCVpro, BIND and VirusMint IDs. The use of 
HCVpro is free and the resource can be accessed via http://apps.sanbi.ac.za/hcvpro/ or 
http://cbrc.kaust.edu.sa/hcvpro/. 
 
 
3.2 Introduction 
Protein-protein interactions (PPIs) are vital in orchestrating molecular cellular events and 
constitute the basis for multitudes of signal transduction pathways and transcriptional 
regulatory networks (Raman, 2010). Efforts towards elucidating HCV protein 
interactions through the use of proteome-wide mapping techniques and the computational 
construction of the entire HCV-human protein interactome map have been reported 
(Flajolet et al., 2000; de Chassey et al., 2008). Additionally, several other HCV research 
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groups have published large amounts of information on HCV PPIs and related enriched 
functionally analysed data vital for the understanding of HCV infection mechanisms. 
This progress has been facilitated by the advent of highly innovative low and high 
throughput techniques essential for the elucidation and characterization of protein 
interactions. Various experimental methods have been widely used to either screen or 
confirm HCV protein-protein interactions, including yeast two-hybrid (Dimitrova et al., 
2003; Ahn et al., 2004; Huang et al., 2005), confocal microscopy (Tong et al., 2002; Lan 
et al., 2003), coimmunoprecipitation (Dimitrova et al., 2003; Wang et al., 2005), surface 
plasmon resonance studies (Sabile et al., 1999; Jennings et al., 2008), spectroscopy (Kang 
et al., 2005; Masumi et al., 2005), immunoblotting (Tan et al., 1999), cross-linking 
(Wang et al., 2002), affinity chromatography (Masumi et al., 2005) and 3-dimensional 
protein structures (Op De Beeck et al., 2000). The use of several types of methods in 
elucidating PPIs has led to the availability of interaction data in heterogeneous formats 
thus requiring standardization. In response, numerous efforts have focused on formatting 
the ever-increasing protein-protein interactions and associated meta-data as well as 
integrating them into public online repositories. The proteomics standards initiative-
molecular interaction (PSI-MI) format (Hermjakob et al., 2004), a community standard 
data model for the representation and exchange of protein interaction data, and MIMIx, 
the minimum information required for reporting a molecular interaction experiment 
guidelines (Orchard et al., 2007) are platforms for harnessing information from structured 
PPI data.  
 
Towards consolidating viral PPI data, VirusMint (Chatr-aryamontri et al., 2009) and 
VirHostNet (Navratil et al., 2009) databases have been developed to house viral PPI data. 
VirHostNet represents more than 180 distinct viral species with unique taxonomy 
identifications as well as a broad diversity spanning about 36 distinct viral families. 
VirusMint represents more than 110 different viral strains and provides PPI information 
on viruses involved in human infections and cancer, including adenovirus, Simian virus 
40 (SV40), human papilloma viruses, Epstein–Barr virus (EBV), hepatitis B virus 
(HBV), hepatitis C virus (HCV), herpes viruses, influenza A virus, vaccinia virus and 
human immunodeficiency virus (HIV). Primarily, both VirusMint and VirHostNet are 
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geared towards online network visualization and analysis of integrated human viral 
interactome maps. A trend is emerging where databases solely dedicated to single 
organisms are constructed instead of multi-organism PPI databases, and a typical 
example is HIV-1 Human Protein Interactions Database (Fu et al., 2009). It is believed 
that a knowledgebase solely focused or customized to answer pertinent biological 
questions related to HCV has the potential to provide detailed and exhaustive information 
suitable to generate functional hypotheses in-silico. In this regard, this thesis describes 
the development of a new online hepatitis C virus protein interaction database (HCVpro), 
an integrated and comprehensive warehouse for storing and managing manually verified 
HCV virus-virus and virus-human protein interactions curated from literature and 
databases. HCVpro stores interaction information on human and viral interacting partners 
as well as meta-data, including interaction detection methods and journal articles 
reporting the interactions. Additionally, HCVpro contains useful contextual data and is 
distinct from other curated viral PPI databases because it provides: (1) consolidated PPI 
data from BIND (Alfarano et al., 2005) and key viral databases comprising of VirusMint 
and VirHostNet, (2) an integrated query platform enabling users to retrieve interaction 
data using HCVpro and other PPI database identifiers (BIND and MINT IDs), 
experiment types and journal article sources, and other genomic qualifiers, (3) useful 
genomic and functional information from notable HCV knowledgebases, including 
VBRC HCVdb (Greene et al., 2007), and euHCVdb (Combet et al., 2007), (4) compiled 
current knowledge on the molecular functions and biochemical features of HCV proteins, 
including post-translational modifications, subunit structure, domains, subcellular 
localization, diseases and links to essential PubMed articles, (5) a detailed review on viral 
drug development and challenges particularly concerning current therapy options and 
state of antiviral discovery, (6)  genes transcriptionally regulated by NetPath  curated 
signaling pathways (Kandasamy et al., 2010) as well as information concerning canonical 
pathways comprising of NCI-Nature curated pathways (Schaefer et al., 2009), KEGG 
(Kanehisa et al., 2010), Reactome (Matthews et al., 2009) and HPD (Chowbina et al., 
2009), (7) links to external databases such as HPRD (Keshava Prasad et al., 2009), 
OMIM (Amberger et al., 2009), PharmGKB (Hodge et al., 2007), PDB (Berman et al., 
2002), Gene Ontologies (Gene Ontology Consortium, 2010) and other essential 
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biological knowledgebases, and (8) comprehensive integration of high-confidence HCV-
related hepatocellular carcinoma (HCC) genes  deciphered from gene expression and 
proteomics studies, HCC gene expression pattern from EHCO (Hsu et al., 2007) and links 
to other major HCC databases consisting of HCCNet (He et al., 2010) and OncoDB.HCC 
(Su et al., 2007). 
 
The diverse integrated information in HCVpro can accelerate the understanding of HCV 
mediated molecular mechanisms and also enable postulation of appropriate hypothesis to 
guide discovery of new knowledge of potential use in drug discovery. Additionally, 
HCVpro can augment efforts towards uncovering novel HCV-related tumorigenic 
biomarkers with therapeutic potential by harnessing integrated data composed of PPIs, 
canonical pathways, and HCC-related gene expression information on the genes encoding 
the host cellular proteins.  
 
 
3.3 Construction and content 
3.3.1 Protein interaction data curation and integration 
Hepatitis C Virus-virus and virus-human protein interactions were manually curated from 
published peer-reviewed journal articles and database sources including BIND, 
VirusMint and VirHostNet. Protein interactions were annotated with associated meta-data 
such as experiment types used in inferring interactions and PubMed identification 
numbers (PMIDs) of journal articles reporting the interactions. The Entrez gene symbols 
of the human genes encoding the interacting cellular proteins were used as protein 
identifiers as well as their assigned non-redundant gene ID. The interacting viral proteins 
consist of 11 distinct proteins encoded by the HCV genome comprising core, E1, E2, p7, 
NS2, NS3, NS4A, NS4B, NS5A, NS5B and F proteins. It must be noted that existing 
curation protocols were followed with particularly emphasis on that of VirHostNet 
(Navratil et al., 2009). Interactions curated from literature must meet the following 
baseline criteria to be considered: (i) physical binary interactions between HCV-HCV 
proteins or HCV-human proteins only; (ii) the interactions must not be predicted (iii) 
interactions merely mentioned in the review section of a journal article are rejected; and 
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(iv) there should be sufficient information in the manuscript to support the reported 
interaction, for example the names of the interacting protein partners and the detection 
methods used to infer the interactions. Interactions obtained from database sources must 
meet the following extra criteria: (i) the source database must be published in a peer-
reviewed journal and details of the curation procedures must be accessible; (ii) each 
provided interaction must be assigned a unique interaction ID; (iii) interaction must be 
annotated with the minimum information comprising the journal article reporting the 
interactions, experimental methods used for detecting the interaction and protein names 
as well as their IDs. Interactions that do not meet the above criteria are not considered for 
incorporation into HCVpro. 
 
For the purpose of HCVpro construction, each annotated protein-protein interaction 
curated from a specific journal article was assigned a unique HCVpro ID (appendix III). 
Therefore, a single type of interaction being reported by many journal sources was 
assigned multiple HCVpro IDs. For example, the binary interactions between HCV core 
and LTBR proteins were assigned two separate HCVpro IDs hcv0001 and hcv0004 since 
they have been reported by two different journal articles (Matsumoto et al., 1997) and 
(Chen et al., 1997), respectively. The hcv0001 has been annotated with interaction meta-
data consisting of PubMed ID 8995654, BIND ID 133606, and experiment types 
comprising of yeast two-hybrid, far-western blot and affinity chromatography. Similar to 
aforementioned convention, hcv0004 has been annotated with interaction meta-data 
consisting of PubMed ID 9371602, BIND IDs 181950 and 182177, and experiment types 
comprising of yeast two-hybrid, affinity chromatography and coimmunoprecipitation. As 
evident, BIND database appears to use a similar convention for annotation as core-LTBR 
interactions reported from separate journal articles were assigned different BIND IDs. In 
addition, different types of interactions being reported in a single journal article are 
assigned different HCVpro IDs. For example, a total of 307 unique viral-human protein 
interactions were obtained from proteome-wide analysis studies (de Chassey et al., 2008), 
although these interactions were curated from a single journal source (PubMed ID 
18985028), each was assigned a unique HCVpro ID. The unique HCVpro IDs assigned to 
multiple protein interactions, number of experiment types confirming the interactions and 
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multiple journal articles reporting the interactions could serve as parameters to evaluate 
the confidence of HCV molecular interaction data. These parameters could, for example, 
serve as weights for scoring binary interactions between two proteins and may be used to 
filter out interactions with a lower confidence threshold. Comprehensive reviews of PPI 
detection methods and challenges involved in curation have been presented elsewhere 
(Phizicky and Fields, 1995; Alfarano et al., 2005; Mathivanan et al., 2006; Berggard et 
al., 2007; Cusick et al., 2009; Turinsky et al., 2010). 
 
The curated experimental methods describing PPIs were converted into PSI-MI 2.5 
controlled vocabularies and assigned PSI-MI 2.5 Term IDs (Hermjakob et al., 2004) 
using the EMBL-EBI Ontology Lookup Service (http://www.ebi.ac.uk/ontology-lookup/) 
(Barsnes et al., 2010). Similar to the approach adopted by VirHostNet, HCVpro provide 
information concerning the two interacting protein partners, experiment type PSI-MI 
Term IDs and PubMed IDs of articles reporting the interactions. The PPI data can be 
downloaded as a tab-delimited file enabling users to convert to any machine-readable 
format of their choice with ease. The downloadable data could be harnessed for 
functional enrichment analysis and the interacting proteins could be leveraged as seed 
nodes for modeling protein network and pathways using third-party software such as 
Cytoscape and its associated plug-ins (Smoot et al., 2010). Furthermore, the data could 
augment efforts towards an integrated bioinformatics approach where the manually 
verified interactions could be employed as datasets for training machine learning models 
to predict protein-protein interactions as well as used in combination with a plethora of 
genomic data to prioritize and identify potential candidate hepatocellular carcinoma 
related genes, therapeutic targets and diagnostic markers associated with HCV infections. 
Due to HCV genetic heterogeneity, this repository provides another downloadable dataset 
supplemented with information on HCV genotypes/strains from which the HCV proteins 
were characterized and obtained from published literature, BIND and VirHostNet 
(appendix IV). This data can be utilized in modeling of genotype- or strain-specific 
interaction networks and could potentially aid in simulating the effect of genetic 
variability on pathobiology of HCV associated diseases. 
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3.3.2 HCV and human protein contextual data sources 
There is an emerging consensus where HCV strain 1a (Isolate H77) has been adopted as 
the reference HCV (Kuiken and Simmonds, 2009), and therefore the HCV protein 
knowledgebase, sequences and annotations housed in VBRC HCVdb are overwhelmingly 
based on this strain. This approach was adopted in the development of HCVpro where 
HCV protein data integrated from Uniprot (UniProt Consortium, 2010), euHCVdb 
(Combet et al., 2007), VBRC HCVdb (Greene et al., 2007), GenBank (Benson, et al., 
2009) and Entrez gene (Maglott et al., 2007) are based on this strain. Other biologically 
relevant HCV data were obtained from OMIM (Amberger et al., 2009), PDB (Berman et 
al., 2002), Gene Ontology (Gene Ontology Consortium, 2010) and published literature 
reviews (Penin et al., 2004; Krekulova et al., 2006; Dubuisson, 2007; Sharma, 2010). 
Additionally, enriched human protein functional data was obtained from Entrez gene 
(Maglott et al., 2007), HPRD (Keshava Prasad et al., 2009), Ensembl (Flicek et al., 
2008), GenBank (Benson et al., 2009), Uniprot (Uniprot Consortium, 2010), Gene 
Ontology (Gene Ontology Consortium, 2010), GeneCards (Safran et al., 2010), Gene ID 
converter (Alibes et al., 2007), Netpath (Kandasamy et al., 2010) and Nature curated 
pathways (Schaefer et al., 2009). Hepatocellular carcinoma associated genes were 
consolidated from the following databases (appendix V): HCCNet (He et al., 2010), 
OncoDB.HCC (Su et al., 2007) and EHCO (Hsu et al., 2007), 
 
In total, HCVpro consist of 621 unique HCVpro IDs comprising of 549 HCV viral-
human protein and 72 viral-viral protein interactions. The detection method and number 
of method distributions are shown in Figures 3.1 and 3.2 respectively. Comprehensive 
information on HCVpro data statistics is also provided on the HCVpro website under the 
menu item „Statistics‟ (appendix VI). 
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FIGURE 3.1. DISTRIBUTION OF EXPERIMENTAL METHODS TO VERIFY PPIS.  
A pie chart showing the detailed breakdown in percentage of the experiment types used 
in verifying the protein-protein interactions. The majority of interactions were detected 
using two-hybrid test (41%). Coimmunoprecipitation, pull down and other experimental 
techniques constituted 14%, 7% and 38% respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.2. PROTEIN-PROTEIN INTERACTION VERIFICATION METHOD DISTRIBUTION.  
A pie chart showing the detailed breakdown in percentage of the number of methods used 
jointly for verifying the protein-protein interactions. 64% of detected interactions were 
inferred by single experimental method, 16% were inferred by two methods whiles 20% 
were inferred by 3 or more methods. 
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3.3.3 Database architecture 
HCVpro is a web-based resource running on platform independent Apache HTTP server 
with MySQL Server as the back-end and open source application programs such as PHP, 
HTML, CSS and JavaScript as the front-end. The database contents are stored in MySQL 
relational database tables and the data fields constituting the tables are linked by unique 
or non-redundant keys to enable cross table integration, multithreading, multipurpose and 
multiuser querying environments. 
 
 
3.4 Utility and discussion 
3.4.1 Database usage 
This chapter describes the implementation of a biological repository known as HCV 
protein interaction database (HCVpro) that integrates a multitude of enriched data from a 
variety of protein and genomic platforms relevant to HCV research. This knowledgebase 
is intended to serve as a “one stop shop” for retrieval of comprehensive data on HCV-
HCV and HCV-human protein interactions, and associated vital information relevant for 
functional characterization experiments. The search menu on the index page of HCVpro 
enables users to navigate through the enhanced or simplified user query interfaces. The 
user query interfaces enable users to perform searches via the HCVpro by browsing three 
sub query menu tabs: (i) protein select, (ii) evidence select, and (iii) identifier search. 
Additionally, HCVpro enables retrieval of data via string searches using gene IDs, names 
and symbols (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 101 
 
 
 
 
 
 
 
 
 
FIGURE 3.3. A DIAGRAM DISPLAYING THE HCVPRO USER QUERY INTERFACE.  
This depicts a screenshot of the integrated query platform enabling users to retrieve 
interaction data using database identifiers, genomic qualifiers and information on 
experiment types as well as PubMed IDs of journal articles reporting the interactions. 
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3.4.1.1 Protein Select 
A search via the “protein select” sub-menu by browsing any of the HCV proteins returns 
a list of entries comprising of HCV-HCV and HCV-human protein interaction data as 
well as relevant contextual data associated with both HCV and human proteins 
participating in the binary interactions. Users can also perform searches by using gene 
names of proteins to retrieve a list of viral-human protein interaction data. For example, a 
query with the protein GRB2 returned an entry result composed of an interaction between 
the oncogenic HCV protein NS5A and cellular protein GRB2 with cross-referenced links 
to external protein interaction databases consisting of BIND and VirusMint. The binary 
interaction between the two proteins was confirmed using affinity chromatography, 
yeast-two hybrid, coimmunoprecipitation, and immunoblotting experiments (Tan et al., 
1999). An additional search option via “chromosome search” allows users to retrieve a 
list of genes located on a particular chromosome, which interact with HCV proteins. 
 
 
3.4.1.2 Evidence Search 
The “evidence search” allows users to perform searches via HCVpro using the 
experiment types used in inferring the interactions and the PubMed sources. By 
performing a search using the experimental evidence, for example 
coimmunoprecipitation, HCVpro returns a list of interactions that were confirmed by 
using coimmunoprecipitation as the experimental technique. This search menu is 
particularly useful during characterization of protein interactions. At a glance 
experimental biologists would narrow down the lists of techniques that may be used to 
elucidate interaction with any of the HCV proteins. For example, knowing the 
experimental evidence for a gene may aid in choosing an appropriate experiment type for 
orthologous genes or genes sharing a variety of genomic features with the retrieved 
genes. Users can also query HCVpro by clicking on a PubMed ID to retrieve all protein-
protein interactions reported in the corresponding journal article present in HCVpro.  
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3.4.1.3 Identifier Search 
The “identifier search” option enables users to search HCVpro using HCVpro, VirusMint 
and BIND IDs. This search option therefore returns the list of interactions annotated with 
HCVpro ID and also integrated from both MINT and BIND databases. Allowing users to 
query HCVpro with other protein interaction database identifiers represents an integrated 
platform for data retrieval. For example, querying HCVpro using VirusMint ID MINT-
16518 returned a binary interaction between NS5A and NS4A proteins confirmed using 
coimmunoprecipitation. This entry is designated as hcv0437 with linked BIND ID 
130456. Users may click the links to freely access other relevant interaction meta-data 
provided by the external databases even though resources such as BIND require user 
registration. 
 
 
3.4.2 Value of the database to prediction of diagnostic biomarkers 
The usefulness of the integrated canonical pathways, Gene Ontologies and microarray 
expression data for exploration of HCV infection associated biomarkers having 
therapeutic potential has been demonstrated using the protein vimentin (for more details 
refer to Section C of the online manual and Figure 3.4). Vimentin was chosen as an 
example query since its potential as a tumor biomarker for HCV-associated 
hepatocellular carcinoma is widely studied. Vimentin-overexpressing and vimentin-
knocked-down experiments showed that cellular vimentin expression enhanced the 
proteasomal degradation of HCV core protein and eventually restricted HCV particle 
production (Nitahara-Kasahara et al., 2009). Performing a string search with the term 
“vimentin” via HCVpro retrieves interaction of vimentin with key oncogenic proteins 
HCV NS3 and core proteins. The interaction with NS3 protein was established using high 
throughput yeast two-hybrid screening, whilst immunoblotting and immunofluorescence 
microscopy were employed with other techniques to confirm interactions with HCV core 
protein. EHCO microarray expression data incorporated in HCVpro indicated vimentin to 
be significantly upregulated in HCV associated hepatocellular carcinoma (HCV-HCC) 
samples in 3 independent datasets (PubMed, mRNA, Protein). Clicking the HCCNet and 
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OncoDB.HCC links in the user interface of HCVpro retrieved information corroborating 
the expression levels of vimentin in HCC samples. Additionally, pathway examination 
pinpointed vimentin as one of the genes transcriptionally upregulated by the NetPath 
curated immune related IL-2 pathway (Kovanen et al., 2003). The IL-2 pathway is 
associated with HCV-host immunologic mechanisms (Morshed et al., 1993; Serti et al., 
2010). Furthermore, IL-2 is involved in the activation of the Ras/MAPK, JAK/Stat and PI 
3-kinase/Akt signaling modules. Interestingly, the JAK/Stat signaling module is a well 
characterized HCV infection pathway (Basu et al., 2001; Luquin et al., 2007). Vimentin 
is also involved in HCV infection associated TLR4 signaling (Agaugue et al., 2007) and 
innate immunity signaling pathways with Reactome IDs 166016 and 168249 
respectively. Vimentin has been mapped onto Gene Ontology terms comprising of 
structural constituents of cytoskeleton, cellular component movement and protein 
binding. Particularly noteworthy are the cytoskeleton constituents comprising of 
microtubules and filaments which are implicated in the provision of tracks for the 
movement of HCV replication complexes (Lai et al., 2008). The significant gene 
expression levels in HCC patient samples coupled with binary protein interaction with 
notable oncogenic HCV proteins and transcriptional regulation by IL-2 signaling 
pathway, provide additional hints that can entice researchers to explore further the 
potential of vimentin as a plausible diagnostic biomarker or therapeutic target for chronic 
hepatitis C related HCC.  
 
To further investigate the relevance of HCVpro to candidate disease biomarker discovery, 
the diagnostic utilities of the other HCVpro integrated cellular proteins were accessed. 
Even though changes in gene expression levels sometimes may not necessarily correlate 
well with protein levels in hepatic tissues or serum (Caillot et al., 2009), it could serve as 
a potentially useful diagnostic indicator. HCC related genes reported in all the three 
major HCC databases (OncoDB.HCC, HCCNet and EHCO) were selected. In all, 23 
genes passed this stringent filter and literature was explored to determine if the genes 
have been reported previously as potential biomarkers. Six genes comprising of APOE 
(Yokoyama et al., 2006), CD5L (Gangadharan et al., 2007), CTGF (Kovalenko et al., 
2009), FAS (El Bassiouny et al., 2008), TP53 (Jeng et al., 2000; Peng et al., 2004; El 
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Bassiouny et al., 2008) and CD81 (Schoniger-Hekele et al., 2005) were suggested or 
exhibited potential as biomarkers earlier, whilst nine consisting of APOA1 (Yokoyama et 
al., 2006), CDKN1A (Kasprzak et al., 2009), CTSB (Lee et al., 2009), FN1 (Yoon et al., 
2006), HSPD1 (Looi et al., 2008), KRT19 (Chang et al., 2009), MCL1 (Sieghart et al., 
2006), SERPINF2 (Caillot et al., 2009), and TF (Mas et al., 2009) have been explored in 
biomarker research.  It appears no article has reported the diagnostic exploration or 
potential of the remaining eight genes comprising of ACLY, AZGP1, DDX3X, FGG, H19, 
SIAH1, SERPING1 and THBS1, and these can serve as a rich source of data for further 
validation. Additionally, some of the 23 genes are associated with cancer related 
pathways and Gene Ontology terms. Although the approach adopted here is purely 
qualitative, the above discourses have amply demonstrated how an integrated repository 
such as HCVpro could be used to harness already existing data to elucidate predictive 
biomarkers with plausible therapeutic potential. 
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FIGURE 3.4. A SCREENSHOT OUTPUT AFTER DATABASE SEARCH WITH VIMENTIN.  
A diagram displaying a portion of information on vimentin as well as links to integrated 
canonical pathways, Gene Ontologies and hepatocellular carcinoma databases. 
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3.4.3 Additional system features 
For ease of usage and understanding of the various data fields incorporated in HCVpro, a 
user manual and frequently asked questions (FAQ) have been provided via the 
corresponding menu items on the HCVpro website (appendix VII and VIII). Users may 
send feedback by writing to the authors via the information given under „Contact‟ and 
also submit novel interactions either before or after publications in MIMIx format 
(Orchard et al., 2007). In addition, links to biologically relevant HCV related and other 
protein interactions resources are provided to facilitate retrieval and harnessing of 
enriched biological data. The links are comprised of VirusMint (Chatr-aryamontri et al., 
2009), VirHostNet (Navratil et al., 2009), BSFINDER (Y. Chen and Han, 2009), 
euHCVdb (Combet et al., 2007), LANL HCV-db (Kuiken et al., 2005), HVDB (Shin et 
al., 2008), VBRC HCVdb (Greene et al., 2007), BIND (Alfarano et al., 2005), DIP 
(Salwinski et al., 2004), HPRD (Keshava Prasad et al., 2009), INTACT (Kerrien et al., 
2007), MINT (Ceol et al., 2010) and DESHCV (Kwofie et al., 2011). 
 
 
3.5 Future prospects 
A content curator and database administrator will constantly be improving the database 
based on user comments and updates will be released twice every year to accommodate 
the ever-growing published protein interactions. Future update will explore the possibility 
of incorporating features that compute the druggability of the integrated interactions, and 
also allow the online screening of potential drugs and cellular drug targets of interest in 
HCV research into HCVpro. Furthermore, data on interaction details such as domains, 
motifs and residues involved in the interaction will be incorporated. HCVpro will be 
integrated with Java web applets that support the visualization and analyze interactions 
such as the Java Universal Network/Graph Framework (http://jung.sourceforge.net/). 
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3.6 Conclusions 
Herein, this report described the development of HCV protein interaction knowledgebase 
(HCVpro), a relational database dedicated to HCV protein interactions. It contains 
manually verified hepatitis C virus-virus and virus-human host cellular protein 
interactions obtained from other databases and curated literature. HCVpro provides 
multitudes of contextualized and functional genomic data pertaining to human and HCV 
proteins and cross-referenced links to enriched biological databases. From the 
aforementioned, the reported resource is therefore not an alternative to the existing 
panoply of protein interaction databases but could augment currents efforts aimed at 
elucidating the complex molecular interplay between viral and host cellular proteins after 
HCV infection. 
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4.1 Research aims revisited 
This section presents solutions to the research aims posed in this thesis. 
 
 
4.1.1 Aim 1 
Development of Hepatitis C Virus (HCV)-focused web-based text mining resource. 
 
Solution 
Chapter 2 of this thesis describes the development of Hepatitis C Virus (HCV) 
customized online text mining resource, the Dragon Exploratory System on Hepatitis C 
Virus (DESHCV) (Kwofie et al., 2011). DESHCV is a dictionary lookup system that 
employs named concept recognition to locate concepts present in a list of HCV-related 
PubMed abstracts. Two concepts are suggested to be associated when both concepts co-
occur in a particular PubMed abstract. As part of the DESHCV implementation, the 
existing data files in the dragon exploratory system were enriched with HCV-related 
biomedical concepts, including their name variants and symbols. The concepts consist of 
the names of biomedical entities that were assigned to variety of dictionaries, including 
“human genes and proteins”, “metabolites and enzymes”, “pathways”, “chemicals with 
pharmacological effects”, “Hepatitis C Virus concepts”, and “disease concepts”. 
DESHCV is therefore a literature-based discovery resource and enables users to query the 
system using specified keywords, phrases and concept names to retrieve text-derived 
association networks, hypothesis and a list of PubMed abstracts containing colour-coded 
tagged concepts. 
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4.1.2 Research aim 2 
Development of HCV online protein knowledgebase. 
 
Solution 
Chapter 2 of this thesis described the development of an online knowledgebase, known as 
the Hepatitis C Virus Protein Interaction Database (HCVpro). HCVpro is a relational 
database that houses manually verified HCV-HCV and HCV-human protein interactions 
obtained from external databases and curated from published biomedical literature as 
well as their associated metadata. A user query via HCVpro retrieves comprehensive 
information on protein-protein interactions (PPIs), as well as rich data on functional 
annotations, hepatocellular carcinoma (HCC) related genes, drug development, canonical 
pathways, and cross-referenced links to other essential biological databases. 
 
 
4.1.3 Research aim 3 
Harnessing the myriad of data in the developed knowledgebases to facilitate generation 
of functional hypothesis of therapeutic relevance. 
 
Solution 
DESHCV is a text mining system that computes possible association between concepts 
and additionally generate hypothesis that can lead to potentially novel discovery. 
DESHCV has been used to reproduce the already confirmed thalidomide-chronic 
hepatitis C hypothesis (Weeber et al., 2003). This system has also been employed to 
suggest a novel hypothesis composed of thalidomide-amantadine association. The 
generated hypotheses were influenced by Swanson‟s ABC model and the open discovery 
approach (Swanson, 1991; Weeber et al., 2001). 
 
HCVpro is an integrated database composed of myriads of data that can be harnessed to 
generate potentially testable baseline hypothesis or obtain clues that may pinpoint to a 
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novel research paradigm to aid in circumventing HCV therapeutic challenges. For 
instance, by combining information on canonical pathways, interactions with key 
oncogenic HCV proteins and gene expression levels in HCC samples, a clue was 
obtained which corroborate the need to further support the ongoing exploration of 
vimentin as a potential therapeutic target or diagnostic biomarker. Additionally, the 
diagnostic potential of a list of 23 HCC associated genes obtained from database sources 
were investigated using literature exploration. Some of the 23 investigated genes were 
related to cancer associated Gene Ontology terms and pathways. Apparently, no literature 
was found to have provided results on the diagnostic potential of the following eight 
genes: ACLY, AZGP1, DDX3X, FGG, H19, SIAH1, SERPING1 and THBS1. Using this 
simple interpretive approach, it is therefore tempting to suggest that the above-mentioned 
eight genes can be investigated to unearth any diagnostic or therapeutic role. 
 
 
4.2 Research contribution 
Understanding the mechanisms underlying viral pathogenesis requires robust approaches, 
including the provision of resources that integrate multiple biologically relevant data to 
augment HCV research. The text mining system and HCV protein knowledgebase 
developed in pursuance of the research aims reported here provide potential platforms 
that can aid researchers with harvested data with which to generate biologically relevant 
hypotheses or formulate plausible research questions worthy of investigation. A 
significant amount of biological data originating from both small- and large-scale 
experiments are reported in published biomedical text. Therefore, harvesting these data in 
a structured format for usage by researchers is critical. The primary data source of 
DESHCV is published biomedical text. HCVpro harvests data from both literature and 
external databases. The availability of both DESHCV and HCVpro is very timely 
because these resources provide enriched consolidated HCV-specific information.  
 
Currently, patients infected with certain HCV genotypes do not derive maximum 
therapeutic benefits from the standard regimen composed of interferon alpha and 
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ribavirin. A number of pharmacological targets are being investigated for HCV therapy, 
including cellular receptors mediating HCV entry, factors facilitating HCV replication 
and assembly, and intracellular pathways (Sato et al., 2008). The essential benefits of 
computational techniques to support investigation of HCV proteins as targets for drug 
development have been highlighted (Lahm et al., 2002). DESHCV utilizes biomedical 
entities such as HCV proteins, cellular receptors and pathways as query concepts to 
generate functional hypothesis. By adding user intuition, the search for therapeutic targets 
with potential to improve sustained virologic response rates, and reduce undesirable side 
effects can be enhanced.  
 
Patients suffering from chronic hepatitis C infection may eventually develop HCV-
induced HCC. HCVpro is populated with protein interaction data consolidated with 
information on HCC genes and this can be harnessed to leverage the current search for 
plausible non-invasive diagnostic markers as well as therapeutic targets. Computed 
topological features obtained from protein networks generated using the interaction 
datasets provided by HCVpro can be combined with the integrated genomic data to 
prioritize candidate HCC related genes. 
 
 
4.3 Limitations and future work 
4.3.1 Limitations and future work on DESHCV 
The heuristic filtering modules of DESHCV will be augmented with simple handcrafted 
rules to enhance the ability of the system to recognize named concepts with poorly 
defined morphological features. Associations suggested by DESHCV must be confirmed 
by manual verification of accompanying literature and also via laboratory 
experimentation when necessary. The updated version of DESHCV will utilize pattern-
matching based approaches to predict the types of association that exist between entities 
within suggested hypothesis or relationships. Full text articles were not used as source of 
data but rather abstracts. Unfortunately, abstracts provide only a bird‟s eye view of the 
summarized results. Currently, the possibility of combining both abstracts and full text 
journal articles as sources of text corpora in DESHCV is being explored. Additionally, 
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robust systems will be designed to circumvent challenges that arise as a result of 
tokenization and indexing of full text documents. 
 
 
4.3.2 Limitations and future work on HCVpro 
HCVpro does not provide interaction reliability scores nor support online exploitation of 
the incorporated data. With possible increase in interaction metadata in the near future, 
protein interactions will be assigned with reliability scores. Subsequent versions of 
HCVpro will accommodate the online visualization and manipulation of protein 
interactions via the use of embedded Java web applets. HCVpro will be integrated with 
separate modules that allow online screening of drugs and drug targets, as well as 
computing of the druggability of incorporated interactions.  
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Appendix I (Chapter 2) 
 
User Manual for Dragon Exploratory System on Hepatitis C Virus 
(DESHCV) 
 
Section A 
A typical user query interface showing the various utility components. DESHCV is free 
for academic and non-profit users via http://apps.sanbi.ac.za/DESHCV/ and its mirror site 
http://cbrc.kaust.edu.sa/deshcv/ 
 
Figure 1. DESHCV user Interface 
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1. For Abstract and Concept queries  
[For further details consult sections B, C and D of this manual] 
 
2. Help 
Click on help menu for detailed explanations of concepts and help manual on DESHCV 
usage. 
 
Section B: Abstract query 
 
 
Figure 2. Displays the simplified abstract query interface 
 
A typical Analysis Flow 
Type any keyword for example: hypervariability -> check abstract radio button -> click 
on search -> a display of PubMed abstracts with tagged colour-coded concepts 
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Section C: Concept query 
 
 
 
 
Figure 3. Displays the simplified concept query interface 
 
A typical Analysis Flow 
Type any concept name for example: “F protein” -> check concept radio button -> click 
on search -> a graphical display of colour-coded concept 
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Concept Search Output and Analysis Flow 
 
Figure 4. Textual display of concept search output 
 
1. Concept query term “F protein” 
 
2. Type: F protein -> click on either display as dictionary or table -> click on concepts 
search button ->concept lists output 
Note: do not re-type F protein if it has been queried already (this is an illustration) 
 
3. Lists of the various color-coded concepts assigned to their respective dictionaries. 
Users can retrieve cross-referenced annotations by clicking on any of the concepts. 
Green: Human proteins and genes 
Light pink: Metabolites and enzymes 
Blue: Pathways 
Yellow: Chemicals with Pharmacological effects 
Purple: Diseases concepts 
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4. Visualization 
Network generator: click on draw network -> generates a network of interconnected 
concepts 
Hypothesis Generator: click on show hypothesis -> generates correlated concepts in a 
graphical format as hypothesis 
Download: click on table download -> retrieves a list of concepts in a CSV format 
Interactive Association Map 
 
 
Figure 5. Graphical display of interacting concepts 
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5. Association Map Analysis flow 
Click on any of the specified dictionaries (For example: metabolites and enzymes) -> 
click on draw graph -> redraws the graph with the newly defined concepts. 
 
Buttons 
Ignore links less than: enable the user to display the network according to the number of 
links. 
Paper size: enables the user to resize the map by choosing from a range of A0 to A5. 
Details [%]: enable the user to enhance the visualization clarity by varying the detail 
slider. 
 
6. Indicates the number of occurrences of the selected concept in PubMed abstracts. 
Clicking on the link retrieves the related PubMed abstracts. 
Note: The network consist of proposed correlations and the user is required to manually 
verify the abstract to either reject or accept the suggested association 
 
Hypothesis Generator 
Generate implicit relationships between disjunct literatures associated with concepts. This 
proposed hypothesis must be manually verified by consulting the linked PubMed 
abstracts 
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Figure 6. Graphical display of generated hypothesis 
 
 
7. Buttons: 
Frequency Sort: enable users to sort the generated hypothesis according to the frequency 
of occurrence of the concepts. 
Name Sort: enable users to retrieve the generated hypothesis in an alphabetical order. 
Graph: enables users to visualize the generated hypothesis in an interactive map 
Text: displays the hypothesis in a textual format 
Manual Test: by checking on this button, users are required to manually verify the 
abstract to ascertain the veracity of the proposed hypothesis. 
Auto test: automatically verifies the abstracts to ascertain whether the proposed 
correlation suggested via the hypothesis has been reported in PubMed abstracts.  
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8. This drop down menu enables users to select dictionaries and associated concepts with 
which to generate the hypothesis. This concept is known as the linking term since it links 
the starting and the targets terms respectively.  
According to Figure 6: 
Starting term: F protein belongs to the human proteins and genes dictionary 
Linking term: Hepatocellular Carcinoma belongs to the disease dictionary 
Target term: Any Concept in the pharmacological chemicals dictionary 
 
9. Click on Get hypothesis -> generates hypothesis according to specified dictionary 
concepts 
 
10. Allow browsing of hypothesis by page 
 
11. Displays the number of PubMed abstracts reporting the association 
 
12. Indicate whether the displayed correlation has been reported 
Not confirmed: Hypothesis has not been reported which could mean a novel discovery 
Found: 68, means 68 abstracts have reported the hypothesis 
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Section D: Simulated concept query examples 
1. Concept query: “Thalidomide” 
 
Figure 7. A screenshot montage of thalidomide concept query. This displays both the 
tabular and graphical output of query. Each concept is assigned a color according to its 
dictionary. Concepts belonging to the same dictionary are grouped together in the tabular 
format. The association map displays a network of interaction nodes consisting of 
concepts. 
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2. Thalidomide-Chronic Hepatitis C Association 
Generate concept query for “thalidomide” -> Click on Get hypothesis -> generates 
hypothesis -> Specify the dictionaries as indicated in figure 8 and re-generate hypothesis.  
-> Click on the linked abstract to verify the hypothesis. -> Explore results for potential 
novel insights. 
 
Figure 8. A screenshot montage showing thalidomide-chronic hepatitis C hypothesis. 
This displays the implicit relationship existing between the two concepts. The red arrow 
linking the hypothesis and PubMed abstract displays the verification of the hypothesis. 
The yellow dash lines and the white question mark sign displays the implicit relationship 
existing between the two concepts. 
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3. Thalidomide-Amantadine Association  
Generate concept query for “thalidomide” -> Click on Get hypothesis -> generates 
hypothesis -> Specify the dictionaries as indicated in figure 9 and re-generate hypothesis. 
-> Explore results for potential novel insights. 
 
 
Figure 9. A screenshot montage displaying thalidomide-amantadine hypothesis. The 
yellow dash lines and the white question mark sign displays the implicit relationship 
existing between the two concepts. 
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Appendix II (Chapter 2) 
 
Frequently asked questions (FAQ) 
 
1. What is DESHCV? 
Dragon Exploratory System on Hepatitis C Virus (DESHCV) is the first reported 
comprehensive Hepatitis C Virus (HCV) customized biomedical text-mining based 
online web resource. A list of abstracts retrieved via PubMed database using specific 
keywords searches related to HCV were processed based on concept recognition of 
concepts from several dictionaries. It is a tool with the potential to assist in discovering 
associations between biomedical concepts and could lead to new research focus and 
possible novel discoveries. 
 
2. What are the benefits of using DESHCV? 
The web query interface enables retrieval of information using specified concepts, 
keywords and phrases, generating text-derived association networks and hypotheses 
which could be tested to identify potentially novel relationship between different 
concepts. 
 
3. Which dictionaries can be retrieved from DESHCV? 
Biomedical concepts related to HCV are retrieved from the following dictionaries: 
"Human genes and proteins", "Metabolites and Enzymes", "Pathways", "Chemicals with 
pharmacological effects", and "Disease concepts".  
 
4. What makes DESHCV unique? 
DESHCV contains pre-compiled dictionaries enriched with biomedical concepts 
pertaining to HCV proteins, their name variants and symbols to make it suitable for 
targeted information exploration and knowledge extraction as focused on HCV.  
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5. Can I download the query results retrieved from the DESHCV? 
Yes, you can download the concept list and pair list spreadsheet. And also the user has 
the option of downloading the retrieved table of concepts for further analysis. The user 
may right-click on the images or figures generated to download. 
 
6. Are there any limitations in the usage of DESHCV? 
Yes, associations generated between paired concepts are inferred from co-occurrences 
and may not necessarily relate to any molecular functionality. Users are required to 
manually confirm the text accompanying the hypothesis to either accept or reject the 
suggested hypothesis. 
  
7. Are there any future updates or modification in the pipeline? 
Yes, we would like to integrate Blast and identifier queries to enhance querying 
capabilities of DESHCV. The possibility of integrating full text document is currently 
being explored and could be added to the database as a separate feature. The database 
would be updated every six months to meet the demands of ever increasing PubMed 
records related to HCV 
 
8. Is there a help manual on DESHCV? 
Yes, a help manual has been developed to ease the exploration of this database and can 
be accessed by clicking the help menu on index page (http://apps.sanbi.ac.za/DESHCV/) 
or via http://apps.sanbi.ac.za/DESHCV/help.pdf/. 
 
9. To whom can I report a bug or discrepancy? 
Please refer all queries via:  
http://apps.sanbi.ac.za/DESHCV/Contact.php 
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Appendix III (Chapter 3) 
 
Annotated protein-protein interactions assigned with HCVpro IDs and experimental 
evidence mapped onto PSI-MI term IDs. 
HCVpro ID Molecule A 
Molecule B 
Gene 
Symbols 
Molecule 
B Gene ID PMID Experimental Evidence (PSI-MI Term ID) 
hcv0001 CORE LTBR 4055 8995654 
Two Hybrid Test (MI:0018); Far-Western blot 
(MI:0047); Affinity Chromatography (MI:0004) 
hcv0002 CORE APOA2 336 9037030 Confocal microscopy (MI:0663) 
hcv0003 CORE TP53 7157 9110985 Mutational analysis (MI:0074) 
hcv0004 CORE LTBR 4055 9371602 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0005 CORE HNRNPK 3190 9651361 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059); Far-Western blot (MI:0047); 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0006 CORE CORE 951475 9851697 
Two Hybrid Test (MI:0018); Mass spectrometry 
(MI:0943); Gel filtration (MI:0071) 
hcv0007 CORE DDX3X 1654 10074132 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0008 CORE DDX3X 1654 10329544 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059); Affinity Chromatography (MI:0004) 
hcv0009 CORE DDX3X 1654 10336476 
Two Hybrid Test (MI:0018); Affinity 
Chromatography (MI:0004); Immunostaining 
(MI:0022) 
hcv0010 CORE APOA2 336 10498661 
Two Hybrid Test (MI:0018); Confocal microscopy 
(MI:0663); surface plasmon resonance (MI:0107); 
Colocalization (MI:0403) 
hcv0011 CORE TP53 7157 10544138 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059); Far-Western blot (MI:0047); 
Mutational analysis (MI:0074); Affinity 
Chromatography (MI:0004); Colocalization 
(MI:0403) 
hcv0012 CORE YWHAB 7529 10644344 
Two Hybrid Test (MI:0018); Colocalization 
(MI:0403); Coimmunoprecipitation (MI:0019); 
Affinity Chromatography (MI:0004) 
hcv0013 CORE YWHAZ 7534 10644344 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059); Coimmunoprecipitation (MI:0019); 
Western blot (MI:0113); Affinity Chromatography 
(MI:0004) 
hcv0014 CORE CREB3 10488 10675342 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0015 CORE CORE 951475 10721731 Two Hybrid Test (MI:0018) 
hcv0016 CORE CDKN1A 1026 10873631 
GST pull-down (MI:0059); Mutational analysis 
(MI:0074); Affinity Chromatography (MI:0004) 
hcv0017 CORE TAF11 6882 10924497 GST pull-down (MI:0059) 
hcv0018 CORE TP53 7157 10924497 
Western blot (MI:0113); GST pull-down 
(MI:0059) 
hcv0019 CORE C1QBP 708 11086025 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0020 CORE TNFRSF1A 7132 11226577 
GST pull-down (MI:0059); Kinase assay 
(MI:0424) (MI:0424); Affinity Chromatography 
(MI:0004) 
hcv0021 CORE FADD 8772 11336543 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
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hcv0022 CORE TNF 7124 11374864 
Western blot (MI:0113); GST pull-down 
(MI:0059); Coimmunoprecipitation (MI:0019) 
hcv0023 CORE TRADD 8717 11374864 
Western blot (MI:0113); GST pull-down 
(MI:0059); Coimmunoprecipitation (MI:0019) 
hcv0024 CORE TRAF2 7186 11374864 
Western blot (MI:0113); GST pull-down 
(MI:0059); Coimmunoprecipitation (MI:0019) 
hcv0025 CORE RXRA 6256 11915042 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019) 
hcv0026 CORE STAT3 6774 12208879 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113); GST pull-down (MI:0059) 
hcv0027 CORE TSN 7247 12532453 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019) 
hcv0028 CORE FUNDC2 65991 12665903 Two Hybrid Test (MI:0018) 
hcv0029 CORE TP73 7161 12730672 
Coimmunoprecipitation (MI:0019); Mutational 
analysis (MI:0074); Immunostaining (MI:0022) 
hcv0030 CORE TP53 7157 12730672 Coimmunoprecipitation (MI:0019) 
hcv0031 CORE JAK1 3716 12764155 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0032 CORE JAK2 3717 12764155 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0033 CORE FAS 355 12919737 
Immunoblotting (MI:0113); 
Coimmunoprecipitation (MI:0019) 
hcv0034 CORE CCNH 902 14711830 
Immunofluorescence (MI:0022); Confocal 
microscopy (MI:0663); GST pull-down (MI:0059); 
Immunoblotting (MI:0113); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113); Immunostaining (MI:0022) 
hcv0035 CORE TBP 6908 14730212 Affinity Chromatography (MI:0004) 
hcv0036 CORE TP53BP2 7159 14985081 
Two Hybrid Test (MI:0018); Affinity 
Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); 
Immunostaining (MI:0022) 
hcv0037 CORE SMAD3 4088 15334054 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059); Affinity Chromatography 
(MI:0004) 
hcv0038 CORE EP300 2033 15380363 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059); Western blot (MI:0113); Affinity 
Chromatography (MI:0004) 
hcv0039 CORE CREBBP 1387 15380363 
GST pull-down (MI:0059); Western blot 
(MI:0113); Affinity Chromatography (MI:0004) 
hcv0040 CORE TLR2 7097 15521019 
Enzyme-linked immunosorbent assay (MI:0411); 
Electrophoretic mobility shift assay (MI:0413); 
Western blot (MI:0113); Kinase assay (MI:0424) 
(MI:0424); Confocal microscopy (MI:0663); Flow 
cytometry (MI:0054); Colocalization (MI:0403) 
hcv0041 CORE HLA-A 3105 15681828 
Fluorescence-activated cell sorting (MI:0054); 
Immunostaining (MI:0022) 
hcv0042 CORE HLA-E 3133 15681828 
Fluorescence-activated cell sorting (MI:0054); 
Immunostaining (MI:0022) 
hcv0043 CORE STAT1 6772 15825084 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0044 CORE ACP1 52 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0045 CORE CFL1 1072 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0046 CORE FKBP7 51661 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0047 CORE HSPD1 3329 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0048 CORE KRT18 3875 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
 
 
 
 
 137 
hcv0049 CORE KRT19 3880 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0050 CORE KRT8 3856 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0051 CORE SLC22A7 10864 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0052 CORE TATDN1 83940 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0053 CORE GLRX3 10539 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0054 CORE VIM 7431 15846844 
2-DE (MI:0982); Mass spectrometry (MI:0943); 
Immunoblotting (MI:0113); Immunofluorescence 
(MI:0022) 
hcv0055 CORE NPM1 4869 16170350 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0056 CORE YY1 7528 16170350 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0057 CORE PML 5371 16322229 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019); Colocalization (MI:0403) 
hcv0058 CORE DICER1 23405 16530526 
Confocal microscopy (MI:0663); 
Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0059 CORE PSME3 10197 16611896 Western blot (MI:0113) 
hcv0060 CORE DICER1 23405 18325616 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019); Immunofluorescence (MI:0022); 
Immunostaining (MI:0022); Mutational analysis 
(MI:0074) 
hcv0061 CORE AGRN 375790 18985028 Two Hybrid Test (MI:0018) 
hcv0062 CORE BCAR1 9564 18985028 Two Hybrid Test (MI:0018) 
hcv0063 CORE CD68 968 18985028 Two Hybrid Test (MI:0018) 
hcv0064 CORE COL4A2 1284 18985028 Two Hybrid Test (MI:0018) 
hcv0065 CORE DDX3Y 8653 18985028 Two Hybrid Test (MI:0018) 
hcv0066 CORE EGFL7 51162 18985028 Two Hybrid Test (MI:0018) 
hcv0067 CORE FBLN2 2199 18985028 Two Hybrid Test (MI:0018) 
hcv0068 CORE FBLN5 10516 18985028 Two Hybrid Test (MI:0018) 
hcv0069 CORE GAPDH 2597 18985028 Two Hybrid Test (MI:0018) 
hcv0070 CORE GRN 2896 18985028 Two Hybrid Test (MI:0018) 
hcv0071 CORE HIVEP2 3097 18985028 Two Hybrid Test (MI:0018) 
hcv0072 CORE HOXD8 3234 18985028 Two Hybrid Test (MI:0018) 
hcv0073 CORE LPXN 9404 18985028 Two Hybrid Test (MI:0018) 
hcv0074 CORE LRRTM1 347730 18985028 Two Hybrid Test (MI:0018) 
hcv0075 CORE LTBP4 8425 18985028 Two Hybrid Test (MI:0018) 
hcv0076 CORE MAGED1 9500 18985028 Two Hybrid Test (MI:0018) 
hcv0077 CORE MEGF6 1953 18985028 Two Hybrid Test (MI:0018) 
hcv0078 CORE MMRN2 79812 18985028 Two Hybrid Test (MI:0018) 
hcv0079 CORE NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0080 CORE PABPN1 8106 18985028 Two Hybrid Test (MI:0018) 
hcv0081 CORE PAK4 10298 18985028 Two Hybrid Test (MI:0018) 
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hcv0082 CORE PLSCR1 5359 18985028 Two Hybrid Test (MI:0018) 
hcv0083 CORE RNF31 55072 18985028 Two Hybrid Test (MI:0018) 
hcv0084 CORE SETD2 29072 18985028 Two Hybrid Test (MI:0018) 
hcv0085 CORE SLC31A2 1318 18985028 Two Hybrid Test (MI:0018) 
hcv0086 CORE VWF 7450 18985028 Two Hybrid Test (MI:0018) 
hcv0087 CORE ZNF271 10778 18985028 Two Hybrid Test (MI:0018) 
hcv0088 CORE YWHAE 7531 10644344 
Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018) 
hcv0089 CORE NS5A 951475 11883187 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Colocalization 
(MI:0403); Affinity Chromatography (MI:0004) 
hcv0090 CORE NS5B 951475 11929715 
Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019) 
hcv0091 CORE RSF1 51773 12401801 GST pull-down (MI:0059) 
hcv0092 CORE E1 951475 12466485 
GST pull-down (MI:0059); Affinity 
Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019) 
hcv0093 CORE SP110 3431 14559998 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0094 CORE KPNA1 3836 15613354 GST pull-down (MI:0059) 
hcv0095 CORE DDX5 1655 15846844 2-DE (MI:0982); Mass spectrometry (MI:0943) 
hcv0096 CORE NS5A 951475 16166788 Two Hybrid Test (MI:0018) 
hcv0097 CORE EIF2AK2 5610 17267064 
Two Hybrid Test (MI:0018); Colocalization 
(MI:0403); Coimmunoprecipitation (MI:0019) 
hcv0098 CORE PPARA 5465 17764115 
Immunoblotting (MI:0113); Affinity 
Chromatography (MI:0004) 
hcv0099 CORE ACY3 91703 18158989 Two Hybrid Test (MI:0018) 
hcv0100 CORE MCL1 4170 19605477 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0101 CORE CORE 951475 8615040 
Two Hybrid Test (MI:0018); Far-Western blot 
(MI:0047); Mutational analysis (MI:0074); GST 
pull-down (MI:0059); Affinity Chromatography 
(MI:0004); Far-Western blot (MI:0047); Cross 
Linking (MI:0030) 
hcv0102 CORE CORE 951475 9191926 
Affinity Chromatography (MI:0004); Two Hybrid 
Test (MI:0018) 
hcv0103 E1 E2 951475 8083956 
Coimmunoprecipitation (MI:0019); Colocalization 
(MI:0403); sedimentation (MI:0029) 
hcv0104 E1 CORE 951475 8764026 
Mutational analysis (MI:0074); 
Coimmunoprecipitation (MI:0019) 
hcv0105 E1 LTF 4057 9223490 
Far-Western blot (MI:0047); 
Coimmunoprecipitation (MI:0019); Pull-down 
(MI:0096) 
hcv0106 E1 CALR 811 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0107 E1 CANX 821 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0108 E1 HSPA5 3309 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0109 E1 E2 951475 10807921 
Coimmunoprecipitation (MI:0019); Mutational 
analysis (MI:0074); circular dichroism 
spectroscopy (MI:0016); Three dimensional 
structure (MI:0105) 
hcv0110 E1 E2 951475 12502883 Coimmunoprecipitation (MI:0019) 
hcv0111 E1 CD209 30835 12634366 Enzyme-linked immunosorbent assay (MI:0411) 
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hcv0112 E1 CLEC4M 10332 12634366 Enzyme-linked immunosorbent assay (MI:0411) 
hcv0113 E1 E2 951475 15136562 
Mutational analysis (MI:0074); 
Coimmunoprecipitation (MI:0019) 
hcv0114 E1 CD209 30835 15254204 
Mutational analysis (MI:0074); Enzyme-linked 
immunosorbent assay (MI:0411) 
hcv0115 E1 JUN 3725 18985028 Two Hybrid Test (MI:0018) 
hcv0116 E1 NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0117 E1 PFN1 5216 18985028 Two Hybrid Test (MI:0018) 
hcv0118 E1 SETD2 29072 18985028 Two Hybrid Test (MI:0018) 
hcv0119 E1 TMSB4X 7114 18985028 Two Hybrid Test (MI:0018) 
hcv0120 E1 NS5A 951475 10721731 Two Hybrid Test (MI:0018) 
hcv0121 E1 E2 951475 8212557 Coimmunoprecipitation (MI:0019) 
hcv0122 E2 LTF 4057 9223490 
Far-Western blot (MI:0047); 
Coimmunoprecipitation (MI:0019); Pull-down 
(MI:0096) 
hcv0123 E2 CALR 811 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0124 E2 CANX 821 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0125 E2 HSPA5 3309 9557669 
Metabolic labeling (MI:2131); 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0126 E2 EIF2AK2 5610 10390359 
Kinase assay (MI:0424) (MI:0424); His pull-down 
(MI:0061) 
hcv0127 E2 NS3 951475 10721731 Two Hybrid Test (MI:0018) 
hcv0128 E2 CD81 975 10846074 
Competition Binding Experiment (MI:0405); 
Enzyme-linked immunosorbent assay (MI:0411) 
hcv0129 E2 CD81 975 11080483 
Enzyme-linked immunosorbent assay (MI:0411); 
Immunofluorescence (MI:0022); Competition 
Binding Experiment (MI:0405) 
hcv0130 E2 SCARB1 949 12356718 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113) 
hcv0131 E2 CD81 975 12522210 Far-Western blot (MI:0047) 
hcv0132 E2 LTF 4057 12522210 Far-Western blot (MI:0047) 
hcv0133 E2 TF 7018 12522210 Far-Western blot (MI:0047) 
hcv0134 E2 CD81 975 12604806 Affinity Chromatography (MI:0004) 
hcv0135 E2 EIF2AK3 9451 12610133 
Coimmunoprecipitation (MI:0019); Western blot 
(MI:0113); Kinase assay (MI:0424) (MI:0424) 
hcv0136 E2 CD209 30835 12634366 
Fluorescence-activated cell sorting (MI:0054); 
Enzyme-linked immunosorbent assay (MI:0411); 
Flow cytometry (MI:0054); Western blot 
(MI:0113); Immunostaining (MI:0022) 
hcv0137 E2 CLEC4M 10332 12634366 
Fluorescence-activated cell sorting (MI:0054); 
Enzyme-linked immunosorbent assay (MI:0411); 
Immunostaining (MI:0022) 
hcv0138 E2 SDC2 6383 12867431 
Enzyme-linked immunosorbent assay (MI:0411); 
Flow cytometry (MI:0054) 
hcv0139 E2 CD209 30835 15254204 
Mutational analysis (MI:0074); Enzyme-linked 
immunosorbent assay (MI:0411) 
hcv0140 E2 HOXD8 3234 18985028 Two Hybrid Test (MI:0018) 
hcv0141 E2 ITGB1 3688 18985028 Two Hybrid Test (MI:0018) 
hcv0142 E2 FAM135A 57579 18985028 Two Hybrid Test (MI:0018) 
hcv0143 E2 NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0144 E2 PSMA6 5687 18985028 Two Hybrid Test (MI:0018) 
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hcv0145 E2 SETD2 29072 18985028 Two Hybrid Test (MI:0018) 
hcv0146 E2 SMEK2 57223 18985028 Two Hybrid Test (MI:0018) 
hcv0147 F C14orf135 64430 16237761 Two Hybrid Test (MI:0018) 
hcv0148 F ZNF83 55769 16237761 Two Hybrid Test (MI:0018) 
hcv0149 F PFDN2 5202 16876117 
Two Hybrid Test (MI:0018); Confocal microscopy 
(MI:0663); Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019) 
hcv0150 F PFDN5 5204 18398700 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059); Coimmunoprecipitation (MI:0019); 
Confocal microscopy (MI:0663) 
hcv0151 F AGT 183 16237761 Two Hybrid Test (MI:0018) 
hcv0152 F AZGP1 563 16237761 Two Hybrid Test (MI:0018) 
hcv0153 F CTSB 1508 16237761 Two Hybrid Test (MI:0018) 
hcv0154 F MPDU1 9526 16237761 Two Hybrid Test (MI:0018) 
hcv0155 F RAB14 51552 16237761 Two Hybrid Test (MI:0018) 
hcv0156 F SERPINC1 462 16237761 Two Hybrid Test (MI:0018) 
hcv0157 F ST3GAL1 6482 16237761 Two Hybrid Test (MI:0018) 
hcv0158 F vitronectin 7448 16237761 Two Hybrid Test (MI:0018) 
hcv0159 F ZG16 653808 16237761 Two Hybrid Test (MI:0018) 
hcv0160 NS2 NS4A 951475 10721731 
Two Hybrid Test (MI:0018); Affinity 
Chromatography (MI:0004) 
hcv0161 NS2 NS3 951475 11559826 
Size-exclusion chromatography (MI:0071); 
Mutational analysis (MI:0074) 
hcv0162 NS2 CIDEB 27141 12595532 
Two Hybrid Test (MI:0018); Colocalization 
(MI:0403); Coimmunoprecipitation (MI:0019);  
Affinity Chromatography (MI:0004) 
hcv0163 NS2 NS4B 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663) 
hcv0164 NS2 NS4A 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663) 
hcv0165 NS2 NS5B 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663) 
hcv0166 NS2 NS2 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Affinity Chromatography (MI:0004) 
hcv0167 NS2 NS3 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Affinity Chromatography (MI:0004); 
Immunostaining (MI:0022) 
hcv0168 NS2 C7 730 18985028 Two Hybrid Test (MI:0018) 
hcv0169 NS2 FBLN5 10516 18985028 Two Hybrid Test (MI:0018) 
hcv0170 NS2 HOXD8 3234 18985028 Two Hybrid Test (MI:0018) 
hcv0171 NS2 NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0172 NS2 POU3F2 5454 18985028 Two Hybrid Test (MI:0018) 
hcv0173 NS2 SETD2 29072 18985028 Two Hybrid Test (MI:0018) 
hcv0174 NS2 TRIM27 5987 18985028 Two Hybrid Test (MI:0018) 
hcv0175 NS2 NS5A 951475 12692242 Coimmunoprecipitation (MI:0019) 
hcv0176 NS3 NS4A 951475 7494258 
Coimmunoprecipitation (MI:0019); Mutational 
analysis (MI:0074) 
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hcv0177 NS3 MBP 4155 8647104 Affinity Chromatography (MI:0004) 
hcv0178 NS3 PRM1 5619 8647104 Affinity Chromatography (MI:0004) 
hcv0179 NS3 HIST4H4 121504 8647104 Affinity Chromatography (MI:0004) 
hcv0180 NS3 
HIST3H2B
B 128312 8647104 Affinity Chromatography (MI:0004) 
hcv0181 NS3 PRKACA 5566 8647104 
GST pull-down (MI:0059); autoradiography 
(MI:0833); Affinity Chromatography (MI:0004) 
hcv0182 NS3 PRKACA 5566 9060639 
Competition Binding Experiment (MI:0405); Far-
Western blot (MI:0047) 
hcv0183 NS3 NS3 951475 9187654 Three dimensional structure (MI:0105) 
hcv0184 NS3 TP53 7157 9827557 Coimmunoprecipitation (MI:0019) 
hcv0185 NS3 NS4A 951475 9827557 Coimmunoprecipitation (MI:0019) 
hcv0186 NS3 NS4A 951475 10220351 
Gel filtration (MI:0071); Affinity Chromatography 
(MI:0004) 
hcv0187 NS3 
HIST3H2B
B 128312 10405893 
Proteolytic fragmentation (MI:0079); 
microsequencing (MI:0093); specific histone 
binding assay (MI:0079); Gel filtration (MI:0071) 
hcv0188 NS3 HIST4H4 121504 10405893 
Proteolytic fragmentation (MI:0079); 
microsequencing (MI:0093); specific histone 
binding assay (MI:0079); Gel filtration (MI:0071) 
hcv0189 NS3 SERPINF2 5345 10570951 
Immunoblotting (MI:0113); Western blot 
(MI:0113) 
hcv0190 NS3 SERPING1 710 10570951 
Immunoblotting (MI:0113); Western blot 
(MI:0113) 
hcv0191 NS3 NS4A 951475 10721731 Two Hybrid Test (MI:0018) 
hcv0192 NS3 PRMT5 10419 11152681 
Two Hybrid Test (MI:0018); Western blot 
(MI:0113) 
hcv0193 NS3 PRMT1 3276 11483748 
Coimmunoprecipitation (MI:0019); 
Immunoblotting (MI:0113); Affinity 
Chromatography (MI:0004); Immunoblotting 
(MI:0113); GST pull-down (MI:0059) 
hcv0194 NS3 NS3 951475 12465917 Three dimensional structure (MI:0105) 
hcv0195 NS3 NS4B 951475 12692242 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
GST pull-down (MI:0059) 
hcv0196 NS3 NS4A 951475 12692242 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Immunostaining (MI:0022); GST pull-down 
(MI:0059) 
hcv0197 NS3 NS3 951475 12692242 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
GST pull-down (MI:0059) 
hcv0198 NS3 IRF3 3661 12702807 
Mutational analysis (MI:0074); Immunoblotting 
(MI:0113) 
hcv0199 NS3 SNRPD1 6632 14524621 
Two Hybrid Test (MI:0018); Mutational analysis 
(MI:0074); Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019) 
hcv0200 NS3 NS4A 951475 14627400 Three dimensional structure (MI:0105) 
hcv0201 NS3 NS4A 951475 14984200 Three dimensional structure (MI:0105) 
hcv0202 NS3 PSMB8 5696 15303969 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0203 NS3 SMAD3 4088 15334054 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0204 NS3 NS4A 951475 15501035 Three dimensional structure (MI:0105) 
hcv0205 NS3 TLR2 7097 15521019 
Electrophoretic mobility shift assay (MI:0413); 
Western blot (MI:0113); Confocal microscopy 
(MI:0663); Flow cytometry (MI:0054) 
hcv0206 NS3 TICAM1 148022 15767257 
Immunoblotting (MI:0113); Affinity 
Chromatography (MI:0004); Immunofluorescence 
(MI:0022); circular dichroism spectroscopy 
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(MI:0016); Three dimensional structure (MI:0105) 
hcv0207 NS3 PTBP2 58155 15823607 
Immunofluorescence (MI:0022); GST pull-down 
(MI:0059); Colocalization (MI:0403); 
Coimmunoprecipitation (MI:0019) 
hcv0208 NS3 IKBKE 9641 15841462 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019) 
hcv0209 NS3 TBK1 29110 15841462 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019) 
hcv0210 NS3 ERC1 23085 16033967 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059); Confocal microscopy (MI:0663); 
immunoelectron microscopy (MI:0040);  Two 
Hybrid Test (MI:0018) 
hcv0211 NS3 NS4A 951475 16078825 Three dimensional structure (MI:0105) 
hcv0212 NS3 NS4A 951475 16112862 Three dimensional structure (MI:0105) 
hcv0213 NS3 NS4A 951475 16413182 Three dimensional structure (MI:0105) 
hcv0214 NS3 NS4A 951475 16876765 
Confocal microscopy (MI:0663); Colocalization 
(MI:0403) 
hcv0215 NS3 VISA 57506 17289677 
Immunoblotting (MI:0113); 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663) 
hcv0216 NS3 NS5B 951475 18179252 
Pull-down (MI:0096); surface plasmon resonance 
(MI:0107); fluorescence polarization binding assay 
(MI:0053) 
hcv0217 NS3 ACTN1 87 18985028 Two Hybrid Test (MI:0018) 
hcv0218 NS3 ACTN2 88 18985028 Two Hybrid Test (MI:0018) 
hcv0219 NS3 AEBP1 165 18985028 Two Hybrid Test (MI:0018) 
hcv0220 NS3 ANKRD12 23253 18985028 Two Hybrid Test (MI:0018) 
hcv0221 NS3 ANKRD28 23243 18985028 Two Hybrid Test (MI:0018) 
hcv0222 NS3 ARFIP2 23647 18985028 Two Hybrid Test (MI:0018) 
hcv0223 NS3 ARHGEF6 9459 18985028 Two Hybrid Test (MI:0018) 
hcv0224 NS3 ARNT 405 18985028 Two Hybrid Test (MI:0018) 
hcv0225 NS3 ARS2 51593 18985028 Two Hybrid Test (MI:0018) 
hcv0226 NS3 ASXL1 171023 18985028 Two Hybrid Test (MI:0018) 
hcv0227 NS3 B2M 567 18985028 Two Hybrid Test (MI:0018) 
hcv0228 NS3 BCAN 63827 18985028 Two Hybrid Test (MI:0018) 
hcv0229 NS3 BCKDK 10295 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0230 NS3 BCL2A1 597 18985028 Two Hybrid Test (MI:0018) 
hcv0231 NS3 BCL6 604 18985028 Two Hybrid Test (MI:0018) 
hcv0232 NS3 BZRAP1 9256 18985028 Two Hybrid Test (MI:0018) 
hcv0233 NS3 C10orf18 54906 18985028 Two Hybrid Test (MI:0018) 
hcv0234 NS3 C10orf6 55719 18985028 Two Hybrid Test (MI:0018) 
hcv0235 NS3 C12orf41 54934 18985028 Two Hybrid Test (MI:0018) 
hcv0236 NS3 INF2 64423 18985028 Two Hybrid Test (MI:0018) 
hcv0237 NS3 C16orf7 9605 18985028 Two Hybrid Test (MI:0018) 
hcv0238 NS3 BEND5 79656 18985028 Two Hybrid Test (MI:0018) 
hcv0239 NS3 C1orf94 84970 18985028 Two Hybrid Test (MI:0018) 
hcv0240 NS3 C9orf30 91283 18985028 Two Hybrid Test (MI:0018) 
hcv0241 NS3 
CALCOCO
2 10241 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
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hcv0242 NS3 CBY1 25776 18985028 Two Hybrid Test (MI:0018) 
hcv0243 NS3 CCDC21 64793 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0244 NS3 CCDC37 348807 18985028 Two Hybrid Test (MI:0018) 
hcv0245 NS3 CCDC52 152185 18985028 Two Hybrid Test (MI:0018) 
hcv0246 NS3 CCDC66 285331 18985028 Two Hybrid Test (MI:0018) 
hcv0247 NS3 INO80E 283899 18985028 Two Hybrid Test (MI:0018) 
hcv0248 NS3 CCHCR1 54535 18985028 Two Hybrid Test (MI:0018) 
hcv0249 NS3 CD5L 922 18985028 Two Hybrid Test (MI:0018) 
hcv0250 NS3 CDC23 8697 18985028 Two Hybrid Test (MI:0018) 
hcv0251 NS3 CELSR2 1952 18985028 Two Hybrid Test (MI:0018) 
hcv0252 NS3 CEP152 22995 18985028 Two Hybrid Test (MI:0018) 
hcv0253 NS3 CEP192 55125 18985028 Two Hybrid Test (MI:0018) 
hcv0254 NS3 CFP 5199 18985028 Two Hybrid Test (MI:0018) 
hcv0255 NS3 CHPF 79586 18985028 Two Hybrid Test (MI:0018) 
hcv0256 NS3 CORO1B 57175 18985028 Two Hybrid Test (MI:0018) 
hcv0257 NS3 CSNK2B 1460 18985028 Two Hybrid Test (MI:0018) 
hcv0258 NS3 CTGF 1490 18985028 Two Hybrid Test (MI:0018) 
hcv0259 NS3 ALG13 79868 18985028 Two Hybrid Test (MI:0018) 
hcv0260 NS3 DEAF1 10522 18985028 Two Hybrid Test (MI:0018) 
hcv0261 NS3 DES 1674 18985028 Two Hybrid Test (MI:0018) 
hcv0262 NS3 DLAT 1737 18985028 Two Hybrid Test (MI:0018) 
hcv0263 NS3 DOCK7 85440 18985028 Two Hybrid Test (MI:0018) 
hcv0264 NS3 DPF1 8193 18985028 Two Hybrid Test (MI:0018) 
hcv0265 NS3 DPP7 29952 18985028 Two Hybrid Test (MI:0018) 
hcv0266 NS3 EEF1A1 1915 18985028 Two Hybrid Test (MI:0018) 
hcv0267 NS3 EFEMP1 2202 18985028 Two Hybrid Test (MI:0018) 
hcv0268 NS3 EFEMP2 30008 18985028 Two Hybrid Test (MI:0018) 
hcv0269 NS3 EIF1 10209 18985028 Two Hybrid Test (MI:0018) 
hcv0270 NS3 EIF4ENIF1 56478 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0271 NS3 FAM120B 84498 18985028 Two Hybrid Test (MI:0018) 
hcv0272 NS3 FAM65A 79567 18985028 Two Hybrid Test (MI:0018) 
hcv0273 NS3 FBF1 85302 18985028 Two Hybrid Test (MI:0018) 
hcv0274 NS3 FBLN1 2192 18985028 Two Hybrid Test (MI:0018) 
hcv0275 NS3 FBLN2 2199 18985028 Two Hybrid Test (MI:0018) 
hcv0276 NS3 FBLN5 10516 18985028 Two Hybrid Test (MI:0018) 
hcv0277 NS3 FBN1 2200 18985028 Two Hybrid Test (MI:0018) 
hcv0278 NS3 FBN3 84467 18985028 Two Hybrid Test (MI:0018) 
hcv0279 NS3 FES 2242 18985028 Two Hybrid Test (MI:0018) 
hcv0280 NS3 FIGNL1 63979 18985028 Two Hybrid Test (MI:0018) 
hcv0281 NS3 FLAD1 80308 18985028 Two Hybrid Test (MI:0018) 
hcv0282 NS3 C19orf66 55337 18985028 Two Hybrid Test (MI:0018) 
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hcv0283 NS3 FN1 2335 18985028 Two Hybrid Test (MI:0018) 
hcv0284 NS3 FRMPD4 9758 18985028 Two Hybrid Test (MI:0018) 
hcv0285 NS3 FRS3 10817 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0286 NS3 FTH1 2495 18985028 Two Hybrid Test (MI:0018) 
hcv0287 NS3 FUCA2 2519 18985028 Two Hybrid Test (MI:0018) 
hcv0288 NS3 GAA 2548 18985028 Two Hybrid Test (MI:0018) 
hcv0289 NS3 GBP2 2634 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0290 NS3 GFAP 2670 18985028 Two Hybrid Test (MI:0018) 
hcv0291 NS3 GNB2 2783 18985028 Two Hybrid Test (MI:0018) 
hcv0292 NS3 GON4L 54856 18985028 Two Hybrid Test (MI:0018) 
hcv0293 NS3 HIVEP2 3097 18985028 Two Hybrid Test (MI:0018) 
hcv0294 NS3 HNRNPK 3190 18985028 Two Hybrid Test (MI:0018) 
hcv0295 NS3 HOMER3 9454 18985028 Two Hybrid Test (MI:0018) 
hcv0296 NS3 IQWD1 55827 18985028 Two Hybrid Test (MI:0018) 
hcv0297 NS3 ITGB4 3691 18985028 Two Hybrid Test (MI:0018) 
hcv0298 NS3 JAG2 3714 18985028 Two Hybrid Test (MI:0018) 
hcv0299 NS3 JUN 3725 18985028 Two Hybrid Test (MI:0018) 
hcv0300 NS3 KHDRBS1 10657 18985028 Two Hybrid Test (MI:0018) 
hcv0301 NS3 KIAA1549 57670 18985028 Two Hybrid Test (MI:0018) 
hcv0302 NS3 KIF17 57576 18985028 Two Hybrid Test (MI:0018) 
hcv0303 NS3 KIF7 374654 18985028 Two Hybrid Test (MI:0018) 
hcv0304 NS3 KPNA1 3836 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0305 NS3 L3MBTL3 84456 18985028 Two Hybrid Test (MI:0018) 
hcv0306 NS3 LAMA5 3911 18985028 Two Hybrid Test (MI:0018) 
hcv0307 NS3 LAMB2 3913 18985028 Two Hybrid Test (MI:0018) 
hcv0308 NS3 LAMC3 10319 18985028 Two Hybrid Test (MI:0018) 
hcv0309 NS3 LDB1 8861 18985028 Two Hybrid Test (MI:0018) 
hcv0310 NS3 LRRC7 57554 18985028 Two Hybrid Test (MI:0018) 
hcv0311 NS3 LRRCC1 85444 18985028 Two Hybrid Test (MI:0018) 
hcv0312 NS3 LTBP4 8425 18985028 Two Hybrid Test (MI:0018) 
hcv0313 NS3 LZTS2 84445 18985028 Two Hybrid Test (MI:0018) 
hcv0314 NS3 MAGED1 9500 18985028 Two Hybrid Test (MI:0018) 
hcv0315 NS3 MAPK7 5598 18985028 Two Hybrid Test (MI:0018) 
hcv0316 NS3 MEGF8 1954 18985028 Two Hybrid Test (MI:0018) 
hcv0317 NS3 MLLT4 4301 18985028 Two Hybrid Test (MI:0018) 
hcv0318 NS3 MLXIP 22877 18985028 Two Hybrid Test (MI:0018) 
hcv0319 NS3 MORC4 79710 18985028 Two Hybrid Test (MI:0018) 
hcv0320 NS3 MORF4L1 10933 18985028 Two Hybrid Test (MI:0018) 
hcv0321 NS3 MVP 9961 18985028 Two Hybrid Test (MI:0018) 
hcv0322 NS3 NAP1L1 4673 18985028 Two Hybrid Test (MI:0018) 
hcv0323 NS3 NAP1L2 4674 18985028 Two Hybrid Test (MI:0018) 
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hcv0324 NS3 NCAN 1463 18985028 Two Hybrid Test (MI:0018) 
hcv0325 NS3 NDC80 10403 18985028 Two Hybrid Test (MI:0018) 
hcv0326 NS3 NEFL 4747 18985028 Two Hybrid Test (MI:0018) 
hcv0327 NS3 NEFM 4741 18985028 Two Hybrid Test (MI:0018) 
hcv0328 NS3 NELL1 4745 18985028 Two Hybrid Test (MI:0018) 
hcv0329 NS3 NELL2 4753 18985028 Two Hybrid Test (MI:0018) 
hcv0330 NS3 NID1 4811 18985028 Two Hybrid Test (MI:0018) 
hcv0331 NS3 NID2 22795 18985028 Two Hybrid Test (MI:0018) 
hcv0332 NS3 NOTCH1 4851 18985028 Two Hybrid Test (MI:0018) 
hcv0333 NS3 N-PAC 84656 18985028 Two Hybrid Test (MI:0018) 
hcv0334 NS3 NUP62 23636 18985028 Two Hybrid Test (MI:0018) 
hcv0335 NS3 OBSCN 84033 18985028 Two Hybrid Test (MI:0018) 
hcv0336 NS3 PARP4 143 18985028 Two Hybrid Test (MI:0018) 
hcv0337 NS3 PCYT2 5833 18985028 Two Hybrid Test (MI:0018) 
hcv0338 NS3 PDE4DIP 9659 18985028 Two Hybrid Test (MI:0018) 
hcv0339 NS3 PDLIM5 10611 18985028 Two Hybrid Test (MI:0018) 
hcv0340 NS3 PICK1 9463 18985028 Two Hybrid Test (MI:0018) 
hcv0341 NS3 PKNOX1 5316 18985028 Two Hybrid Test (MI:0018) 
hcv0342 NS3 PLEKHG4 25894 18985028 Two Hybrid Test (MI:0018) 
hcv0343 NS3 PNPLA8 50640 18985028 Two Hybrid Test (MI:0018) 
hcv0344 NS3 PRRC1 133619 18985028 Two Hybrid Test (MI:0018) 
hcv0345 NS3 PSMB9 5698 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0346 NS3 PSME3 10197 18985028 Two Hybrid Test (MI:0018) 
hcv0347 NS3 PTPRN2 5799 18985028 Two Hybrid Test (MI:0018) 
hcv0348 NS3 RABEP1 9135 18985028 Two Hybrid Test (MI:0018) 
hcv0349 NS3 RAI14 26064 18985028 Two Hybrid Test (MI:0018) 
hcv0350 NS3 RASAL2 9462 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0351 NS3 RBM4 5936 18985028 Two Hybrid Test (MI:0018) 
hcv0352 NS3 RCN3 57333 18985028 Two Hybrid Test (MI:0018) 
hcv0353 NS3 RGNEF 64283 18985028 Two Hybrid Test (MI:0018) 
hcv0354 NS3 RICS 9743 18985028 Two Hybrid Test (MI:0018) 
hcv0355 NS3 RINT1 60561 18985028 Two Hybrid Test (MI:0018) 
hcv0356 NS3 RNF31 55072 18985028 Two Hybrid Test (MI:0018) 
hcv0357 NS3 ROGDI 79641 18985028 Two Hybrid Test (MI:0018) 
hcv0358 NS3 KIAA2022 340533 18985028 Two Hybrid Test (MI:0018) 
hcv0359 NS3 RUSC2 9853 18985028 Two Hybrid Test (MI:0018) 
hcv0360 NS3 SBF1 6305 18985028 Two Hybrid Test (MI:0018) 
hcv0361 NS3 SDCCAG8 10806 18985028 Two Hybrid Test (MI:0018) 
hcv0362 NS3 SECISBP2 79048 18985028 Two Hybrid Test (MI:0018) 
hcv0363 NS3 10-Sep 151011 18985028 Two Hybrid Test (MI:0018) 
hcv0364 NS3 SERTAD1 29950 18985028 Two Hybrid Test (MI:0018) 
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hcv0365 NS3 SESTD1 91404 18985028 Two Hybrid Test (MI:0018) 
hcv0366 NS3 SF3B2 10992 18985028 Two Hybrid Test (MI:0018) 
hcv0367 NS3 SIAH1 6477 18985028 Two Hybrid Test (MI:0018) 
hcv0368 NS3 SLIT1 6585 18985028 Two Hybrid Test (MI:0018) 
hcv0369 NS3 SLIT2 9353 18985028 Two Hybrid Test (MI:0018) 
hcv0370 NS3 SLIT3 6586 18985028 Two Hybrid Test (MI:0018) 
hcv0371 NS3 SMURF2 64750 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0372 NS3 SNX4 8723 18985028 Two Hybrid Test (MI:0018) 
hcv0373 NS3 SPOCK3 50859 18985028 Two Hybrid Test (MI:0018) 
hcv0374 NS3 SPON1 10418 18985028 Two Hybrid Test (MI:0018) 
hcv0375 NS3 SRPX2 27286 18985028 Two Hybrid Test (MI:0018) 
hcv0376 NS3 SSX2IP 117178 18985028 Two Hybrid Test (MI:0018) 
hcv0377 NS3 STAB1 23166 18985028 Two Hybrid Test (MI:0018) 
hcv0378 NS3 STAT3 6774 18985028 Two Hybrid Test (MI:0018) 
hcv0379 NS3 SVEP1 79987 18985028 Two Hybrid Test (MI:0018) 
hcv0380 NS3 SYNE1 23345 18985028 Two Hybrid Test (MI:0018) 
hcv0381 NS3 SYNPO2 171024 18985028 Two Hybrid Test (MI:0018) 
hcv0382 NS3 TAF1 6872 18985028 Two Hybrid Test (MI:0018) 
hcv0383 NS3 TBC1D2B 23102 18985028 Two Hybrid Test (MI:0018) 
hcv0384 NS3 TBXAS1 6916 18985028 Two Hybrid Test (MI:0018) 
hcv0385 NS3 TGFB1I1 7041 18985028 Two Hybrid Test (MI:0018) 
hcv0386 NS3 THAP1 55145 18985028 Two Hybrid Test (MI:0018) 
hcv0387 NS3 TMEM63B 55362 18985028 Two Hybrid Test (MI:0018) 
hcv0388 NS3 TRIM23 373 18985028 Two Hybrid Test (MI:0018) 
hcv0389 NS3 TRIM27 5987 18985028 Two Hybrid Test (MI:0018) 
hcv0390 NS3 TRIO 7204 18985028 Two Hybrid Test (MI:0018) 
hcv0391 NS3 TRIP11 9321 18985028 Two Hybrid Test (MI:0018) 
hcv0392 NS3 TXNDC11 51061 18985028 Two Hybrid Test (MI:0018) 
hcv0393 NS3 UBA3 9039 18985028 Two Hybrid Test (MI:0018) 
hcv0394 NS3 USHBP1 83878 18985028 Two Hybrid Test (MI:0018) 
hcv0395 NS3 UXT 8409 18985028 Two Hybrid Test (MI:0018) 
hcv0396 NS3 VCAN 1462 18985028 Two Hybrid Test (MI:0018) 
hcv0397 NS3 VIM 7431 18985028 Two Hybrid Test (MI:0018) 
hcv0398 NS3 VWF 7450 18985028 Two Hybrid Test (MI:0018) 
hcv0399 NS3 XAB2 56949 18985028 Two Hybrid Test (MI:0018) 
hcv0400 NS3 XRN2 22803 18985028 Two Hybrid Test (MI:0018) 
hcv0401 NS3 YY1AP1 55249 18985028 Two Hybrid Test (MI:0018) 
hcv0402 NS3 ZBTB1 22890 18985028 Two Hybrid Test (MI:0018) 
hcv0403 NS3 ZCCHC7 84186 18985028 Two Hybrid Test (MI:0018) 
hcv0404 NS3 ZHX3 23051 18985028 Two Hybrid Test (MI:0018) 
hcv0405 NS3 ZMYM2 7750 18985028 Two Hybrid Test (MI:0018) 
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hcv0406 NS3 ZNF281 23528 18985028 Two Hybrid Test (MI:0018) 
hcv0407 NS3 ZNF410 57862 18985028 Two Hybrid Test (MI:0018) 
hcv0408 NS3 ZZZ3 26009 18985028 Two Hybrid Test (MI:0018) 
hcv0409 NS3 NS5B 951475 10721731 Two Hybrid Test (MI:0018) 
hcv0410 NS3 NS3 951475 11119590 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018) 
hcv0411 NS3 NS5B 951475 12235135 Far-Western blot (MI:0047) 
hcv0412 NS3 NS4B 951475 12235135 Far-Western blot (MI:0047) 
hcv0413 NS3 NS5B 951475 12692242 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018) 
hcv0414 NS3 CASP8 841 15476874 Coimmunoprecipitation (MI:0019) 
hcv0415 NS3 NS3 951475 16166788 Two Hybrid Test (MI:0018) 
hcv0416 NS3 NS4A 951475 16324764 
Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019) 
hcv0417 NS3 RSPH3 83861 18985028 Two Hybrid Test (MI:0018) 
hcv0418 NS4A NS3 951475 8861917 Three dimensional structure (MI:0105) 
hcv0419 NS4A NS3 951475 9568891 Three dimensional structure (MI:0105) 
hcv0420 NS4A NS3 951475 10702283 Three dimensional structure (MI:0105) 
hcv0421 NS4A NS3 951475 12465917 Three dimensional structure (MI:0105) 
hcv0422 NS4A NS4A 951475 12692242 
Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
GST pull-down (MI:0059) 
hcv0423 NS4A NS4B 951475 12692242 
Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Immunostaining (MI:0022); Affinity 
Chromatography (MI:0004) 
hcv0424 NS4A NS5B 951475 12692242 
Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Immunostaining (MI:0022) 
hcv0425 NS4A CREB3 10488 18985028 Two Hybrid Test (MI:0018) 
hcv0426 NS4A ELAC2 60528 18985028 Two Hybrid Test (MI:0018) 
hcv0427 NS4A HOXD8 3234 18985028 Two Hybrid Test (MI:0018) 
hcv0428 NS4A NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0429 NS4A TRAF3IP3 80342 18985028 Two Hybrid Test (MI:0018) 
hcv0430 NS4A UBQLN1 29979 18985028 Two Hybrid Test (MI:0018) 
hcv0431 NS4A NS5A 951475 12692242 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Affinity Chromatography 
(MI:0004); Immunostaining (MI:0022) 
hcv0432 NS4A MT2A 4502 16248944 Two Hybrid Test (MI:0018) 
hcv0433 NS4A TUT1 64852 16248944 Two Hybrid Test (MI:0018) 
hcv0434 NS4A MT-CO2 4513 16248944 Two Hybrid Test (MI:0018) 
hcv0435 NS4A EEF1A1 1915 16927014 GST pull-down (MI:0059) 
hcv0436 NS4A CAMLG 819 17429534 Two Hybrid Test (MI:0018) 
hcv0437 NS4A NS5A 951475 9261364 Coimmunoprecipitation (MI:0019) 
hcv0438 NS4B NS4A 951475 9261364 Coimmunoprecipitation (MI:0019) 
hcv0439 NS4B ATF6B 1388 12445808 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663) 
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hcv0440 NS4B ATF6A 22926 12445808 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663) 
hcv0441 NS4B NS5B 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Immunostaining (MI:0022); Affinity 
Chromatography (MI:0004) 
hcv0442 NS4B NS4B 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Affinity Chromatography (MI:0004) 
hcv0443 NS4B NS5B 951475 12235135 Far-Western blot (MI:0047) 
hcv0444 NS4B TNXB 7148 12445808 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663) 
hcv0445 NS4B NS5A 951475 12692242 Coimmunoprecipitation (MI:0019) 
hcv0446 NS4B NS5A 951475 15016871 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0447 NS4B RTN3 10313 16261208 Two Hybrid Test (MI:0018) 
hcv0448 NS4B RBP4 5950 16261208 Two Hybrid Test (MI:0018) 
hcv0449 NS4B NDUFV3 4731 16261208 Two Hybrid Test (MI:0018) 
hcv0450 NS4B FGG 2266 16261208 Two Hybrid Test (MI:0018) 
hcv0451 NS4B MT-CO3 4514 16261208 Two Hybrid Test (MI:0018) 
hcv0452 NS4B RAB5A 5868 17301141 Coimmunoprecipitation (MI:0019) 
hcv0453 NS5A EIF2AK2 5610 9143277 Two Hybrid Test (MI:0018) 
hcv0454 NS5A CSNK2A1 1457 10208859 
GST pull-down (MI:0059); Affinity 
Chromatography (MI:0004); Kinase assay 
(MI:0424) (MI:0424); Mutational analysis 
(MI:0074) 
hcv0455 NS5A GRB2 2885 10318918 
Immunoblotting (MI:0113); Affinity 
Chromatography (MI:0004); Two Hybrid Test 
(MI:0018); Coimmunoprecipitation (MI:0019) 
hcv0456 NS5A VAPA 9218 10544080 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Immunostaining 
(MI:0022); Affinity Chromatography (MI:0004) 
hcv0457 NS5A SRCAP 10847 10702287 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004); Immunostaining 
(MI:0022); Pull-down (MI:0096) 
hcv0458 NS5A IPO5 3843 10799599 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019);  Affinity 
Chromatography (MI:0004) 
hcv0459 NS5A TP53 7157 11152513 
Pull-down (MI:0096); Coimmunoprecipitation 
(MI:0019); Two Hybrid Test (MI:0018); Confocal 
microscopy (MI:0663); Colocalization (MI:0403); 
Affinity Chromatography (MI:0004); 
Immunostaining (MI:0022) 
hcv0460 NS5A CDC2 983 11278402 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019) 
hcv0461 NS5A CDK2 1017 11278402 
Western blot (MI:0113); Coimmunoprecipitation 
(MI:0019) 
hcv0462 NS5A APOA1 335 11878923 
Immunofluorescence (MI:0022); Confocal 
microscopy (MI:0663); Coimmunoprecipitation 
(MI:0019); Affinity Chromatography (MI:0004); 
Immunostaining (MI:0022) 
hcv0463 NS5A TP53 7157 12101418 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663); Affinity Chromatography 
(MI:0004) 
hcv0464 NS5A TAF9 6880 12101418 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022) 
hcv0465 NS5A PIK3R1 5295 12186904 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
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hcv0466 NS5A TP53 7157 12379483 
Coimmunoprecipitation (MI:0019); Pull-down 
(MI:0096); Affinity Chromatography (MI:0004) 
hcv0467 NS5A TBP 6908 12379483 
Coimmunoprecipitation (MI:0019); Pull-down 
(MI:0096); Affinity Chromatography (MI:0004) 
hcv0468 NS5A BIN1 274 12604805 
Mass spectrometry (MI:0943); Mutational analysis 
(MI:0074); Coimmunoprecipitation (MI:0019); 
Colocalization (MI:0403); Affinity 
Chromatography (MI:0004); Immunostaining 
(MI:0022) 
hcv0469 NS5A PITX1 5307 12620797 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019) 
hcv0470 NS5A NS5B 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Immunostaining (MI:0022); Affinity 
Chromatography (MI:0004) 
hcv0471 NS5A NS5A 951475 12692242 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018); Confocal microscopy (MI:0663); 
Affinity Chromatography (MI:0004) 
hcv0472 NS5A BAX 581 12925958 
Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019) 
hcv0473 NS5A SSB 6741 12963047 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0474 NS5A HCK 3055 14993658 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0475 NS5A LCK 3932 14993658 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0476 NS5A LYN 4067 14993658 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0477 NS5A FYN 2534 14993658 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0478 NS5A VAPA 9218 15016871 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059); autoradiography (MI:0833); 
Affinity Chromatography (MI:0004) 
hcv0479 NS5A OAS1 4938 15039538 
GST pull-down (MI:0059); Immunoblotting 
(MI:0113); Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022) 
hcv0480 NS5A JAK1 3716 15063116 Coimmunoprecipitation (MI:0019) 
hcv0481 NS5A APOE 348 15326295 Two Hybrid Test (MI:0018) 
hcv0482 NS5A VAPA 9218 15326295 
Western blot (MI:0113); Two Hybrid Test 
(MI:0018) 
hcv0483 NS5A NS5A 951475 15326295 Two Hybrid Test (MI:0018) 
hcv0484 NS5A AHNAK 79026 15607035 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0485 NS5A SFRP4 6424 15607035 Two Hybrid Test (MI:0018) 
hcv0486 NS5A CRABP1 1381 15607035 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0487 NS5A FTH1 2495 15607035 Two Hybrid Test (MI:0018) 
hcv0488 NS5A CCDC86 79080 15607035 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0489 NS5A TACSTD2 4070 15607035 Two Hybrid Test (MI:0018) 
hcv0490 NS5A PI4KA 5297 15607035 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0491 NS5A PTMA 5757 15607035 Two Hybrid Test (MI:0018) 
hcv0492 NS5A ARAP1 116985 15607035 
Two Hybrid Test (MI:0018); GST pull-down 
(MI:0059) 
hcv0493 NS5A NDRG1 10397 15607035 Two Hybrid Test (MI:0018) 
hcv0494 NS5A MGP 4256 15607035 Two Hybrid Test (MI:0018) 
hcv0495 NS5A CEP57 9702 15607035 Two Hybrid Test (MI:0018) 
hcv0496 NS5A C9orf6 54942 15607035 Two Hybrid Test (MI:0018) 
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hcv0497 NS5A FBXL2 25827 15893726 
[(3)H]mevalonate labeling (MI:2131); 
Coimmunoprecipitation (MI:0019) 
hcv0498 NS5A NS5A 951475 15902263 Three dimensional structure (MI:0105) 
hcv0499 NS5A CSK 1445 16139795 
Affinity Chromatography (MI:0004); Mass 
spectrometry (MI:0943); GST pull-down 
(MI:0059) 
hcv0500 NS5A SRC 6714 16139795 
Affinity Chromatography (MI:0004); Mass 
spectrometry (MI:0943); GST pull-down 
(MI:0059) 
hcv0501 NS5A APOB 338 16203724 Coimmunoprecipitation (MI:0019) 
hcv0502 NS5A VAPB 9217 16227268 
Coimmunoprecipitation (MI:0019); Mutational 
analysis (MI:0074) 
hcv0503 NS5A RAF1 5894 16405965 
Affinity Chromatography (MI:0004); 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Western blot 
(MI:0113) 
hcv0504 NS5A TGFBR1 7046 16407286 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019) 
hcv0505 NS5A PPP2R4 5524 16460864 
GST pull-down (MI:0059); His pull-down 
(MI:0061); Immunofluorescence (MI:0022); 
Coimmunoprecipitation (MI:0019); 
Immunoblotting (MI:0113) 
hcv0506 NS5A BIN1 274 16530520 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663); Mutational analysis 
(MI:0074) 
hcv0507 NS5A TRAF2 7186 16581780 Coimmunoprecipitation (MI:0019) 
hcv0508 NS5A FKBP8 23770 16844119 Two Hybrid Test (MI:0018) 
hcv0509 NS5A FKBP8 23770 17024179 Coimmunoprecipitation (MI:0019) 
hcv0510 NS5A HSP90AA1 3320 17024179 Coimmunoprecipitation (MI:0019) 
hcv0511 NS5A PTPLAD1 51495 18160438 Two Hybrid Test (MI:0018) 
hcv0512 NS5A ACLY 47 18985028 Two Hybrid Test (MI:0018) 
hcv0513 NS5A ARFIP1 27236 18985028 Two Hybrid Test (MI:0018) 
hcv0514 NS5A AXIN1 8312 18985028 Two Hybrid Test (MI:0018) 
hcv0515 NS5A BEND7 222389 18985028 Two Hybrid Test (MI:0018) 
hcv0516 NS5A CADPS 8618 18985028 Two Hybrid Test (MI:0018) 
hcv0517 NS5A CADPS2 93664 18985028 Two Hybrid Test (MI:0018) 
hcv0518 NS5A CEP120 153241 18985028 Two Hybrid Test (MI:0018) 
hcv0519 NS5A CENPC1 1060 18985028 Two Hybrid Test (MI:0018) 
hcv0520 NS5A CEP250 11190 18985028 Two Hybrid Test (MI:0018) 
hcv0521 NS5A CEP63 80254 18985028 Two Hybrid Test (MI:0018) 
hcv0522 NS5A DNAJA3 9093 18985028 Two Hybrid Test (MI:0018) 
hcv0523 NS5A EFEMP1 2202 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0524 NS5A FHL2 2274 18985028 Two Hybrid Test (MI:0018) 
hcv0525 NS5A GOLGA2 2801 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0526 NS5A GPS2 2874 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0527 NS5A IGLL1 3543 18985028 Two Hybrid Test (MI:0018) 
hcv0528 NS5A ITGAL 3683 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0529 NS5A LIMS2 55679 18985028 Two Hybrid Test (MI:0018) 
hcv0530 NS5A MOBK1B 55233 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
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hcv0531 NS5A NAP1L1 4673 18985028 Two Hybrid Test (MI:0018) 
hcv0532 NS5A NAP1L2 4674 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0533 NS5A NFE2 4778 18985028 Two Hybrid Test (MI:0018) 
hcv0534 NS5A NUCB1 4924 18985028 Two Hybrid Test (MI:0018) 
hcv0535 NS5A PARVG 64098 18985028 Two Hybrid Test (MI:0018) 
hcv0536 NS5A PMVK 10654 18985028 Two Hybrid Test (MI:0018) 
hcv0537 NS5A PPP1R13L 10848 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0538 NS5A PSMB9 5698 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0539 NS5A RPL18A 6142 18985028 Two Hybrid Test (MI:0018) 
hcv0540 NS5A RRBP1 6238 18985028 Two Hybrid Test (MI:0018) 
hcv0541 NS5A SHARPIN 81858 18985028 Two Hybrid Test (MI:0018) 
hcv0542 NS5A SMYD3 64754 18985028 Two Hybrid Test (MI:0018) 
hcv0543 NS5A SORBS2 8470 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0544 NS5A SORBS3 10174 18985028 Two Hybrid Test (MI:0018) 
hcv0545 NS5A THBS1 7057 18985028 Two Hybrid Test (MI:0018) 
hcv0546 NS5A TMF1 7110 18985028 Two Hybrid Test (MI:0018) 
hcv0547 NS5A TP53BP2 7159 18985028 Two Hybrid Test (MI:0018) 
hcv0548 NS5A TRIOBP 11078 18985028 Two Hybrid Test (MI:0018) 
hcv0549 NS5A TXNDC11 51061 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0550 NS5A UBASH3A 53347 18985028 Two Hybrid Test (MI:0018) 
hcv0551 NS5A USP19 10869 18985028 Two Hybrid Test (MI:0018) 
hcv0552 NS5A VPS52 6293 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0553 NS5A GIN1 54826 18985028 Two Hybrid Test (MI:0018) 
hcv0554 NS5A ZNF646 9726 18985028 Two Hybrid Test (MI:0018) 
hcv0555 NS5A NS5B 951475 11801599 
GST pull-down (MI:0059); Affinity 
Chromatography (MI:0004) 
hcv0556 NS5A TRAF2 7186 11821416 
Coimmunoprecipitation (MI:0019); Colocalization 
(MI:0403); Immunostaining (MI:0022); Affinity 
Chromatography (MI:0004) 
hcv0557 NS5A TRADD 8717 11886269 
Pull-down (MI:0096); Coimmunoprecipitation 
(MI:0019); Colocalization (MI:0403) 
hcv0558 NS5A GAB1 2549 12186904 Coimmunoprecipitation (MI:0019) 
hcv0559 NS5A NS3 951475 12692242 GST pull-down (MI:0059) 
hcv0560 NS5A PIK3CB 5291 14709551 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0561 NS5A FBXL20 84961 15893726 Coimmunoprecipitation (MI:0019) 
hcv0562 NS5A STAT1 6772 17275127 
Coimmunoprecipitation (MI:0019); Confocal 
microscopy (MI:0663) 
hcv0563 NS5A MYD88 4615 17567694 Coimmunoprecipitation (MI:0019) 
hcv0564 NS5A PDPK1 5170 17616579 
GST pull-down (MI:0059); Kinase assay 
(MI:0424) (MI:0424) 
hcv0565 NS5A AKT1 207 17616579 
GST pull-down (MI:0059); Kinase assay 
(MI:0424) (MI:0424) 
hcv0566 NS5A VPS35 55737 17616579 Two Hybrid Test (MI:0018) 
hcv0567 NS5A MAPK12 6300 17616579 
Kinase assay (MI:0424) (MI:0424); GST pull-
down (MI:0059) 
hcv0568 NS5A IPO4 79711 17616579 Two Hybrid Test (MI:0018) 
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hcv0569 NS5A GSK3B 2932 17616579 
GST pull-down (MI:0059); Kinase assay 
(MI:0424) (MI:0424) 
hcv0570 NS5A AHSA1 10598 17616579 Two Hybrid Test (MI:0018) 
hcv0571 NS5A GSK3A 2931 17616579 
GST pull-down (MI:0059); Kinase assay 
(MI:0424) (MI:0424) 
hcv0572 NS5A CDK6 1021 17616579 
Kinase assay (MI:0424) (MI:0424); GST pull-
down (MI:0059) 
hcv0573 NS5A TBC1D20 128637 17686842 Two Hybrid Test (MI:0018) 
hcv0574 NS5B VAPA 9218 10544080 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Affinity 
Chromatography (MI:0004); Immunostaining 
(MI:0022) 
hcv0575 NS5B EIF4A2 1974 11922617 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); Affinity 
Chromatography (MI:0004) 
hcv0576 NS5B NCL 4691 12427757 
GST pull-down (MI:0059); Affinity 
Chromatography (MI:0004); Immunostaining 
(MI:0022) 
hcv0577 NS5B NS5B 951475 12692242 Two Hybrid Test (MI:0018) 
hcv0578 NS5B HAO1 54363 14623081 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Confocal 
microscopy (MI:0663); Two Hybrid Test 
(MI:0018) 
hcv0579 NS5B TTC4 7268 14623081 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Confocal 
microscopy (MI:0663); Two Hybrid Test 
(MI:0018) 
hcv0580 NS5B ACTN1 87 14623081 
Two Hybrid Test (MI:0018); 
Coimmunoprecipitation (MI:0019); 
Immunofluorescence (MI:0022); Confocal 
microscopy (MI:0663); Immunostaining (MI:0022) 
hcv0581 NS5B VAPA 9218 15016871 
Coimmunoprecipitation (MI:0019); GST pull-
down (MI:0059) 
hcv0582 NS5B DDX5 1655 15113910 
Coimmunoprecipitation (MI:0019); 
Immunostaining (MI:0022); Two Hybrid Test 
(MI:0018) 
hcv0583 NS5B PKN2 5586 15364941 
Coimmunoprecipitation (MI:0019); Colocalization 
(MI:0403); Kinase assay (MI:0424) (MI:0424); 
Metabolic labeling (MI:2131) 
hcv0584 NS5B PTBP2 58155 15823607 
Immunofluorescence (MI:0022); GST pull-down 
(MI:0059); Colocalization (MI:0403); 
Coimmunoprecipitation (MI:0019) 
hcv0585 NS5B FBXL2 25827 15893726 
[(3)H]mevalonate labeling (MI:2131); 
Coimmunoprecipitation (MI:0019) 
hcv0586 NS5B PPIB 5479 15989969 
GST pull-down (MI:0059); 
Coimmunoprecipitation (MI:0019); Colocalization 
(MI:0403); Cross Linking (MI:0030) 
hcv0587 NS5B VAPB 9217 16227268 
Coimmunoprecipitation (MI:0019); Mutational 
analysis (MI:0074);  Affinity Chromatography 
(MI:0004) 
hcv0588 NS5B CHUK 1147 16581780 Coimmunoprecipitation (MI:0019) 
hcv0589 NS5B CEP250 11190 18985028 Two Hybrid Test (MI:0018) 
hcv0590 NS5B CEP68 23177 18985028 Two Hybrid Test (MI:0018) 
hcv0591 NS5B HOXD8 3234 18985028 Two Hybrid Test (MI:0018) 
hcv0592 NS5B MGC2752 65996 18985028 Two Hybrid Test (MI:0018) 
hcv0593 NS5B MOBK1B 55233 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0594 NS5B NR4A1 3164 18985028 Two Hybrid Test (MI:0018) 
hcv0595 NS5B OS9 10956 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0596 NS5B PKM2 5315 18985028 Two Hybrid Test (MI:0018) 
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hcv0597 NS5B PSMB9 5698 18985028 
Two Hybrid Test (MI:0018); Co-affinity 
purification (MI:0025) 
hcv0598 NS5B SETD2 29072 18985028 Two Hybrid Test (MI:0018) 
hcv0599 NS5B SHARPIN 81858 18985028 Two Hybrid Test (MI:0018) 
hcv0600 NS5B TUBB2C 10383 18985028 Two Hybrid Test (MI:0018) 
hcv0601 NS5B NS5B 951475 11907226 
Gel filtration (MI:0071); Cross Linking (MI:0030); 
Two Hybrid Test (MI:0018); Three dimensional 
structure (MI:0105); Temperature sensitivity 
(MI:0271) 
hcv0602 NS5B UBQLN1 29979 12634373 
Two Hybrid Test (MI:0018);  
Coimmunoprecipitation (MI:0019) 
hcv0603 NS5B CINP 51550 14623081 Two Hybrid Test (MI:0018) 
hcv0604 NS5B PSMB4 5692 14623081 Two Hybrid Test (MI:0018) 
hcv0605 NS5B 6-Sep 23157 17229681 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018) 
hcv0606 NS5B HNRNPA1 3178 17229681 
Coimmunoprecipitation (MI:0019); Two Hybrid 
Test (MI:0018) 
hcv0607 p7 P7 951475 12560074 
Cross Linking (MI:0030); Immunoblotting 
(MI:0113) 
hcv0608 p7 FMNL1 752 16094715 Two Hybrid Test (MI:0018) 
hcv0609 p7 H19 283120 16094715 Two Hybrid Test (MI:0018) 
hcv0610 p7 ISLR 3671 16094715 Two Hybrid Test (MI:0018) 
hcv0611 p7 MS4A6A 64231 16094715 Two Hybrid Test (MI:0018) 
hcv0612 p7 NUP214 8021 16094715 Two Hybrid Test (MI:0018) 
hcv0613 p7 SSR4 6748 16094715 Two Hybrid Test (MI:0018) 
hcv0614 p7 STRBP 55342 16094715 Two Hybrid Test (MI:0018) 
hcv0615 p7 CREB3 10488 18985028 Two Hybrid Test (MI:0018) 
hcv0616 p7 FBLN2 2199 18985028 Two Hybrid Test (MI:0018) 
hcv0617 p7 FXYD6 53826 18985028 Two Hybrid Test (MI:0018) 
hcv0618 p7 LMNB1 4001 18985028 Two Hybrid Test (MI:0018) 
hcv0619 p7 SLIT2 9353 18985028 Two Hybrid Test (MI:0018) 
hcv0620 p7 UBQLN1 29979 18985028 Two Hybrid Test (MI:0018) 
hcv0621 p7 UBQLN4 56893 18985028 Two Hybrid Test (MI:0018)  
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Appendix IV (Chapter 3) 
 
HCV proteins assigned with information relating to their genotype/strain sources. 
HCVpro 
ID 
Molecule 
A 
HCV 
Genotype 
HCV 
isolate/strain 
HCV 
Molecule A 
Protein 
Accession 
Molecule B 
Gene Symbols 
HCV 
Molecule B 
Protein 
Accession 
Genotype 
Source 
hcv0001 CORE 
HCV 
genotype 1a H77 NP_751919 LTBR  VirHostNet 
hcv0002 CORE 
HCV 
genotype 1b   APOA2  HCVpro 
hcv0003 CORE 
HCV 
genotype 1b   TP53  HCVpro 
hcv0004 CORE 
HCV 
genotype 1a H77 NP_751919 LTBR  VirHostNet 
hcv0005 CORE 
HCV 
genotype 1a H77 NP_751919 HNRNPK  BIND 
hcv0006 CORE 
HCV 
genotype 1a H77 NP_751919 CORE NP_751919 BIND 
hcv0007 CORE 
HCV 
genotype 1a H77 NP_751919 DDX3X  VirHostNet 
hcv0008 CORE 
HCV 
genotype 1a H77 NP_751919 DDX3X  BIND 
hcv0009 CORE 
HCV 
genotype 1a  AAA45676 DDX3X  BIND 
hcv0010 CORE 
HCV 
genotype 1a H77 NP_751919 APOA2  VirHostNet 
hcv0011 CORE 
HCV 
genotype 1a H77 NP_751919 TP53  BIND 
hcv0012 CORE 
HCV 
genotype 1b   YWHAB  HCVpro 
hcv0013 CORE 
HCV 
genotype 1b   YWHAZ  HCVpro 
hcv0014 CORE 
HCV 
genotype 1a H77 NP_751919 CREB3  VirHostNet 
hcv0015 CORE 
HCV 
genotype 1a strain H AAA45534 CORE AAA45534 HCVpro 
hcv0016 CORE 
HCV 
genotype 1b Isolate S98 BAC54273 CDKN1A  BIND 
hcv0017 CORE 
HCV 
genotype 1b   TAF11  HCVpro 
hcv0018 CORE 
HCV 
genotype 1b   TP53  HCVpro 
hcv0019 CORE 
HCV 
genotype 1a H77 NP_751919 C1QBP  VirHostNet 
hcv0020 CORE 
HCV 
genotype 1b Isolate S98 BAC54273 TNFRSF1A  BIND 
hcv0021 CORE 
HCV 
genotype 1a H77 NP_751919 FADD  VirHostNet 
hcv0022 CORE 
Genotype 
1b 
Korean 
isolate BAA01943.1 TNF  HCVpro 
hcv0023 CORE 
Genotype 
1b 
Korean 
isolate BAA01943.1 TRADD  HCVpro 
hcv0024 CORE 
Genotype 
1b 
Korean 
isolate BAA01943.1 TRAF2  HCVpro 
hcv0025 CORE 
HCV 
genotype 1a H77 NP_751919 RXRA  VirHostNet 
hcv0026 CORE 
HCV 
genotype 1a H77 NP_751919 STAT3  VirHostNet 
hcv0027 CORE 
HCV 
genotype 1a H77 NP_671491 TSN  BIND 
hcv0028 CORE 
HCV 
genotype 1a H77 NP_751919 FUNDC2  VirHostNet 
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hcv0029 CORE 
HCV 
genotype 1a   TP73  HCVpro 
hcv0030 CORE 
HCV 
genotype 1a   TP53  HCVpro 
hcv0031 CORE 
HCV 
genotype 1b   JAK1  HCVpro 
hcv0032 CORE 
HCV 
genotype 1b   JAK2  HCVpro 
hcv0033 CORE 
HCV 
genotype 1a   FAS  HCVpro 
hcv0034 CORE 
HCV 
genotype 1a H77 NP_751919 CCNH  VirHostNet 
hcv0035 CORE 
HCV 
genotype 1a H77 NP_751919 TBP  VirHostNet 
hcv0036 CORE 
HCV 
genotype 1b  AAR06173.1 TP53BP2  BIND 
hcv0037 CORE 
HCV 
genotype 1a H77 NP_751919 SMAD3  VirHostNet 
hcv0038 CORE 
HCV 
genotype 1b L02 AB077729.1 EP300  HCVpro 
hcv0039 CORE 
HCV 
genotype 1b L02 AB077729.1 CREBBP  HCVpro 
hcv0040 CORE    TLR2  
Not 
assigned 
hcv0041 CORE 
HCV 
genotype 1a H77 NP_751919 HLA-A  VirHostNet 
hcv0042 CORE 
HCV 
genotype 1a H77 NP_751919 HLA-E  VirHostNet 
hcv0043 CORE 
HCV 
genotype 1a H77 NP_751919 STAT1  VirHostNet 
hcv0044 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 ACP1  HCVpro 
hcv0045 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 CFL1  HCVpro 
hcv0046 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 FKBP7  HCVpro 
hcv0047 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 HSPD1  HCVpro 
hcv0048 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 KRT18  HCVpro 
hcv0049 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 KRT19  HCVpro 
hcv0050 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 KRT8  HCVpro 
hcv0051 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 SLC22A7  HCVpro 
hcv0052 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 TATDN1  HCVpro 
hcv0053 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 GLRX3  HCVpro 
hcv0054 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 VIM  HCVpro 
hcv0055 CORE 
HCV 
genotype 1a H77 NP_751919 NPM1  VirHostNet 
hcv0056 CORE 
HCV 
genotype 1a H77 NP_751919 YY1  VirHostNet 
hcv0057 CORE 
HCV 
genotype 1a H77 NP_751919 PML  VirHostNet 
hcv0058 CORE 
HCV 
genotype 1a strain H77 NP_751919 DICER1  VirHostNet 
hcv0059 CORE 
HCV 
genotype 1a   PSME3  HCVpro 
hcv0060 CORE 
HCV 
genotype 1a   DICER1  HCVpro 
hcv0061 CORE 
HCV 
genotype 1b isolate con1 AJ238799 AGRN  HCVpro 
hcv0062 CORE 
HCV 
genotype 1b isolate con1 AJ238799 BCAR1  HCVpro 
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hcv0063 CORE 
HCV 
genotype 1b isolate con1 AJ238799 CD68  HCVpro 
hcv0064 CORE 
HCV 
genotype 1b isolate con1 AJ238799 COL4A2  HCVpro 
hcv0065 CORE 
HCV 
genotype 1b isolate con1 AJ238799 DDX3Y  HCVpro 
hcv0066 CORE 
HCV 
genotype 1b isolate con1 AJ238799 EGFL7  HCVpro 
hcv0067 CORE 
HCV 
genotype 1b isolate con1 AJ238799 FBLN2  HCVpro 
hcv0068 CORE 
HCV 
genotype 1b isolate con1 AJ238799 FBLN5  HCVpro 
hcv0069 CORE 
HCV 
genotype 1b isolate con1 AJ238799 GAPDH  HCVpro 
hcv0070 CORE 
HCV 
genotype 1b isolate con1 AJ238799 GRN  HCVpro 
hcv0071 CORE 
HCV 
genotype 1b isolate con1 AJ238799 HIVEP2  HCVpro 
hcv0072 CORE 
HCV 
genotype 1b isolate con1 AJ238799 HOXD8  HCVpro 
hcv0073 CORE 
HCV 
genotype 1b isolate con1 AJ238799 LPXN  HCVpro 
hcv0074 CORE 
HCV 
genotype 1b isolate con1 AJ238799 LRRTM1  HCVpro 
hcv0075 CORE 
HCV 
genotype 1b isolate con1 AJ238799 LTBP4  HCVpro 
hcv0076 CORE 
HCV 
genotype 1b isolate con1 AJ238799 MAGED1  HCVpro 
hcv0077 CORE 
HCV 
genotype 1b isolate con1 AJ238799 MEGF6  HCVpro 
hcv0078 CORE 
HCV 
genotype 1b isolate con1 AJ238799 MMRN2  HCVpro 
hcv0079 CORE 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0080 CORE 
HCV 
genotype 1b isolate con1 AJ238799 PABPN1  HCVpro 
hcv0081 CORE 
HCV 
genotype 1b isolate con1 AJ238799 PAK4  HCVpro 
hcv0082 CORE 
HCV 
genotype 1b isolate con1 AJ238799 PLSCR1  HCVpro 
hcv0083 CORE 
HCV 
genotype 1b isolate con1 AJ238799 RNF31  HCVpro 
hcv0084 CORE 
HCV 
genotype 1b isolate con1 AJ238799 SETD2  HCVpro 
hcv0085 CORE 
HCV 
genotype 1b isolate con1 AJ238799 SLC31A2  HCVpro 
hcv0086 CORE 
HCV 
genotype 1b isolate con1 AJ238799 VWF  HCVpro 
hcv0087 CORE 
HCV 
genotype 1b isolate con1 AJ238799 ZNF271  HCVpro 
hcv0088 CORE 
HCV 
genotype 1b   YWHAE  HCVpro 
hcv0089 CORE 
HCV 
genotype 1a H77 NP_751919 NS5A NP_751927 BIND 
hcv0090 CORE 
HCV 
genotype 1a H77 NP_751919 NS5B NP_751928 VirHostNet 
hcv0091 CORE 
HCV 
genotype 1a H77 NP_751919 RSF1  VirHostNet 
hcv0092 CORE 
HCV 
genotype 1a H77 NP_751919 E1 NP_751920 BIND 
hcv0093 CORE 
HCV 
genotype 1a H77 NP_751919 SP110  VirHostNet 
hcv0094 CORE 
HCV 
genotype 1a H77 NP_751919 KPNA1  VirHostNet 
hcv0095 CORE 
HCV 
genotype 1b pCV-J4L8 AAC15730 DDX5  HCVpro 
hcv0096 CORE 
HCV 
genotype 1b 
Singapore 
strain  NS5A  HCVpro 
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hcv0097 CORE 
HCV 
genotype 1a strain H77 NP_751919 EIF2AK2  VirHostNet 
hcv0098 CORE 
HCV 
genotype 1a strain H77 NP_751919 PPARA  VirHostNet 
hcv0099 CORE 
HCV 
genotype 1a strain H77 NP_751919 ACY3  VirHostNet 
hcv0100 CORE 
HCV 
genotype 1a H77 NP_751919 MCL1  VirHostNet 
hcv0101 CORE 
HCV 
genotype 1a H77 NP_751919 CORE NP_751919 VirHostNet 
hcv0102 CORE 
HCV 
genotype 1a H77 NP_751919 CORE  VirHostNet 
hcv0103 E1 
HCV 
genotype 1a H77 NP_751920 E2 NP_751921 VirHostNet 
hcv0104 E1 
HCV 
genotype 1a H77 NP_751920 CORE NP_751919 VirHostNet 
hcv0105 E1 
HCV 
genotype 1a H77 NP_751920 LTF  VirHostNet 
hcv0106 E1 
HCV 
genotype 1a H77 NP_751920 CALR  VirHostNet 
hcv0107 E1 
HCV 
genotype 1a H77 NP_751920 CANX  VirHostNet 
hcv0108 E1 
HCV 
genotype 1a H77 NP_751920 HSPA5  VirHostNet 
hcv0109 E1 
HCV 
genotype 1a Isolate H P27958 E2 P27958 BIND 
hcv0110 E1 
HCV 
genotype 1a H77 NP_751920 E2 NP_751921 BIND 
hcv0111 E1 
HCV 
genotype 1a H77 AF009606 CD209  HCVpro 
hcv0112 E1 
HCV 
genotype 1a H77 AF009606 CLEC4M  HCVpro 
hcv0113 E1 
HCV 
genotype 1a H77 NP_671491 E2  BIND 
hcv0114 E1 
HCV 
genotype 1b   CD209  HCVpro 
hcv0115 E1 
HCV 
genotype 1b isolate con1 AJ238799 JUN  HCVpro 
hcv0116 E1 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0117 E1 
HCV 
genotype 1b isolate con1 AJ238799 PFN1  HCVpro 
hcv0118 E1 
HCV 
genotype 1b isolate con1 AJ238799 SETD2  HCVpro 
hcv0119 E1 
HCV 
genotype 1b isolate con1 AJ238799 TMSB4X  HCVpro 
hcv0120 E1 
HCV 
genotype 1a strain H AAA45534 NS5A AAA45534 HCVpro 
hcv0121 E1 
HCV 
genotype 1a H77 NP_751920 E2 NP_751921 VirHostNet 
hcv0122 E2 
HCV 
genotype 1a H77 NP_751921 LTF  VirHostNet 
hcv0123 E2 
HCV 
genotype 1a H77 NP_751921 CALR  VirHostNet 
hcv0124 E2 
HCV 
genotype 1a H77 NP_751921 CANX  VirHostNet 
hcv0125 E2 
HCV 
genotype 1a H77 NP_751921 HSPA5  VirHostNet 
hcv0126 E2 
HCV 
genotype 1a H77 NP_751921 EIF2AK2  VirHostNet 
hcv0127 E2 
HCV 
genotype 1a strain H AAA45534 NS3 AAA45534 HCVpro 
hcv0128 E2 
HCV 
genotype 1a H77 NP_671491 CD81  BIND 
hcv0129 E2 
HCV 
genotype 1a isolate H P27958 CD81  BIND 
hcv0130 E2 
HCV 
genotype 1a H77 NP_751921 SCARB1  VirHostNet 
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hcv0131 E2 
HCV 
genotype 1b   CD81  HCVpro 
hcv0132 E2 
HCV 
genotype 1b   LTF  HCVpro 
hcv0133 E2 
HCV 
genotype 1b   TF  HCVpro 
hcv0134 E2 
HCV 
genotype 1a H77 NP_751921 CD81  BIND 
hcv0135 E2 
HCV 
genotype 1a H77 NP_751921 EIF2AK3  VirHostNet 
hcv0136 E2 
HCV 
genotype 1a H77 AF009606 CD209  HCVpro 
hcv0137 E2 
HCV 
genotype 1a H77 AF009606 CLEC4M  HCVpro 
hcv0138 E2 
HCV 
genotype 1a H77 NP_751921 SDC2  VirHostNet 
hcv0139 E2 
HCV 
genotype 1b   CD209  HCVpro 
hcv0140 E2 
HCV 
genotype 1b isolate con1 AJ238799 HOXD8  HCVpro 
hcv0141 E2 
HCV 
genotype 1b isolate con1 AJ238799 ITGB1  HCVpro 
hcv0142 E2 
HCV 
genotype 1b isolate con1 AJ238799 FAM135A  HCVpro 
hcv0143 E2 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0144 E2 
HCV 
genotype 1b isolate con1 AJ238799 PSMA6  HCVpro 
hcv0145 E2 
HCV 
genotype 1b isolate con1 AJ238799 SETD2  HCVpro 
hcv0146 E2 
HCV 
genotype 1b isolate con1 AJ238799 SMEK2  HCVpro 
hcv0147 F 
HCV 
genotype 1b   C14orf135  HCVpro 
hcv0148 F 
HCV 
genotype 1b   ZNF83  HCVpro 
hcv0149 F 
HCV 
genotype 1a strain H77 NP_803170 PFDN2  VirHostNet 
hcv0150 F 
HCV 
genotype 1a strain H77 NP_803170 PFDN5  VirHostNet 
hcv0151 F 
HCV 
genotype 1b   AGT  HCVpro 
hcv0152 F 
HCV 
genotype 1b   AZGP1  HCVpro 
hcv0153 F 
HCV 
genotype 1b   CTSB  HCVpro 
hcv0154 F 
HCV 
genotype 1b   MPDU1  HCVpro 
hcv0155 F 
HCV 
genotype 1b   RAB14  HCVpro 
hcv0156 F 
HCV 
genotype 1b   SERPINC1  HCVpro 
hcv0157 F 
HCV 
genotype 1b   ST3GAL1  HCVpro 
hcv0158 F 
HCV 
genotype 1b   vitronectin  HCVpro 
hcv0159 F 
HCV 
genotype 1b   ZG16  HCVpro 
hcv0160 NS2 
HCV 
genotype 1a strain H AAA45534 NS4A AAA45534 HCVpro 
hcv0161 NS2 
HCV 
genotype 1b Strain J  NS3  HCVpro 
hcv0162 NS2 
HCV 
genotype 1a Strain H  CIDEB  BIND 
hcv0163 NS2 
HCV 
genotype 1a H77 AF009606 NS4B AF009606 HCVpro 
hcv0164 NS2 
HCV 
genotype 1a H77 AF009606 NS4A AF009606 HCVpro 
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hcv0165 NS2 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
hcv0166 NS2 
HCV 
genotype 1a H77 AF009606 NS2 AF009606 HCVpro 
hcv0167 NS2 
HCV 
genotype 1a H77 AF009606 NS3 AF009606 HCVpro 
hcv0168 NS2 
HCV 
genotype 1b isolate con1 AJ238799 C7  HCVpro 
hcv0169 NS2 
HCV 
genotype 1b isolate con1 AJ238799 FBLN5  HCVpro 
hcv0170 NS2 
HCV 
genotype 1b isolate con1 AJ238799 HOXD8  HCVpro 
hcv0171 NS2 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0172 NS2 
HCV 
genotype 1b isolate con1 AJ238799 POU3F2  HCVpro 
hcv0173 NS2 
HCV 
genotype 1b isolate con1 AJ238799 SETD2  HCVpro 
hcv0174 NS2 
HCV 
genotype 1b isolate con1 AJ238799 TRIM27  HCVpro 
hcv0175 NS2 
HCV 
genotype 1a H77 AF009606 NS5A AF009606 HCVpro 
hcv0176 NS3    NS4A  
Not 
assigned 
hcv0177 NS3 
HCV 
genotype 1b  AAA72945 MBP  VirHostNet 
hcv0178 NS3 
HCV 
genotype 1b  AAA72945 PRM1  VirHostNet 
hcv0179 NS3 
HCV 
genotype 1b  AAA72945 HIST4H4  VirHostNet 
hcv0180 NS3 
HCV 
genotype 1b  AAA72945 HIST3H2BB  VirHostNet 
hcv0181 NS3 
HCV 
genotype 1b  AAA72945 PRKACA  VirHostNet 
hcv0182 NS3 
HCV 
genotype 1b 
HCV isolate 
BK P26663 PRKACA  BIND 
hcv0183 NS3 
HCV 
genotype 1a H77 NP_671491 NS3 NP_671491 BIND 
hcv0184 NS3 
HCV 
genotype 1a H77 AAB66324 TP53  VirHostNet 
hcv0185 NS3 
HCV 
genotype 1a H77 AAB66324 NS4A AAB66324 VirHostNet 
hcv0186 NS3 
HCV 
genotype 1b 
HCV isolate 
BK P26663 NS4A P26663 BIND 
hcv0187 NS3 
HCV 
genotype 1a H77 AAB66324 HIST3H2BB  VirHostNet 
hcv0188 NS3 
HCV 
genotype 1a H77 AAB66324 HIST4H4  VirHostNet 
hcv0189 NS3 
HCV 
genotype 1b Isolate G01  SERPINF2  HCVpro 
hcv0190 NS3 
HCV 
genotype 1b Isolate G01  SERPING1  HCVpro 
hcv0191 NS3 
HCV 
genotype 1a strain H AAA45534 NS4A AAA45534 HCVpro 
hcv0192 NS3 
HCV 
genotype 1a H77 NP_803144 PRMT5  BIND 
hcv0193 NS3 
HCV 
genotype 1b Con1 CAB46677 PRMT1  BIND 
hcv0194 NS3 
HCV 
genotype 1a H77 AAB66324 NS3  VirHostNet 
hcv0195 NS3 
HCV 
genotype 1a H77 AF009606 NS4B AF009606 HCVpro 
hcv0196 NS3 
HCV 
genotype 1a H77 AF009606 NS4A AF009606 HCVpro 
hcv0197 NS3 
HCV 
genotype 1a H77 AF009606 NS3 AF009606 HCVpro 
hcv0198 NS3 
HCV 
genotype 1a   IRF3  HCVpro 
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hcv0199 NS3 
HCV 
genotype 1a  AAA45676.1 SNRPD1  BIND 
hcv0200 NS3    NS4A  
Not 
assigned 
hcv0201 NS3    NS4A  
Not 
assigned 
hcv0202 NS3 
HCV 
genotype 1b 
Isolate HCV-
S1 AAL00900 PSMB8  BIND 
hcv0203 NS3 
HCV 
genotype 1a H77 NP_803144 SMAD3  VirHostNet 
hcv0204 NS3    NS4A  
Not 
assigned 
hcv0205 NS3    TLR2  
Not 
assigned 
hcv0206 NS3 
HCV 
genotype 1a H77 NP_803144 TICAM1  VirHostNet 
hcv0207 NS3 
HCV 
genotype 1a H77 NP_803144 PTBP2  VirHostNet 
hcv0208 NS3 
HCV 
genotype 1a H77 NP_803144 IKBKE  VirHostNet 
hcv0209 NS3 
HCV 
genotype 1a H77 NP_803144 TBK1  VirHostNet 
hcv0210 NS3 
HCV 
genotype 1a H77 NP_803144 ERC1  VirHostNet 
hcv0211 NS3    NS4A  
Not 
assigned 
hcv0212 NS3    NS4A  
Not 
assigned 
hcv0213 NS3    NS4A  
Not 
assigned 
hcv0214 NS3    NS4A  
Not 
assigned 
hcv0215 NS3 
HCV 
genotype 1a   VISA  HCVpro 
hcv0216 NS3 
HCV 
genotype 1b   NS5B  HCVpro 
hcv0217 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ACTN1  HCVpro 
hcv0218 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ACTN2  HCVpro 
hcv0219 NS3 
HCV 
genotype 1b isolate con1 AJ238799 AEBP1  HCVpro 
hcv0220 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ANKRD12  HCVpro 
hcv0221 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ANKRD28  HCVpro 
hcv0222 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ARFIP2  HCVpro 
hcv0223 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ARHGEF6  HCVpro 
hcv0224 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ARNT  HCVpro 
hcv0225 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ARS2  HCVpro 
hcv0226 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ASXL1  HCVpro 
hcv0227 NS3 
HCV 
genotype 1b isolate con1 AJ238799 B2M  HCVpro 
hcv0228 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BCAN  HCVpro 
hcv0229 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BCKDK  HCVpro 
hcv0230 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BCL2A1  HCVpro 
hcv0231 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BCL6  HCVpro 
hcv0232 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BZRAP1  HCVpro 
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hcv0233 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C10orf18  HCVpro 
hcv0234 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C10orf6  HCVpro 
hcv0235 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C12orf41  HCVpro 
hcv0236 NS3 
HCV 
genotype 1b isolate con1 AJ238799 INF2  HCVpro 
hcv0237 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C16orf7  HCVpro 
hcv0238 NS3 
HCV 
genotype 1b isolate con1 AJ238799 BEND5  HCVpro 
hcv0239 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C1orf94  HCVpro 
hcv0240 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C9orf30  HCVpro 
hcv0241 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CALCOCO2  HCVpro 
hcv0242 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CBY1  HCVpro 
hcv0243 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CCDC21  HCVpro 
hcv0244 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CCDC37  HCVpro 
hcv0245 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CCDC52  HCVpro 
hcv0246 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CCDC66  HCVpro 
hcv0247 NS3 
HCV 
genotype 1b isolate con1 AJ238799 INO80E  HCVpro 
hcv0248 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CCHCR1  HCVpro 
hcv0249 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CD5L  HCVpro 
hcv0250 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CDC23  HCVpro 
hcv0251 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CELSR2  HCVpro 
hcv0252 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CEP152  HCVpro 
hcv0253 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CEP192  HCVpro 
hcv0254 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CFP  HCVpro 
hcv0255 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CHPF  HCVpro 
hcv0256 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CORO1B  HCVpro 
hcv0257 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CSNK2B  HCVpro 
hcv0258 NS3 
HCV 
genotype 1b isolate con1 AJ238799 CTGF  HCVpro 
hcv0259 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ALG13  HCVpro 
hcv0260 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DEAF1  HCVpro 
hcv0261 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DES  HCVpro 
hcv0262 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DLAT  HCVpro 
hcv0263 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DOCK7  HCVpro 
hcv0264 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DPF1  HCVpro 
hcv0265 NS3 
HCV 
genotype 1b isolate con1 AJ238799 DPP7  HCVpro 
hcv0266 NS3 
HCV 
genotype 1b isolate con1 AJ238799 EEF1A1  HCVpro 
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hcv0267 NS3 
HCV 
genotype 1b isolate con1 AJ238799 EFEMP1  HCVpro 
hcv0268 NS3 
HCV 
genotype 1b isolate con1 AJ238799 EFEMP2  HCVpro 
hcv0269 NS3 
HCV 
genotype 1b isolate con1 AJ238799 EIF1  HCVpro 
hcv0270 NS3 
HCV 
genotype 1b isolate con1 AJ238799 EIF4ENIF1  HCVpro 
hcv0271 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FAM120B  HCVpro 
hcv0272 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FAM65A  HCVpro 
hcv0273 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBF1  HCVpro 
hcv0274 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBLN1  HCVpro 
hcv0275 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBLN2  HCVpro 
hcv0276 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBLN5  HCVpro 
hcv0277 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBN1  HCVpro 
hcv0278 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FBN3  HCVpro 
hcv0279 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FES  HCVpro 
hcv0280 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FIGNL1  HCVpro 
hcv0281 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FLAD1  HCVpro 
hcv0282 NS3 
HCV 
genotype 1b isolate con1 AJ238799 C19orf66  HCVpro 
hcv0283 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FN1  HCVpro 
hcv0284 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FRMPD4  HCVpro 
hcv0285 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FRS3  HCVpro 
hcv0286 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FTH1  HCVpro 
hcv0287 NS3 
HCV 
genotype 1b isolate con1 AJ238799 FUCA2  HCVpro 
hcv0288 NS3 
HCV 
genotype 1b isolate con1 AJ238799 GAA  HCVpro 
hcv0289 NS3 
HCV 
genotype 1b isolate con1 AJ238799 GBP2  HCVpro 
hcv0290 NS3 
HCV 
genotype 1b isolate con1 AJ238799 GFAP  HCVpro 
hcv0291 NS3 
HCV 
genotype 1b isolate con1 AJ238799 GNB2  HCVpro 
hcv0292 NS3 
HCV 
genotype 1b isolate con1 AJ238799 GON4L  HCVpro 
hcv0293 NS3 
HCV 
genotype 1b isolate con1 AJ238799 HIVEP2  HCVpro 
hcv0294 NS3 
HCV 
genotype 1b isolate con1 AJ238799 HNRNPK  HCVpro 
hcv0295 NS3 
HCV 
genotype 1b isolate con1 AJ238799 HOMER3  HCVpro 
hcv0296 NS3 
HCV 
genotype 1b isolate con1 AJ238799 IQWD1  HCVpro 
hcv0297 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ITGB4  HCVpro 
hcv0298 NS3 
HCV 
genotype 1b isolate con1 AJ238799 JAG2  HCVpro 
hcv0299 NS3 
HCV 
genotype 1b isolate con1 AJ238799 JUN  HCVpro 
hcv0300 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KHDRBS1  HCVpro 
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hcv0301 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KIAA1549  HCVpro 
hcv0302 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KIF17  HCVpro 
hcv0303 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KIF7  HCVpro 
hcv0304 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KPNA1  HCVpro 
hcv0305 NS3 
HCV 
genotype 1b isolate con1 AJ238799 L3MBTL3  HCVpro 
hcv0306 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LAMA5  HCVpro 
hcv0307 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LAMB2  HCVpro 
hcv0308 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LAMC3  HCVpro 
hcv0309 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LDB1  HCVpro 
hcv0310 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LRRC7  HCVpro 
hcv0311 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LRRCC1  HCVpro 
hcv0312 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LTBP4  HCVpro 
hcv0313 NS3 
HCV 
genotype 1b isolate con1 AJ238799 LZTS2  HCVpro 
hcv0314 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MAGED1  HCVpro 
hcv0315 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MAPK7  HCVpro 
hcv0316 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MEGF8  HCVpro 
hcv0317 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MLLT4  HCVpro 
hcv0318 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MLXIP  HCVpro 
hcv0319 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MORC4  HCVpro 
hcv0320 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MORF4L1  HCVpro 
hcv0321 NS3 
HCV 
genotype 1b isolate con1 AJ238799 MVP  HCVpro 
hcv0322 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NAP1L1  HCVpro 
hcv0323 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NAP1L2  HCVpro 
hcv0324 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NCAN  HCVpro 
hcv0325 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NDC80  HCVpro 
hcv0326 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NEFL  HCVpro 
hcv0327 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NEFM  HCVpro 
hcv0328 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NELL1  HCVpro 
hcv0329 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NELL2  HCVpro 
hcv0330 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NID1  HCVpro 
hcv0331 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NID2  HCVpro 
hcv0332 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NOTCH1  HCVpro 
hcv0333 NS3 
HCV 
genotype 1b isolate con1 AJ238799 N-PAC  HCVpro 
hcv0334 NS3 
HCV 
genotype 1b isolate con1 AJ238799 NUP62  HCVpro 
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hcv0335 NS3 
HCV 
genotype 1b isolate con1 AJ238799 OBSCN  HCVpro 
hcv0336 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PARP4  HCVpro 
hcv0337 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PCYT2  HCVpro 
hcv0338 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PDE4DIP  HCVpro 
hcv0339 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PDLIM5  HCVpro 
hcv0340 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PICK1  HCVpro 
hcv0341 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PKNOX1  HCVpro 
hcv0342 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PLEKHG4  HCVpro 
hcv0343 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PNPLA8  HCVpro 
hcv0344 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PRRC1  HCVpro 
hcv0345 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PSMB9  HCVpro 
hcv0346 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PSME3  HCVpro 
hcv0347 NS3 
HCV 
genotype 1b isolate con1 AJ238799 PTPRN2  HCVpro 
hcv0348 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RABEP1  HCVpro 
hcv0349 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RAI14  HCVpro 
hcv0350 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RASAL2  HCVpro 
hcv0351 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RBM4  HCVpro 
hcv0352 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RCN3  HCVpro 
hcv0353 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RGNEF  HCVpro 
hcv0354 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RICS  HCVpro 
hcv0355 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RINT1  HCVpro 
hcv0356 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RNF31  HCVpro 
hcv0357 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ROGDI  HCVpro 
hcv0358 NS3 
HCV 
genotype 1b isolate con1 AJ238799 KIAA2022  HCVpro 
hcv0359 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RUSC2  HCVpro 
hcv0360 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SBF1  HCVpro 
hcv0361 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SDCCAG8  HCVpro 
hcv0362 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SECISBP2  HCVpro 
hcv0363 NS3 
HCV 
genotype 1b isolate con1 AJ238799 10-Sep  HCVpro 
hcv0364 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SERTAD1  HCVpro 
hcv0365 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SESTD1  HCVpro 
hcv0366 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SF3B2  HCVpro 
hcv0367 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SIAH1  HCVpro 
hcv0368 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SLIT1  HCVpro 
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hcv0369 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SLIT2  HCVpro 
hcv0370 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SLIT3  HCVpro 
hcv0371 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SMURF2  HCVpro 
hcv0372 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SNX4  HCVpro 
hcv0373 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SPOCK3  HCVpro 
hcv0374 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SPON1  HCVpro 
hcv0375 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SRPX2  HCVpro 
hcv0376 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SSX2IP  HCVpro 
hcv0377 NS3 
HCV 
genotype 1b isolate con1 AJ238799 STAB1  HCVpro 
hcv0378 NS3 
HCV 
genotype 1b isolate con1 AJ238799 STAT3  HCVpro 
hcv0379 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SVEP1  HCVpro 
hcv0380 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SYNE1  HCVpro 
hcv0381 NS3 
HCV 
genotype 1b isolate con1 AJ238799 SYNPO2  HCVpro 
hcv0382 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TAF1  HCVpro 
hcv0383 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TBC1D2B  HCVpro 
hcv0384 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TBXAS1  HCVpro 
hcv0385 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TGFB1I1  HCVpro 
hcv0386 NS3 
HCV 
genotype 1b isolate con1 AJ238799 THAP1  HCVpro 
hcv0387 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TMEM63B  HCVpro 
hcv0388 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TRIM23  HCVpro 
hcv0389 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TRIM27  HCVpro 
hcv0390 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TRIO  HCVpro 
hcv0391 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TRIP11  HCVpro 
hcv0392 NS3 
HCV 
genotype 1b isolate con1 AJ238799 TXNDC11  HCVpro 
hcv0393 NS3 
HCV 
genotype 1b isolate con1 AJ238799 UBA3  HCVpro 
hcv0394 NS3 
HCV 
genotype 1b isolate con1 AJ238799 USHBP1  HCVpro 
hcv0395 NS3 
HCV 
genotype 1b isolate con1 AJ238799 UXT  HCVpro 
hcv0396 NS3 
HCV 
genotype 1b isolate con1 AJ238799 VCAN  HCVpro 
hcv0397 NS3 
HCV 
genotype 1b isolate con1 AJ238799 VIM  HCVpro 
hcv0398 NS3 
HCV 
genotype 1b isolate con1 AJ238799 VWF  HCVpro 
hcv0399 NS3 
HCV 
genotype 1b isolate con1 AJ238799 XAB2  HCVpro 
hcv0400 NS3 
HCV 
genotype 1b isolate con1 AJ238799 XRN2  HCVpro 
hcv0401 NS3 
HCV 
genotype 1b isolate con1 AJ238799 YY1AP1  HCVpro 
hcv0402 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZBTB1  HCVpro 
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hcv0403 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZCCHC7  HCVpro 
hcv0404 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZHX3  HCVpro 
hcv0405 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZMYM2  HCVpro 
hcv0406 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZNF281  HCVpro 
hcv0407 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZNF410  HCVpro 
hcv0408 NS3 
HCV 
genotype 1b isolate con1 AJ238799 ZZZ3  HCVpro 
hcv0409 NS3 
HCV 
genotype 1a strain H AAA45534 NS5B AAA45534 HCVpro 
hcv0410 NS3 
HCV 
genotype 1a H77 NP_803144 NS3 NP_803144 VirHostNet 
hcv0411 NS3 
HCV 
genotype 1b   NS5B  HCVpro 
hcv0412 NS3 
HCV 
genotype 1b   NS4B  HCVpro 
hcv0413 NS3 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
hcv0414 NS3 
HCV 
genotype 1a H77 NP_803144 CASP8  VirHostNet 
hcv0415 NS3 
HCV 
genotype 1b 
Singapore 
strain  NS3  HCVpro 
hcv0416 NS3 
HCV 
genotype 1a H77 NP_803144 NS4A NP_751925 VirHostNet 
hcv0417 NS3 
HCV 
genotype 1b isolate con1 AJ238799 RSPH3  HCVpro 
hcv0418 NS4A 
HCV 
genotype 1a H77 NP_751925 NS3 NP_803144 VirHostNet 
hcv0419 NS4A 
HCV 
genotype 1b Isolate Bk 1JXP_D NS3 BAA09073 BIND 
hcv0420 NS4A 
HCV isolate 
1 
Isolate 
Taiwanese 1DY9_D NS3 BAA28515 BIND 
hcv0421 NS4A 
HCV 
genotype 1a H77 AAB66324 NS3  VirHostNet 
hcv0422 NS4A 
HCV 
genotype 1a H77 AF009606 NS4A AF009606 HCVpro 
hcv0423 NS4A 
HCV 
genotype 1a H77 AF009606 NS4B AF009606 HCVpro 
hcv0424 NS4A 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
hcv0425 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 CREB3  HCVpro 
hcv0426 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 ELAC2  HCVpro 
hcv0427 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 HOXD8  HCVpro 
hcv0428 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0429 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 TRAF3IP3  HCVpro 
hcv0430 NS4A 
HCV 
genotype 1b isolate con1 AJ238799 UBQLN1  HCVpro 
hcv0431 NS4A 
HCV 
genotype 1a H77 AF009606 NS5A AF009606 HCVpro 
hcv0432 NS4A 
HCV 
genotype 1a H77 NP_751925 MT2A  VirHostNet 
hcv0433 NS4A 
HCV 
genotype 1a H77 NP_751925 TUT1  VirHostNet 
hcv0434 NS4A 
HCV 
genotype 1a H77 NP_751925 MT-CO2  VirHostNet 
hcv0435 NS4A 
HCV 
genotype 1a strain H77 NP_751925 EEF1A1  VirHostNet 
hcv0436 NS4A 
HCV 
genotype 1a strain H77 NP_751925 CAMLG  VirHostNet 
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hcv0437 NS4A 
HCV 
genotype 1a H77 AAB66324 NS5A AAB66324 VirHostNet 
hcv0438 NS4B 
HCV 
genotype 1a H77 AAB66324 NS4A AAB66324 VirHostNet 
hcv0439 NS4B 
HCV 
genotype 1b   ATF6B  HCVpro 
hcv0440 NS4B 
HCV 
genotype 1b   ATF6A  HCVpro 
hcv0441 NS4B 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
hcv0442 NS4B 
HCV 
genotype 1a H77 AF009606 NS4B AF009606 HCVpro 
hcv0443 NS4B 
HCV 
genotype 1b   NS5B  HCVpro 
hcv0444 NS4B 
HCV 
genotype 1b   TNXB  HCVpro 
hcv0445 NS4B 
HCV 
genotype 1a H77 AF009606 NS5A AF009606 HCVpro 
hcv0446 NS4B 
HCV 
genotype 1b   NS5A  HCVpro 
hcv0447 NS4B 
HCV 
genotype 1a H77 NP_751926 RTN3  VirHostNet 
hcv0448 NS4B 
HCV 
genotype 1a H77 NP_751926 RBP4  VirHostNet 
hcv0449 NS4B 
HCV 
genotype 1a H77 NP_751926 NDUFV3  VirHostNet 
hcv0450 NS4B 
HCV 
genotype 1a H77 NP_751926 FGG  VirHostNet 
hcv0451 NS4B 
HCV 
genotype 1a H77 NP_751926 MT-CO3  VirHostNet 
hcv0452 NS4B 
HCV 
genotype 1a strain H77 NP_751926 RAB5A  VirHostNet 
hcv0453 NS5A 
HCV 
genotype 1a H77 NP_751927 EIF2AK2  BIND 
hcv0454 NS5A 
HCV 
genotype 1b   CSNK2A1  HCVpro 
hcv0455 NS5A 
HCV 
genotype 1b Con1 CAB46677 GRB2  BIND 
hcv0456 NS5A 
HCV 
genotype 1a H77 NP_751927 VAPA  VirHostNet 
hcv0457 NS5A 
HCV 
genotype 1a H77 NP_751927 SRCAP  BIND 
hcv0458 NS5A 
HCV 
genotype 1a H77 NP_751927 IPO5  BIND 
hcv0459 NS5A 
HCV 
genotype 1a H77 NP_751927 TP53  BIND 
hcv0460 NS5A 
HCV 
genotype 1a strain H AAA45534 CDC2  HCVpro 
hcv0461 NS5A 
HCV 
genotype 1a strain H AAA45534 CDK2  HCVpro 
hcv0462 NS5A 
HCV 
genotype 1a H77 NP_751927 APOA1  BIND 
hcv0463 NS5A 
HCV 
genotype 1b   TP53  HCVpro 
hcv0464 NS5A 
HCV 
genotype 1b   TAF9  HCVpro 
hcv0465 NS5A 
HCV 
genotype 1b   PIK3R1  HCVpro 
hcv0466 NS5A 
HCV 
genotype 1b   TP53  HCVpro 
hcv0467 NS5A 
HCV 
genotype 1b   TBP  HCVpro 
hcv0468 NS5A 
HCV 
genotype 1b isolate con1 CAB46677 BIN1  BIND 
hcv0469 NS5A 
HCV 
genotype 1a H77 NP_751927 PITX1  VirHostNet 
hcv0470 NS5A 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
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hcv0471 NS5A 
HCV 
genotype 1a H77 AF009606 NS5A AF009606 HCVpro 
hcv0472 NS5A 
HCV 
genotype 1a H77 NP_751927 BAX  VirHostNet 
hcv0473 NS5A 
HCV 
genotype 1a H77 NP_671491.1 SSB  BIND 
hcv0474 NS5A 
HCV 
genotype 1a H77 AF009606 HCK  HCVpro 
hcv0475 NS5A 
HCV 
genotype 1a H77 AF009606 LCK  HCVpro 
hcv0476 NS5A 
HCV 
genotype 1a H77 AF009606 LYN  HCVpro 
hcv0477 NS5A 
HCV 
genotype 1a H77 AF009606 FYN  HCVpro 
hcv0478 NS5A 
HCV 
genotype 1b   VAPA  HCVpro 
hcv0479 NS5A 
HCV 
genotype 1a H77 NP_751927 OAS1  VirHostNet 
hcv0480 NS5A 
HCV 
genotype 1a H77 NP_751927 JAK1  BIND 
hcv0481 NS5A 
HCV 
genotype 1b Con1 CAB46677 APOE  HCVpro 
hcv0482 NS5A 
HCV 
genotype 1b Con1 CAB46677 VAPA  HCVpro 
hcv0483 NS5A 
HCV 
genotype 1b Con1 CAB46677 NS5A  HCVpro 
hcv0484 NS5A 
HCV 
genotype 1b Con1 CAB46677 AHNAK  VirHostNet 
hcv0485 NS5A 
HCV 
genotype 1b Con1 CAB46677 SFRP4  VirHostNet 
hcv0486 NS5A 
HCV 
genotype 1b Con1 CAB46677 CRABP1  VirHostNet 
hcv0487 NS5A 
HCV 
genotype 1b Con1 CAB46677 FTH1  VirHostNet 
hcv0488 NS5A 
HCV 
genotype 1b Con1 CAB46677 CCDC86  VirHostNet 
hcv0489 NS5A 
HCV 
genotype 1b Con1 CAB46677 TACSTD2  VirHostNet 
hcv0490 NS5A 
HCV 
genotype 1b Con1 CAB46677 PI4KA  VirHostNet 
hcv0491 NS5A 
HCV 
genotype 1b Con1 CAB46677 PTMA  VirHostNet 
hcv0492 NS5A 
HCV 
genotype 1b Con1 CAB46677 ARAP1  VirHostNet 
hcv0493 NS5A 
HCV 
genotype 1b Con1 CAB46677 NDRG1  VirHostNet 
hcv0494 NS5A 
HCV 
genotype 1b Con1 CAB46677 MGP  VirHostNet 
hcv0495 NS5A 
HCV 
genotype 1b Con1 CAB46677 CEP57  VirHostNet 
hcv0496 NS5A 
HCV 
genotype 1b Con1 CAB46677 C9orf6  VirHostNet 
hcv0497 NS5A 
HCV 
genotype 1b   FBXL2  HCVpro 
hcv0498 NS5A 
HCV 
genotype 1b strain MD13 AAF65944.1 NS5A  BIND 
hcv0499 NS5A 
HCV 
genotype 1a H77 NP_751927 CSK  VirHostNet 
hcv0500 NS5A 
HCV 
genotype 1a H77 NP_751927 SRC  VirHostNet 
hcv0501 NS5A 
HCV 
genotype 1a H77 NP_751927 APOB  VirHostNet 
hcv0502 NS5A 
HCV 
genotype 1b Strain J1 D89815 VAPB  HCVpro 
hcv0503 NS5A 
HCV 
genotype 1a H77 NP_751927 RAF1  VirHostNet 
hcv0504 NS5A 
HCV 
genotype 1b 
Korean 
isolate  TGFBR1  HCVpro 
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hcv0505 NS5A 
HCV 
genotype 1a strain H77 NP_751927 PPP2R4  VirHostNet 
hcv0506 NS5A 
HCV 
genotype 1a strain H77 NP_751927 BIN1  VirHostNet 
hcv0507 NS5A 
HCV 
genotype 1b   TRAF2  HCVpro 
hcv0508 NS5A 
HCV 
genotype 1a strain H77 NP_751927 FKBP8  VirHostNet 
hcv0509 NS5A 
HCV 
genotype 1a strain H77C  FKBP8  HCVpro 
hcv0510 NS5A 
HCV 
genotype 1a strain H77C  HSP90AA1  HCVpro 
hcv0511 NS5A 
HCV 
genotype 1a strain H77 NP_751927 PTPLAD1  VirHostNet 
hcv0512 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 ACLY  HCVpro 
hcv0513 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 ARFIP1  HCVpro 
hcv0514 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 AXIN1  HCVpro 
hcv0515 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 BEND7  HCVpro 
hcv0516 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CADPS  HCVpro 
hcv0517 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CADPS2  HCVpro 
hcv0518 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CEP120  HCVpro 
hcv0519 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CENPC1  HCVpro 
hcv0520 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CEP250  HCVpro 
hcv0521 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 CEP63  HCVpro 
hcv0522 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 DNAJA3  HCVpro 
hcv0523 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 EFEMP1  HCVpro 
hcv0524 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 FHL2  HCVpro 
hcv0525 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 GOLGA2  HCVpro 
hcv0526 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 GPS2  HCVpro 
hcv0527 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 IGLL1  HCVpro 
hcv0528 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 ITGAL  HCVpro 
hcv0529 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 LIMS2  HCVpro 
hcv0530 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 MOBK1B  HCVpro 
hcv0531 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 NAP1L1  HCVpro 
hcv0532 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 NAP1L2  HCVpro 
hcv0533 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 NFE2  HCVpro 
hcv0534 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 NUCB1  HCVpro 
hcv0535 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 PARVG  HCVpro 
hcv0536 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 PMVK  HCVpro 
hcv0537 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 PPP1R13L  HCVpro 
hcv0538 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 PSMB9  HCVpro 
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hcv0539 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 RPL18A  HCVpro 
hcv0540 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 RRBP1  HCVpro 
hcv0541 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 SHARPIN  HCVpro 
hcv0542 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 SMYD3  HCVpro 
hcv0543 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 SORBS2  HCVpro 
hcv0544 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 SORBS3  HCVpro 
hcv0545 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 THBS1  HCVpro 
hcv0546 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 TMF1  HCVpro 
hcv0547 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 TP53BP2  HCVpro 
hcv0548 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 TRIOBP  HCVpro 
hcv0549 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 TXNDC11  HCVpro 
hcv0550 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 UBASH3A  HCVpro 
hcv0551 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 USP19  HCVpro 
hcv0552 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 VPS52  HCVpro 
hcv0553 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 GIN1  HCVpro 
hcv0554 NS5A 
HCV 
genotype 1b isolate con1 AJ238799 ZNF646  HCVpro 
hcv0555 NS5A 
HCV 
genotype 1a H77 NP_751927 NS5B NP_751928 BIND 
hcv0556 NS5A 
HCV 
genotype 1a H77 NP_751927 TRAF2  BIND 
hcv0557 NS5A 
HCV 
genotype 1a H77 NP_751927 TRADD  VirHostNet 
hcv0558 NS5A 
HCV 
genotype 1b   GAB1  HCVpro 
hcv0559 NS5A 
HCV 
genotype 1a H77 AF009606 NS3 AF009606 HCVpro 
hcv0560 NS5A 
HCV 
genotype 1a H77 NP_751927 PIK3CB  VirHostNet 
hcv0561 NS5A 
HCV 
genotype 1b   FBXL20  HCVpro 
hcv0562 NS5A 
HCV 
genotype 1a strain H77 NP_751927 STAT1  VirHostNet 
hcv0563 NS5A 
HCV 
genotype 1a strain H77 NP_751927 MYD88  VirHostNet 
hcv0564 NS5A 
HCV 
genotype 2a   PDPK1  HCVpro 
hcv0565 NS5A 
HCV 
genotype 2a   AKT1  HCVpro 
hcv0566 NS5A 
HCV 
genotype 2a   VPS35  HCVpro 
hcv0567 NS5A 
HCV 
genotype 2a   MAPK12  HCVpro 
hcv0568 NS5A 
HCV 
genotype 2a   IPO4  HCVpro 
hcv0569 NS5A 
HCV 
genotype 2a   GSK3B  HCVpro 
hcv0570 NS5A 
HCV 
genotype 2a   AHSA1  HCVpro 
hcv0571 NS5A 
HCV 
genotype 2a   GSK3A  HCVpro 
hcv0572 NS5A 
HCV 
genotype 2a   CDK6  HCVpro 
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hcv0573 NS5A 
HCV 
genotype 1a strain H77 NP_751927 TBC1D20  VirHostNet 
hcv0574 NS5B 
HCV 
genotype 1a H77 NP_751928 VAPA  VirHostNet 
hcv0575 NS5B 
HCV 
genotype 1a H77 NP_751928 EIF4A2  BIND 
hcv0576 NS5B 
HCV 
genotype 1a H77 NP_751928 NCL  BIND 
hcv0577 NS5B 
HCV 
genotype 1a H77 AF009606 NS5B AF009606 HCVpro 
hcv0578 NS5B 
HCV 
genotype 1b   HAO1  HCVpro 
hcv0579 NS5B 
HCV 
genotype 1b   TTC4  HCVpro 
hcv0580 NS5B 
HCV 
genotype 1b   ACTN1  HCVpro 
hcv0581 NS5B 
HCV 
genotype 1b   VAPA  HCVpro 
hcv0582 NS5B 
HCV 
genotype 1b HCV-S1 AAL00900 DDX5  BIND 
hcv0583 NS5B 
HCV 
genotype 1a H77 NP_751928 PKN2  VirHostNet 
hcv0584 NS5B 
HCV 
genotype 1a H77 NP_751928 PTBP2  VirHostNet 
hcv0585 NS5B 
HCV 
genotype 1b   FBXL2  HCVpro 
hcv0586 NS5B 
HCV 
genotype 1a H77 NP_751928 PPIB  BIND 
hcv0587 NS5B 
HCV 
genotype 1b Strain J1 D89815 VAPB  HCVpro 
hcv0588 NS5B 
HCV 
genotype 1b 
Korean 
isolate  CHUK  HCVpro 
hcv0589 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 CEP250  HCVpro 
hcv0590 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 CEP68  HCVpro 
hcv0591 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 HOXD8  HCVpro 
hcv0592 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 MGC2752  HCVpro 
hcv0593 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 MOBK1B  HCVpro 
hcv0594 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 NR4A1  HCVpro 
hcv0595 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 OS9  HCVpro 
hcv0596 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 PKM2  HCVpro 
hcv0597 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 PSMB9  HCVpro 
hcv0598 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 SETD2  HCVpro 
hcv0599 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 SHARPIN  HCVpro 
hcv0600 NS5B 
HCV 
genotype 1b isolate con1 AJ238799 TUBB2C  HCVpro 
hcv0601 NS5B 
HCV 
genotype 1b Isolate Con1 CAB46677 NS5B CAB46677 BIND 
hcv0602 NS5B 
HCV 
genotype 1a H77 NP_751928 UBQLN1  VirHostNet 
hcv0603 NS5B 
HCV 
genotype 1b   CINP  HCVpro 
hcv0604 NS5B 
HCV 
genotype 1b   PSMB4  HCVpro 
hcv0605 NS5B 
HCV 
genotype 1a strain H77 NP_751928 6-Sep  VirHostNet 
hcv0606 NS5B 
HCV 
genotype 1a strain H77 NP_751928 HNRNPA1  VirHostNet 
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hcv0607 p7 
HCV 
genotype 1b 
strain (HC-
J4)  P7  HCVpro 
hcv0608 p7 
HCV 
genotype 1b   FMNL1  HCVpro 
hcv0609 p7 
HCV 
genotype 1b   H19  HCVpro 
hcv0610 p7 
HCV 
genotype 1b   ISLR  HCVpro 
hcv0611 p7 
HCV 
genotype 1b   MS4A6A  HCVpro 
hcv0612 p7 
HCV 
genotype 1b   NUP214  HCVpro 
hcv0613 p7 
HCV 
genotype 1b   SSR4  HCVpro 
hcv0614 p7 
HCV 
genotype 1b   STRBP  HCVpro 
hcv0615 p7 
HCV 
genotype 1b isolate con1 AJ238799 CREB3  HCVpro 
hcv0616 p7 
HCV 
genotype 1b isolate con1 AJ238799 FBLN2  HCVpro 
hcv0617 p7 
HCV 
genotype 1b isolate con1 AJ238799 FXYD6  HCVpro 
hcv0618 p7 
HCV 
genotype 1b isolate con1 AJ238799 LMNB1  HCVpro 
hcv0619 p7 
HCV 
genotype 1b isolate con1 AJ238799 SLIT2  HCVpro 
hcv0620 p7 
HCV 
genotype 1b isolate con1 AJ238799 UBQLN1  HCVpro 
hcv0621 p7 
HCV 
genotype 1b isolate con1 AJ238799 UBQLN4  HCVpro  
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Appendix V (Chapter 3) 
 
Appendix Va 
Hepatocellular carcinoma genes obtained from HCCNet and OncoDB.HCC databases 
Gene Name Entrez Gene Source Source 
ACLY 47 HCCNet Oncodb.hcc  
AEBP1 165 HCCNet  
AGT 183 HCCNet  
AHNAK 79026 HCCNet  
AKT1 207 HCCNet  
APOA1 335 HCCNet Oncodb.hcc  
APOB 338 HCCNet  
APOE 348 HCCNet Oncodb.hcc  
ARNT 405 HCCNet  
AXIN1 8312 HCCNet Oncodb.hcc  
AZGP1 563 HCCNet Oncodb.hcc  
BCL2A1 597 HCCNet  
C7 730 HCCNet  
CANX 821 HCCNet  
CASP8 841 HCCNet  
CD209 30835 HCCNet  
CD5L 922 HCCNet Oncodb.hcc  
CD68 968 HCCNet  
CD81 975 HCCNet Oncodb.hcc  
CDC2 983 HCCNet  
CDK2 1017 HCCNet  
CDK6 1021 HCCNet  
CDKN1A 1026 HCCNet Oncodb.hcc  
CEP152 22995 HCCNet  
CEP68 23177 HCCNet  
CFP 5199 HCCNet  
CHUK 1147 HCCNet  
CIDEB 27141 HCCNet  
CLEC4M 10332 HCCNet  
COL4A2 1284 HCCNet  
CTGF 1490 HCCNet Oncodb.hcc  
CTSB 1508 HCCNet Oncodb.hcc  
DDX3X 1654 HCCNet  
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DDX3Y 8653 HCCNet  
EEF1A1 1915 HCCNet  
EFEMP1 2202 HCCNet  
FAS 355 HCCNet Oncodb.hcc  
FBN1 2200 HCCNet  
FGG 2266 HCCNet Oncodb.hcc  
FHL2 2274 HCCNet  
FIGNL1 63979 HCCNet  
FN1 2335 HCCNet  
FYN 2534 HCCNet  
GAB1 2549 HCCNet  
GAPDH 2597 HCCNet  
GBP2 2634 HCCNet  
GRB2 2885 HCCNet  
H19 283120 HCCNet Oncodb.hcc  
HAO1 54363 HCCNet  
HLA-A 3105 HCCNet  
HSPD1 3329 HCCNet  
IKBKE 9641 HCCNet  
IRF3 3661 HCCNet  
JAK2 3717 HCCNet  
JUN 3725 HCCNet  
KRT19 3880 HCCNet Oncodb.hcc  
KRT8 3856 HCCNet  
LAMB2 3913 HCCNet  
APOA2 336 HCCNet  
MAGED1 9500 HCCNet  
MBP 4155 HCCNet  
MCL1 4170 HCCNet Oncodb.hcc  
MS4A6A 64231 HCCNet  
MT2A 4502 HCCNet  
MVP 9961 HCCNet  
NAP1L1 4673 HCCNet  
NDC80 10403 HCCNet  
NDRG1 10397 HCCNet  
NOTCH1 4851 HCCNet  
NUP62 23636 HCCNet  
OAS1 4938 HCCNet  
PDE4DIP 9659 HCCNet  
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PDLIM5 10611 HCCNet  
PKM2 5315 HCCNet  
PPARA 5465 HCCNet  
PRKACA 5566 HCCNet  
PSMB4 5692 HCCNet  
PTMA 5757 HCCNet  
RAB14 51552 HCCNet  
RASAL2 9462 HCCNet  
RGNEF 64283 HCCNet  
RXRA 6256 HCCNet  
SCARB1 949 HCCNet  
SEPT6 23157 HCCNet  
SERPINC1 462 HCCNet  
SERPINF2 5345 HCCNet Oncodb.hcc  
SERPING1 710 HCCNet Oncodb.hcc  
SESTD1 91404 HCCNet  
SIAH1 6477 HCCNet Oncodb.hcc  
SLC22A7 10864 HCCNet  
SLIT2 9353 HCCNet  
SMAD3 4088 HCCNet  
SMURF2 64750 HCCNet  
SMYD3 64754 HCCNet  
SRC 6714 HCCNet Oncodb.hcc  
STAB1 23166 HCCNet  
STAT1 6772 HCCNet  
STAT3 6774 HCCNet  
SYNE1 23345 HCCNet  
SYNPO2 171024 HCCNet  
TACSTD2 4070 HCCNet  
TBP 6908 HCCNet  
TF 7018 HCCNet Oncodb.hcc  
THBS1 7057 HCCNet Oncodb.hcc  
TMF1 7110 HCCNet  
TP53 7157 HCCNet Oncodb.hcc  
TP53BP2 7159 HCCNet  
UBQLN4 56893 HCCNet  
VCAN 1462 HCCNet  
VIM 7431 HCCNet Oncodb.hcc  
VWF 7450 HCCNet  
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YWHAE 7531 HCCNet  
YWHAZ 7534 HCCNet  
YY1 7528 HCCNet  
ZCCHC7 84186 HCCNet  
ZG16 653808 HCCNet  
ACY3 91703 HCCNet  
GRN 2896  Oncodb.hcc  
HSPA5 3309  Oncodb.hcc  
TP73 7161  Oncodb.hcc  
HSP90AA1 3320  Oncodb.hcc  
BAX 581  Oncodb.hcc  
GSK3A 2931  Oncodb.hcc  
Vitronectin  7448  Oncodb.hcc  
ATF6A 22926  Oncodb.hcc  
KHDRBS1 10657  Oncodb.hcc  
NR4A1 3164  Oncodb.hcc  
IGLL1 3543  Oncodb.hcc  
RAF1 5894  Oncodb.hcc  
RBP4 5950  Oncodb.hcc  
ITGB1 3688  Oncodb.hcc  
YY1AP1 55249  Oncodb.hcc  
HNRNPK 3190  Oncodb.hcc  
FADD 8772  Oncodb.hcc  
NPM1 4869  Oncodb.hcc  
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Appendix Vb  
Hepatocellular carcinoma genes obtained from EHCO database with expression levels 
Gene_Symbol Dataset UP regulated 
Down 
regulated 
ACLY GIS, SMD, UCSF, TOKYO 4 0 
AEBP1 SMD 0 1 
AGRN SMD, UCSF 2 0 
AGT SAGE, PubMed, mRNA 1 1 
AKT1 PubMed 1 0 
ANKRD12 KIM 1 0 
APOA1 SMD, SAGE, CGED 0 3 
APOA2 SAGE, PubMed, FUDAN 1 1 
APOB SAGE 0 1 
APOE SAGE 0 1 
ARNT PubMed, UCSF 1 0 
ARS2 FUDAN 0 1 
AXIN1 PubMed 0 0 
AZGP1 SMD, LEE, CGED 0 3 
B2M PubMed, mRNA, CGED 1 1 
BAX PubMed, mRNA 1 0 
BCL2A1 FUDAN 0 1 
BIN1 PubMed, mRNA, FUDAN, OncoFetal 2 1 
C1QBP TOKYO 0 1 
C7 GIS, SMD, mRNA 0 3 
CALR UCSF, CGED 2 0 
CAMLG SMD 1 0 
CANX SMD, SAGE, UCSF 2 1 
CASP8 PubMed 0 0 
CCDC21 SMD, UCSF 2 0 
CCDC66 SAGE 1 0 
CD5L GIS, KIM, TOKYO 0 3 
CD68 PubMed, LEE 1 0 
CD81 SMD, PubMed, mRNA 1 1 
CDC2 SMD, PubMed, UCSF, FUDAN 3 0 
CDC23 GIS, TOKYO 2 0 
CDK2 PubMed, FUDAN 1 0 
CDKN1A PubMed, mRNA, CGED, PASTEUR 0 3 
CFP PubMed, TOKYO 0 1 
CHUK PubMed, FUDAN 0 1 
CLEC4M mRNA 0 1 
COL4A2 SMD, UCSF 2 0 
CRABP1 PubMed 0 0 
CSNK2B SMD, UCSF, FUDAN 3 0 
CTGF PubMed, mRNA 0 1 
CTSB PubMed, Protein 0 1 
DDX3X PubMed, mRNA 2 0 
DDX3Y SMD, FUDAN 0 2 
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DES PubMed, TOKYO 0 1 
DNAJA3 OncoFetal 1 0 
DPP7 SMD 0 1 
EEF1A1 Protein 0 1 
EFEMP1 SAGE 1 0 
EIF1 CGED 0 1 
EIF2AK2 PubMed 0 0 
FADD PubMed, CGED 1 1 
FAS SMD, PubMed 0 1 
FBLN5 mRNA 0 1 
FBN1 PubMed, LEE 1 0 
FES FUDAN 1 0 
FGG SMD, SAGE, mRNA, Protein, CGED 1 5 
FLAD1 SMD, UCSF 2 0 
FN1 mRNA, PASTEUR 2 1 
FTH1 mRNA 1 0 
FUCA2 CGED 1 0 
FYN SMD, PubMed 0 1 
GAA mRNA 1 0 
GAB1 SMD 1 0 
GAPDH PubMed, mRNA, Protein, OncoFetal 4 0 
GFAP PubMed 0 0 
GLRX3 Protein, FUDAN 1 1 
GON4L UCSF 1 0 
GRB2 Protein, PASTEUR 0 2 
GRN GIS, SMD, UCSF 3 0 
H19 SAGE, PubMed 1 0 
HAO1 Protein, CGED 0 2 
HCK LEE 1 0 
HLA-A SAGE, PubMed, mRNA 1 1 
HNRNPA1 LEE, mRNA 2 0 
HSP90AA1 mRNA, Protein, CGED 3 0 
HSPA5 GIS, SAGE, Protein, CGED 3 1 
HSPD1 SAGE, PubMed, mRNA, Protein 3 1 
IGLL1 SMD 0 1 
IQWD1 CGED 1 0 
ITGB1 GIS, PubMed, mRNA 1 1 
ITGB4 PASTEUR 1 0 
JAK1 PubMed 0 0 
JAK2 PubMed 0 0 
JUN SMD, FUDAN 1 1 
KRT19 SAGE, PubMed, LEE, mRNA, Protein 5 0 
KRT8 SMD, CGED, PASTEUR 1 2 
LAMB2 OncoFetal 1 0 
LMNB1 Protein 1 0 
LTBP4 TOKYO 0 1 
LTBR PubMed 0 0 
LZTS2 SAGE 1 0 
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MAPK12 PubMed 0 0 
MAPK7 SMD 0 1 
MBP PubMed 0 0 
MCL1 SMD, CGED 0 2 
MT2A SAGE, mRNA, CGED, TOKYO 0 4 
MYD88 FUDAN 0 1 
NAP1L1 SMD, UCSF 2 0 
NCL GIS, PubMed, mRNA 1 1 
NDRG1 SMD, PubMed, LEE, UCSF, CGED 4 0 
NEFL PubMed 0 0 
NOTCH1 LEE 1 0 
NPM1 
SMD, PubMed, LEE, mRNA, Protein, 
UCSF 6 0 
NR4A1 SMD, mRNA 1 1 
NUCB1 SAGE, CGED, OncoFetal 1 2 
NUP62 KIM 1 0 
OS9 mRNA 0 1 
PABPN1 PubMed 0 0 
PDPK1 KIM 1 0 
PFDN2 Protein 1 0 
PIK3CB PubMed 1 0 
PIK3R1 PubMed 1 0 
PKM2 LEE, mRNA 2 0 
PLSCR1 SMD 0 1 
PML PubMed 0 0 
PPARA PubMed 0 0 
PPIB GIS, SAGE, PubMed, mRNA 3 1 
PSMB4 GIS, CGED, FUDAN 3 0 
PSMB8 PubMed, FUDAN 0 1 
PSMB9 PubMed 0 0 
PTPLAD1 SMD, UCSF 2 0 
PTPRN2 SMD 0 1 
RAB14 mRNA 0 1 
RAF1 PubMed 1 0 
RBP4 SMD, SAGE, PubMed, Protein, CGED 1 3 
RRBP1 Protein, CGED 0 2 
RSF1 PubMed, CGED 1 0 
RTN3 SMD, UCSF 2 0 
RXRA LEE 0 1 
SCARB1 PubMed, CGED 1 0 
SDC2 SAGE, mRNA, CGED 1 2 
SERPINC1 SAGE, KIM, mRNA, FUDAN 0 4 
SERPINF2 SAGE, mRNA, FUDAN 0 3 
SERPING1 SMD, SAGE, mRNA, CGED, TOKYO 1 4 
SHARPIN UCSF 1 0 
SIAH1 SMD, PubMed 0 1 
SLC22A7 SAGE, CGED 0 2 
SLC31A2 SMD, KIM 0 2 
SMYD3 PubMed 0 0 
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SORBS2 mRNA 0 1 
SORBS3 SMD 0 1 
SRC PubMed 0 0 
SSB PubMed 0 0 
SSX2IP FUDAN 0 1 
STAT1 PubMed 0 0 
STAT3 PubMed, Protein, CGED, PASTEUR 0 3 
SVEP1 SMD 0 1 
TACSTD2 SAGE 1 0 
TAF1 PubMed, mRNA 1 0 
TAF9 GIS, CGED 2 0 
TF 
SMD, SAGE, PubMed, KIM, mRNA, 
Protein, CGED 1 6 
THBS1 SMD, LEE, FUDAN 1 2 
TLR2 KIM 0 1 
TMSB4X SAGE, CGED 1 1 
TNF PubMed 1 0 
TP53 PubMed, mRNA, FUDAN, TOKYO 0 3 
TP53BP2 GIS, SMD, UCSF 3 0 
TP73 PubMed 0 0 
TRADD PubMed 0 0 
TRAF2 PubMed, LEE, mRNA 1 1 
TRIM23 FUDAN 0 1 
TRIM27 PubMed 0 0 
TRIO UCSF 1 0 
TRIOBP SMD 0 1 
TRIP11 UCSF 1 0 
TSN PubMed, mRNA, UCSF 2 0 
UBA3 FUDAN 1 0 
UBQLN1 FUDAN 0 1 
UXT PubMed 0 0 
VCAN PubMed 0 0 
VIM PubMed, mRNA, Protein 3 0 
VPS35 Protein 1 0 
VPS52 GIS 1 0 
VWF SMD, PubMed, UCSF 2 0 
YWHAB GIS 1 0 
YWHAZ SMD, UCSF 2 0 
YY1AP1 UCSF 1 0 
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Appendix VI (Chapter 3) 
 
Appendix Va 
Summary of data statistics of host proteins incorporated in HCVpro 
Features Number of human proteins 
Gene Name 455 
Entrez Gene 455 
HPRD ID 453 
HCCNet 116 
EHCO 178 
Oncodb.hcc 41 
Category 455 
Description 455 
Aliases 446 
Previous Symbols  117 
Previous Names 126 
Chromosome 455 
Entrez Gene Cytoband 453 
Strand 455 
Gene start 453 
Gene end 453 
Gene size 454 
RefSeq RNA 453 
RefSeq peptide 452 
Ensembl Gene 455 
UniGene 453 
GenBank Accession 439 
EMBL 444 
OMIM 383 
FUNCTION 384 
SwissProt (name) 447 
SwissProt (acc) 447 
PDB id 186 
IPI 450 
Ensembl Protein ID 454 
PharmGKB 398 
InterPro 408 
Pfam 355 
KEGG 163 
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Reactome Pathway 
IdD 86 
Nature Pathway 42 
HPD 85 
NetPath Pathway 187 
GO 435 
 
 
Appendix Vb  
Summary of data statistics of viral proteins incorporated in HCVpro 
Features Number of viral proteins 
Short Name 11 
Recommended Name 11 
Other Names 11 
Enzyme Commission 3 
euHCVdb 11 
OMIM 11 
euhcvdb protein 11 
GenBank 11 
VBRC HCVdb Accession 11 
Uniprot Post-translational 
modification 10 
Uniprot Functions 11 
Uniprot Subunit Structure 10 
Uniprot Domain 4 
Uniprot Subcellular Localization 11 
Functions 11 
Drug Development 11 
Description 11 
Molecular Mass by SDS-Page 11 
Current State of Antiviral 11 
Antiviral Progress 7 
Uniprot IDs 11 
Protein Type 11 
Genome 11 
Family 11 
Genus 11 
Strain Name 11 
Molecule Type 11 
Amino Acid Length 11 
pI 11 
 
 
 
 
 183 
Gene Size 11 
Molecular Weight 11 
Proteolytic Enzymes 10 
NCBI CDD Pfam 9 
Entrez Gene ID 11 
GI 11 
NCBI RefSeq 11 
Pfam 9 
Interpro 9 
PDB 7 
Recommended PubMed Readings 11 
GO 11 
 
 
Appendix Vc 
Summary of data distribution in HCVpro 
Features Number 
Redundant virus-virus protein interactions 72 
Non-redundant virus-virus protein interactions 29 
Redundant virus-human protein interactions 549 
Non-redundant virus-human protein 
interactions 524 
Journal articles reporting interactions 174 
BIND IDs mapped in HCVpro 162 
VirusMint IDs mapped in HCVpro 53 
HCVpro IDs 621 
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Appendix VII (Chapter 3) 
 
User manual for Hepatitis C Virus protein interaction database 
(HCVpro) 
Section A 
1.  Home Page 
The index page accessible via http://apps.sanbi.ac.za/hcvpro/ displays brief information 
about HCVpro and the menus (Search, manual, statistics, FAQ, links, download and 
contact) 
 
 
 
 
 
 
 
 
 
 
 
 
 185 
2. Querying database 
 
 
3. Sub menu queries 
The enhanced user query interfaces enable users to perform searches via HCVpro by 
browsing the following sub query menus: 
Protein Select 
 HCV proteins: e.g. E2 
 Human proteins: e.g. CD81 
 Human Chromosome number: e.g. 10 
 
Evidence 
 Experiment type: e.g. coimmunoprecipitation 
 PubMed ID: e.g. 10846074 
 
Identifier Search 
 HCVpro ID: e.g. hcv0128 
 BIND ID: e.g. 183964 
 MINT ID: e.g. MINT-14803 
 
String Search  
 Gene Name: e.g. Vimentin 
 Gene ID: e.g. 7431 
 Gene symbol: e.g. VIM 
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Section B 
Protein Search 
Here, we demonstrate querying of the HCVpro via the Hepatitis C Virus (HCV) proteins 
sub menu by browsing the list of HCV proteins. To retrieve interaction details on 
“NS5A” protein: 
 
 
1. Click on “NS5A” protein 
(NB: you may perform multiple queries by holding on the CTRL key and 
selecting the proteins simultaneously.) 
2. Click on select to return a list of protein interactions as shown below: 
 
 
 
 
 
 
 
 187 
 
 
 
3. Click on “SRCAP” protein to retrieve interaction details and enriched 
functional biological information on both “NS5A” and “SRCAP” proteins as 
below: 
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Click on all cross-referenced links to familiarize yourself with the information they 
provide. 
4. Click on “Details Molecule A” link to retrieve comprehensive information on “NS5A”  
For illustration view here: 
http://apps.sanbi.ac.za/hcvpro/details_hcvprot.php?id=457&mol=a 
5. Click on “Details Molecule B” to retrieve comprehensive information on “SRCAP”  
For illustration view here: http://apps.sanbi.ac.za/hcvpro/details_humanprot.php?id=457 
Explained data fields 
Hepatocellular carcinoma associated genes are cross-referenced to the sources below: 
 HCCNet: Hepatocellular carcinoma network database 
 EHCO: Encyclopedia of hepatocellular carcinoma genes online 
 Oncodb.hcc: Oncogenomic Database of hepatocellular carcinoma 
 
NB: For details on EHCO gene expression levels consult: http://ehco.iis.sinica.edu.tw/ 
You may also consult the frequently asked questions and HCVpro data statistics at: 
http://apps.sanbi.ac.za/hcvpro/FAQ.php and http://apps.sanbi.ac.za/hcvpro/Statistics.php/ 
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Section C 
Here, we demonstrate querying of the HCVpro via string search using the protein 
“vimentin” 
 
 
1. Type “Vimentin” in the search area 
2. Click on “search” to return a list of protein as shown below: 
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3. Click on “HCV interactions” as indicated above to access the protein 
interactions 
 
 Click on “details” as indicated above to retrieve detailed interaction data on 
vimentin: 
 
 
 Click on all cross-referenced links to familiarize yourself with the information 
they provide. 
4. Click on “Details Molecule A” link to retrieve comprehensive information on 
“NS3”  
For illustration view here: 
http://apps.sanbi.ac.za/hcvpro/details_hcvprot.php?id=397&mol=a 
5. Click on “Details Molecule B” to retrieve comprehensive information on 
“vimentin”  
For illustration view here: 
http://apps.sanbi.ac.za/hcvpro/details_humanprot.php?id=397 
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 The diagram below shows a snapshot of data on vimentin and links to GO 
ontologies, hepatocellular carcinoma databases, canonical pathways and other 
essential databases. 
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Appendix VIII (Chapter 3) 
 
Frequently asked questions 
 
1. What is HCVpro? 
 
HCVpro is a freely accessible online knowledgebase comprising of Hepatitis C Virus 
(HCV) and human protein interactions.  
 
2. Why was HCVpro created? 
 
Currently HCV protein interactions data are found in literature and other publicly 
available databases but there is no single database solely focused on HCV protein 
interactions. HCVpro was thus created to offer "a one stop" knowledgebase on HCV 
protein interactions. Data integrated in HCVpro may enhance understanding of HCV life 
cycle, molecular function of its proteins, pathways and infection, and thereby augment 
efforts towards discovery of drugs, drug targets and diagnostic biomarkers.  
 
3. What are the data sources in HCVpro? 
 
HCVpro comprises of both manually verified literature- and database-curated 
interactions. Protein interactions databases employed for the curations were: BIND, 
VirusMint and VirHostNet. Additionally, functional annotation data were obtained from 
publicly available annotation resources and published literature.  
 
4. What is unique about HCVpro, which cannot be found in other databases? 
 
HCVpro provides enriched comprehensive and integrated data on HCV and human 
protein interactions, functional annotations, hepatocellular carcinoma (HCC) related gene 
expression, drug development, pathways, and cross-referenced links to other external 
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databases. 
 
5. What type of interaction data can be obtained from HCVpro? 
 
HCVpro provides two types of interactions:  
 1.HCV viral-viral protein interactions 
 2.HCV viral-human protein interactions 
 
6. How can I query HCVpro? 
 
The enhanced user query interface enables users to perform searches via the HCVpro by 
browsing the following sub query menus:  
 Protein Select 
- HCV proteins: e.g. E2  
- Human proteins: e.g. CD81  
- Human Chromosome number: e.g. 10  
 Evidence 
- Experiment type: e.g. coimmunoprecipitation  
- PubMed ID: e.g. 10846074  
 Identifier Search 
- HCVpro ID: e.g. hcv0128  
- BIND ID: e.g. 183964  
- MINT ID: e.g. MINT-14803 
 
 
 
 
 
 
 194 
 String Search  
- Gene Name: e.g. Vimentin 
- Gene ID: e.g. 7431 
- Gene symbol: e.g. VIM 
 
7. Are there any future updates or modification in the pipeline? 
 
Yes, we would like to integrate Blast queries to enhance querying capabilities of 
HCVpro. Data on microRNA and siRNA would be integrated to augment efforts towards 
drug discovery. A complete HCV interactome would be provided in the background to 
enable users retrieve protein interaction sub-network and topological statistical features. 
Additionally, we will include features for computing druggability of protein interactions 
and also enable ligand and protein target screening online. 
 
8. Can researchers submit interactions to HCVpro? 
 
Yes, upon enquiries researchers may submit novel interactions either before or after 
publications in MIMIx compatible format. Data on interaction details such as domains, 
motif and residues involved in the interaction would be incorporated in the next update. 
Authors who have previously published HCV protein interactions would be called upon 
to submit interaction details or the developers involved in the HCVpro project will 
computationally infer as an alternative.  
 
The basic format for submission of interactions has been adapted from VirHostNet 
and is found below: 
 
Protein A id Protein B id   PSI-MI 2.5 method id     PubMed id 
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Users may use the following links to convert interaction detection methods to PSI-MI 
2.5:  
http://obo.cvs.sourceforge.net/*checkout*/obo/obo/ontology/genomic-
proteomic/protein/psi-mi.obo  
or at  
http://www.ebi.ac.uk/ontology-lookup/ 
 
Click the links below for more details on PSI-MI data format: 
http://www.ncbi.nlm.nih.gov/pubmed/20078892 
http://www.ncbi.nlm.nih.gov/pubmed/18936051 
Click the links below for more details on MIMIx data formats: 
http://www.ncbi.nlm.nih.gov/pubmed/17687370 
 
9. Can I download interaction data from HCVpro? 
 
Yes, users may download the full HCVpro interaction data in a tab-delimited format via 
the Download menu item.  
 
10. Is there a user manual on HCVpro? 
 
Yes, users can access the manual via the Manual menu item.  
11. To whom can I report a bug or discrepancy? 
 
Please report all queries via the Contact menu item. 
 
 
 
 
 
 
 
 
